


**Funding Opportunities Monthly Edition  
June 2020 Due Dates**

## Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2020. The opportunities are organized in the following order:

1. National Institutes of Health (NIH)
2. National Science Foundation (NSF)
3. Other Federal
4. Non Federal

Use the bookmarks to navigate to each section.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
081353	<a href="#">International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)</a>	Fogarty International Center/NIH/DHHS	PAR-19-244	04-Jun-2020	1,150,000 USD
	Contact Name	Barbara Sina, Ph.D.			
	Contact Telephone	301-402-9467			
	Contact Email	<a href="mailto:sinab@mail.nih.gov">sinab@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	04-Jun-2020 , 04-Jun-2021			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. Courses for Skills Development Mentoring Activities Curriculum or Methods Development The goal of this initiative is to support educational activities that foster a better understanding of the ethics of international biomedical, behavioral and clinical research and enhance the application of research ethics principles in low- and middle-income countries (LMICs). This program aims to increase the number of LMIC research intensive institutions that can provide advanced education in international research ethics. Education programs supported by this initiative will equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international clinical and public health research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their institutions, governments and international research organizations. To accomplish this goal, this FOA will support innovative LMIC masters level research ethics education programs proposing integrated activities to develop curriculum, courses for skills development, including practicum experiences, and creative mentoring approaches.</p>			
081350	<a href="#">International Bioethics Research Training Program (D43 Clinical Trial Optional)</a>	Fogarty International Center/NIH/DHHS	PAR-19-243	04-Jun-2020	1,150,000 USD
	Contact Name	Barbara Sina, Ph.D.			
	Contact Telephone	301-402-9467			
	Contact Email	<a href="mailto:sinab@mail.nih.gov">sinab@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	04-Jun-2020 , 04-Jun-2021			
	Synopsis	The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare multiple individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary study to an existing trial; or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

079769	<a href="#">Biology of Bladder Cancer (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-184	05-Jun-2020	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Ron Johnson, Ph. D.
Contact Telephone	240-276-6250
Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022
Synopsis	This Funding Opportunity Announcement (FOA) seeks applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

079767	<a href="#">Biology of Bladder Cancer (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-183	05-Jun-2020	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Ron Johnson, Ph. D.
Contact Telephone	240-276-6250
Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>
Sponsor Website	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.</p>				
070100	<a href="#">NCI Transition Career Development Award (K22 Independent Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-18-466	12-Jun-2020	450,000 USD
	<p>Contact Name Sonia Jakowlew, Ph.D., Program Director</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) provides support to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This program will use the NIH K22 Career Transition Award mechanism.</p>				
065399	<a href="#">The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01)</a>	National Cancer Institute/NIH/DHHS	PA-17-440	05-Jun-2020	Not Specified
	<p>Contact Name Konstantin Salnikow, Ph.D</p> <p>Contact Telephone 240-276-6230</p> <p>Contact Email <a href="mailto:salnikok@mail.nih.gov">salnikok@mail.nih.gov</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
064201	<a href="#">Integration of Individual Residential Histories into Cancer Research (R01)</a>	National Cancer Institute/NIH/DHHS	PA-17-298	05-Jun-2020	Not Specified
	<p>Contact Name Zaria Tatalovich, Ph.D.</p> <p>Contact Telephone 240-276-6976</p> <p>Contact Email <a href="mailto:tatalovichzp@mail.nih.gov">tatalovichzp@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020</p> <p>Synopsis National Cancer Institute (NCI) invites applications for substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
062723	<a href="#">Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21)</a>	National Cancer Institute/NIH/DHHS	PA-17-288	16-Jun-2020	275,000 USD
	<p>Contact Name Kathleen Cronin</p> <p>Contact Telephone 240-276-6836</p> <p>Contact Email <a href="mailto:cronink@mail.nih.gov">cronink@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	16-Jun-2020			
	Synopsis	National Cancer Institute (NCI) invites applications to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.			
070181	<a href="#">Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-18-492	16-Jun-2020	275,000 USD
	Contact Name	Gurvaneet S. Randhawa, M.D., MPH			
	Contact Telephone	240-276-6940			
	Contact Email	<a href="mailto:gurvaneet.randhawa@nih.gov">gurvaneet.randhawa@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021			
	Synopsis	National Cancer Institute (NCI) invites applications to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
070179	<a href="#">Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-18-493	05-Jun-2020	Not Specified
	Contact Name	Gurvaneet S. Randhawa, M.D., MPH			
	Contact Telephone	240-276-6940			
	Contact Email	<a href="mailto:gurvaneet.randhawa@nih.gov">gurvaneet.randhawa@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Cancer Institute (NCI) invites applications to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models. This FOA will use the NIH Research Project (R01) award mechanism.			
069612	<a href="#">NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)</a>	National Cancer Institute/NIH/DHHS	PAR-18-366	12-Jun-2020	450,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.			
	Contact Telephone	240-276-6553			
	Contact Email	<a href="mailto:abigail.soyombo@nih.gov">abigail.soyombo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020			
	Synopsis	National Cancer Institute (NCI) invites applications for the National Cancer Institute (NCI) Career Transition Award. The purpose of the award is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) ( <a href="http://crchd.cancer.gov/">http://crchd.cancer.gov/</a> ) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. This program will use the NIH Transition Career Development Award (K22) mechanism.			
069610	<a href="#">NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-18-367	12-Jun-2020	450,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.			
	Contact Telephone	240-276-6553			
	Contact Email	<a href="mailto:abigail.soyombo@nih.gov">abigail.soyombo@nih.gov</a>			
	Sponsor Website				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
069282	<a href="#">NCI Mentored Research Scientist Development Award to Promote Diversity (Parent K01 - Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-18-365	12-Jun-2020	650,000 USD

Program URL [Link to program URL](#)

Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020

Synopsis National Cancer Institute (NCI) invites applications for the National Cancer Institute (NCI) Career Transition Award. The purpose of the award is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) (<http://crchd.cancer.gov/>) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This program will use the NIH Transition Career Development Award (K22) mechanism.

Contact Name Abigail Soyombo, Ph.D., M.B.A.

Contact Telephone 240-276-6553

Contact Email [Abigail.Soyombo@mail.nih.gov](mailto:Abigail.Soyombo@mail.nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020

Synopsis National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the NIH Mentored Research Scientist Development Award (K01) mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
067236	<a href="#">Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-17-495	05-Jun-2020	Not Specified
	Contact Name	Erica S. Breslau, Ph.D., M.P.H.,			
	Contact Telephone	240-276-6773			
	Contact Email	<a href="mailto:breslaue@mail.nih.gov">breslaue@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	National Cancer Institute (NCI) invites applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels. This FOA will use the NIH Research Project (R01) award mechanism.			
073410	<a href="#">Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-18-739	16-Jun-2020	275,000 USD
	Contact Name	Gabriela Riscuta MD, CNS, MS			
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
072031	<a href="#">Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-18-655	18-Jun-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Jennifer Isaacs, Ph.D.</p> <p>Contact Telephone   240-276-6251</p> <p>Contact Email   <a href="mailto:jennifer.isaacs@nih.gov">jennifer.isaacs@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   18-Jun-2020 , 19-Nov-2020</p> <p>Synopsis   National Cancer Institute (NCI) invites applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. This FOA will use the NIH R21 Exploratory/Developmental Research award mechanism.</p>				
073406	<a href="#">Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-18-738	05-Jun-2020	Not Specified

	<p>Contact Name   Gabriela Riscuta MD, CNS, MS</p> <p>Contact Telephone  </p> <p>Contact Email  </p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
--	--	--	--	--	--

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
072357	<a href="#">U.S. Tobacco Control Policies to Reduce Health Disparities (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-674	15-Jun-2020	275,000 USD
	Contact Name	Bob Vollinger, MSPH			
	Contact Telephone	240-276-6919			
	Contact Email	<a href="mailto:Bob.Vollinger@nih.gov">Bob.Vollinger@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that applications align with NIH mission priorities in health economics research. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
072358	<a href="#">U.S. Tobacco Control Policies to Reduce Health Disparities (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-675	15-Jun-2020	Not Specified
	Contact Name	Bob Vollinger, MSPH			
	Contact Telephone	240-276-6919			
	Contact Email	<a href="mailto:Bob.Vollinger@nih.gov">Bob.Vollinger@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that applications align with NIH mission priorities in health economics research. This FOA will use the NIH R01</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Research Project Grant award mechanism.

072029	<a href="#">Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-18-654	18-Jun-2020	Not Specified
	Contact Name	Jennifer Isaacs, Ph.D.			
	Contact Telephone	240-276-6251			
	Contact Email	<a href="mailto:jennifer.isaacs@nih.gov">jennifer.isaacs@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jun-2020 , 19-Nov-2020			
	Synopsis	National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.			
076806	<a href="#">Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-892	07-May-2020	275,000 USD
	Contact Name	Frank M. Perna, Ed.D., Ph.D.			
	Contact Telephone	240-276-6782			
	Contact Email	<a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
076909	<a href="#">Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-18-902	07-May-2020	Not Specified

Contact Name	Gabriela Riscuta, MD, CNS
Contact Telephone	240-276-7118
Contact Email	<a href="mailto:gabriela.riscuta@nih.gov">gabriela.riscuta@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. The purpose of this funding opportunity announcement (FOA) is twofold: 1) to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2) to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA will use the NIH Research Project (R01) award mechanism.

080575	<a href="#">RFA-CA-19-034 -- Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-034	20-May-2020 [Optional][LOI/Pre-App]	800,000 USD
Contact Name	Tiffany Wallace, Ph.D.				
Contact Telephone	240-276-5114				
Contact Email	<a href="mailto:wallaceti@mail.nih.gov">wallaceti@mail.nih.gov</a>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-May-2020 [Optional][LOI/Pre-App], 19-Jun-2020 , 18-Sep-2020 [Optional][LOI/Pre-App], 18-Oct-2020			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees</p>			
076805	<a href="#">Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-893	07-May-2020	Not Specified
	Contact Name	Frank M. Perna, Ed.D., Ph.D.			
	Contact Telephone	240-276-6782			
	Contact Email	<a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs),</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R01 Research Project Grant award mechanism.

076579	<a href="#">Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PA-18-876	07-May-2020	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	Dr. Roberto Flores
Contact Telephone	240-276-7119
Contact Email	<a href="mailto:floresr2@mail.nih.gov">floresr2@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.

075883	<a href="#">Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-841	15-Jun-2020	2,500,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Huiming Zhang, Ph.D.
Contact Telephone	240-276-5979
Contact Email	<a href="mailto:zhanghui@mail.nih.gov">zhanghui@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2020 , 17-Nov-2020 , 14-Jun-2021
Synopsis	National Cancer Institute (NCI) invites applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients' malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource. This FOA will use the NIH U24 Resource-Related Research Projects – Cooperative Agreements award mechanism.

084813	<a href="#">Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-339	10-Jun-2020	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Todd S Horowitz, Ph.D
Contact Telephone	240-276-6963
Contact Email	<a href="mailto:todd.horowitz@mail.nih.gov">todd.horowitz@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-Jun-2020 , 14-Oct-2020 , 09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022
Synopsis	This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.

084812	<a href="#">Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-340	10-Jun-2020	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Todd S Horowitz, Ph.D
Contact Telephone	240-276-6963
Contact Email	<a href="mailto:todd.horowitz@mail.nih.gov">todd.horowitz@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-Jun-2020 , 14-Oct-2020 , 09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022
Synopsis	This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085275	<a href="#">Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-355	16-Jun-2020	275,000 USD
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN			
	Contact Telephone	240-276-7621			
	Contact Email	<a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes			
085282	<a href="#">NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-356	19-Jun-2020	275,000 USD
	Contact Name	William C. Timmer, Ph.D			
	Contact Telephone	240-276-6130			
	Contact Email	<a href="mailto:william.timmer@nih.gov">william.timmer@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	19-Jun-2020 , 20-Jul-2020 , 20-Oct-2020 , 18-Dec-2020 , 19-Feb-2021 , 19-Mar-2021 , 21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021 , 17-Dec-2021 , 22-Feb-2022 , 21-Mar-2022 , 21-Jun-2022 , 20-Jul-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| research (pre-clinical or clinical).

085257	<a href="#">Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-352	05-Jun-2020	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Michelle Mollica, PhD, MPH, RN, OCN
Contact Telephone	240-276-7621
Contact Email	<a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022
Synopsis	This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

085337	<a href="#">Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-358	16-Jun-2020	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Sarah Kobrin, Ph.D., MPH
Contact Telephone	240-276-6931
Contact Email	<a href="mailto:kobrins@mail.nih.gov">kobrins@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022
Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

085343	<a href="#">Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-359	16-Jun-2020	100,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name | Sarah Kobrin, Ph.D., MPH

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6931</p> <p>Contact Email <a href="mailto:kobrins@mail.nih.gov">kobrins@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p>				
085330	<a href="#">Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-360	05-Jun-2020	Not Specified
	<p>Contact Name Sarah Kobrin, Ph.D., MPH</p> <p>Contact Telephone 240-276-6931</p> <p>Contact Email <a href="mailto:kobrins@mail.nih.gov">kobrins@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p>				
084510	<a href="#">RFA-CA-19-045 -- Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-045	30-Jun-2020 [Optional][LOI/Pre-App]	12,500,000 USD
	<p>Contact Name Leah E. Mechanic, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-6847</p> <p>Contact Email <a href="mailto:NCI_PEACS@mail.nih.gov">NCI_PEACS@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 30-Jul-2020			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement". The National Cancer Institute (NCI) intends to support the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network, which will include: Several U2C Research Centers (to be supported under this FOA); and One U24 Coordinating Center (to be supported under companion RFA-CA-19-046). The overall purpose of the PE-CGS Network is twofold: To promote and support direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research; and To use such approaches for rigorous cancer genome sequencing programs addressing important knowledge gaps in the genomic characterizations of tumors in areas such as, but not limited to: Rare cancers or rare cancer subsets; Highly lethal cancers; Cancers with an early age of onset; Cancers with high disparities in incidence and/or mortality; or Cancers in understudied populations. In addition to conducting a Center-specific research program, PE-CGS U2C Research Centers will be expected to operate as a collaborative network. Various trans-network activities will be facilitated by the PE-CGS Network Coordinating Center (U24).</p>			
085422	<a href="#">Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-19-363	07-May-2020	499,999 USD
	Contact Name	Anne Menkens, Ph.D.			
	Contact Telephone	240-276-6510			
	Contact Email	<a href="mailto:menkensa@mail.nih.gov">menkensa@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
085441	<a href="#">RFA-CA-19-051 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U54 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-051	24-May-2020 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name	Laurence (Austin) Doyle, MD			
	Contact Telephone	240-276-6112			
	Contact Email	<a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 22-Sep-2020 [Optional][LOI/Pre-App], 22-Oct-2020 , 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U54 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.			
085440	<a href="#">RFA-CA-19-050 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-050	24-May-2020 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name	Laurence (Austin) Doyle, MD			
	Contact Telephone	240-276-6112			
	Contact Email	<a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 22-Sep-2020 [Optional][LOI/Pre-App], 22-Oct-2020 , 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.			
085445	<a href="#">RFA-CA-19-053 -- Revision Applications for Mechanisms of Cancer Drug Resistance (P50 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-053	24-May-2020 [Optional][LOI/Pre-App]	750,000 USD
	Contact Name	Laurence (Austin) Doyle, MD			
	Contact Telephone	240-276-6112			
	Contact Email	<a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 24-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 22-Sep-2020 [Optional][LOI/Pre-App], 22-Oct-2020 , 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P50 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p>				
077667	<a href="#">Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-18-932	07-May-2020	Not Specified
	<p>Contact Name Erica S. Breslau, PhD, MPH</p> <p>Contact Telephone 240-276-6773</p> <p>Contact Email <a href="mailto:breslaue@mail.nih.gov">breslaue@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
085437	<a href="#">RFA-CA-19-049 -- Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-049	24-May-2020 [Optional][LOI/Pre-App]	750,000 USD
	<p>Contact Name Laurence (Austin) Doyle, MD</p> <p>Contact Telephone 240-276-6112</p> <p>Contact Email <a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 24-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 22-Sep-2020 [Optional][LOI/Pre-App], 22-Oct-2020 , 23-May-2021</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				[Optional][LOI/Pre-App], 23-Jun-2021	
	Synopsis	This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.			
085717	<a href="#">RFA-CA-19-042 -- Informatics Technology for Cancer Research Education Resource (UE5 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-042	30-Jun-2020 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name	Elizabeth Hsu, Ph.D., M.P.H.			
	Contact Telephone	240-276-5733			
	Contact Email	<a href="mailto:hsuel@mail.nih.gov">hsuel@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 31-Jul-2020			
	Synopsis	This UE5 FOA is a part of the NCI's Informatics Technology for Cancer Research (ITCR) program ( <a href="https://itcr.cancer.gov/">https://itcr.cancer.gov/</a> ). The UE5 awardee to be supported under this FOA will serve as an ITCR Education Resource for educational activities that will help their participants to enhance the use and usability of the informatics tools and other resources developed and supported by the ITCR program.			
086150	<a href="#">Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-389	16-Jun-2020	400,000 USD
	Contact Name	Todd S. Horowitz, Ph.D.			
	Contact Telephone	240-276-6963			
	Contact Email	<a href="mailto:todd.horowitz@nih.gov">todd.horowitz@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.			
086149	<a href="#">Perception and Cognition Research to Inform Cancer Image Interpretation (R01)</a>	National Cancer	PAR-19-	05-Jun-2020	Not



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Clinical Trial Optional</a>		Institute/NIH/DHHS	387	Specified
	Contact Name	Todd S. Horowitz, Ph.D.			
	Contact Telephone	240-276-6963			
	Contact Email	<a href="mailto:todd.horowitz@nih.gov">todd.horowitz@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.			
070402	<a href="#">Early-life Factors and Cancer Development Later in Life (R01 - Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PA-18-529	07-May-2020	Not Specified
	Contact Name	Somdat Mahabir, Ph.D., M.PH			
	Contact Telephone	240-276-6941			
	Contact Email	<a href="mailto:mahabir@mail.nih.gov">mahabir@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention. This FOA will use the NIH Research Project (R01) award mechanism.			
072438	<a href="#">Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility</a>	National Cancer	PA-18-	16-Jun-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">(R21 Clinical Trial Not Allowed)</a>		Institute/NIH/DHHS	678	
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	<a href="mailto:Tram.Lam@nih.gov">Tram.Lam@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021			
	Synopsis	National Cancer Institute (NCI) invites applications for epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.			
072431	<a href="#">Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PA-18-677	05-Jun-2020	Not Specified
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	<a href="mailto:Tram.Lam@nih.gov">Tram.Lam@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021			
	Synopsis	National Cancer Institute (NCI) invites applications for epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. This FOA will use the NIH Research Project (R01) award mechanism.			
070405	<a href="#">Early-life Factors and Cancer Development Later in Life (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PA-18-532	07-May-2020	275,000 USD
	Contact Name	Somdat Mahabir, Ph.D., M.PH			
	Contact Telephone	240-276-6941			
	Contact Email	<a href="mailto:mahabir@mail.nih.gov">mahabir@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
086487	<a href="#">Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-20-034	05-Jun-2020	Not Specified
	<p>Contact Name Rebecca A Ferrer, Ph.D.</p> <p>Contact Telephone 240-276-6963</p> <p>Contact Email <a href="mailto:ferrerra@mail.nih.gov">ferrerra@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.</p>				
064234	<a href="#">Integration of Individual Residential Histories into Cancer Research (R21)</a>	National Cancer Institute/NIH/DHHS	PA-17-295	16-Jun-2020	275,000 USD
	Contact Name Zaria Tatalovich, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-276-6976</p> <p>Contact Email   <a href="mailto:tatalovichzp@mail.nih.gov">tatalovichzp@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2020</p> <p>Synopsis   National Cancer Institute (NCI) invites applications for substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
082219	<a href="#">Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-277	08-Jun-2020	275,000 USD
	<p>Contact Name   Dr. Mukesh Verma, Ph.D.</p> <p>Contact Telephone   240-276-6889</p> <p>Contact Email   <a href="mailto:vermam@mail.nih.gov">vermam@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jun-2020 , 08-Oct-2020 , 08-Jun-2021 , 08-Oct-2021</p> <p>Synopsis   This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations.</p>				
085444	<a href="#">RFA-CA-19-052 -- Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-19-052	24-May-2020 [Optional][LOI/Pre-App]	750,000 USD
	<p>Contact Name   Laurence (Austin) Doyle, MD</p> <p>Contact Telephone   240-276-6112</p> <p>Contact Email   <a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   24-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 22-Sep-2020 [Optional][LOI/Pre-App], 22-Oct-2020 , 23-May-2021</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Optional][LOI/Pre-App], 23-Jun-2021

Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.

079067	<a href="#">Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-19-112	05-Jun-2020	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name Nonniekaye Shelburne, MS, CRNP, AOCN

Contact Telephone 240-276-6897

Contact Email [nshelburne@mail.nih.gov](mailto:nshelburne@mail.nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021

Synopsis This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).

062707	<a href="#">Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)</a>	National Cancer Institute/NIH/DHHS	PA-17-289	05-Jun-2020	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name Kathleen Cronin

Contact Telephone 240-276-6836

Contact Email [cronink@mail.nih.gov](mailto:cronink@mail.nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 05-Jun-2020

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Synopsis National Cancer Institute (NCI) invites applications to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. Specifically, this FOA will support the study of factors influencing observed health disparities within the framework of population-based cancer registries by the inclusion of data not routinely collected by or linked to the registries. The studies should be hypothesis-driven and multidisciplinary approaches are encouraged. Investigators are encouraged to leverage the data already collected by the registries to investigate the determinates of health disparities. The goal of these analyses will be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
065402	<a href="#">The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)</a>	National Cancer Institute/NIH/DHHS	PA-17-449	16-Jun-2020	275,000 USD

Contact Name Konstantin Salnikow, Ph.D  
Contact Telephone 240-276-6230  
Contact Email [salnikok@mail.nih.gov](mailto:salnikok@mail.nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 16-Jun-2020

Synopsis National Cancer Institute (NCI) invites applications for research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

079333	<a href="#">Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-150	07-May-2020	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name Miguel R. Ossandon, Ph.D.  
Contact Telephone 240-276-5714  
Contact Email [ossandom@mail.nih.gov](mailto:ossandom@mail.nih.gov)  
Sponsor Website

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</p>				
064983	<a href="#">Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)</a>	National Cancer Institute/NIH/DHHS	PAR-17-331	07-May-2020	Not Specified
	<p>Contact Name Sundar Venkatachalam, Ph.D.</p> <p>Contact Telephone 240-276-7304</p> <p>Contact Email <a href="mailto:sundarv@nih.gov">sundarv@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020</p> <p>Synopsis National Cancer Institute (NCI) offers this funding opportunity with the purpose of promoting the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079076	<a href="#">Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-19-111	16-Jun-2020	275,000 USD
	<p>Contact Name Nonniekaye Shelburne, MS, CRNP, AOCN</p> <p>Contact Telephone 240-276-6897</p> <p>Contact Email <a href="mailto:nshelburne@mail.nih.gov">nshelburne@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).			
079335	<a href="#">Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-19-149	07-May-2020	275,000 USD
	Contact Name	Miguel R. Ossandon, Ph.D.			
	Contact Telephone	240-276-5714			
	Contact Email	<a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.			
087229	<a href="#">Co-infection and Cancer (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-20-061	16-Jun-2020	275,000 USD
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	<a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	(pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.				
087228	<a href="#">Co-infection and Cancer (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-20-062	05-Jun-2020	Not Specified
	<p>Contact Name   Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone   240-276-6967</p> <p>Contact Email   <a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment</p>				
075930	<a href="#">Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-18-845	27-Jun-2020	Not Specified
	<p>Contact Name   Ron Johnson, PhD</p> <p>Contact Telephone   240-276-6228</p> <p>Contact Email   <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Jun-2020 , 15-Oct-2020 , 15-Jun-2021</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
075939	<a href="#">Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied</a>	National Cancer	PAR-18-	27-Jun-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Prevention Research (R21 - Clinical Trial Optional)</a>		Institute/NIH/DHHS	848	
	Contact Name	Rachel Grana Mayne, PhD, MPH			
	Contact Telephone	240-276-5899			
	Contact Email	<a href="mailto:rachel.mayne@nih.gov">rachel.mayne@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Jun-2020 , 26-Oct-2020 , 25-Jun-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. This FOA will use the NIH R21 Exploratory/Developmental Research Grantaward mechanism.			
075934	<a href="#">Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 - Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-847	27-Jun-2020	Not Specified
	Contact Name	Rachel Grana Mayne, PhD, MPH			
	Contact Telephone	240-276-5899			
	Contact Email	<a href="mailto:rachel.mayne@nih.gov">rachel.mayne@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Jun-2020 , 26-Oct-2020 , 25-Jun-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. This FOA will use the NIH R01 Research Project Grant award mechanism.			
075931	<a href="#">Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-18-846	27-Jun-2020	275,000 USD
	Contact Name	Ron Johnson, PhD			
	Contact Telephone	240-276-6228			
	Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Jun-2020 , 26-Oct-2020 , 25-Jun-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
088454	<a href="#">RFA-CA-20-010 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-010	10-May-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	301-480-5778			
	Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.			
088452	<a href="#">RFA-CA-20-009 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-009	10-May-2020 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	301-480-5778			
	Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.</p>			
088448	<a href="#">RFA-CA-20-008 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-008	10-May-2020 [Optional][LOI/Pre-App]	900,000 USD
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	301-480-5778			
	Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

088443	<a href="#">RFA-CA-20-007 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-007	10-May-2020 [Optional][LOI/Pre-App]	275,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	301-480-5778
Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs.

088463	<a href="#">RFA-CA-20-012 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-012	10-May-2020 [Optional][LOI/Pre-App]	200,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Juli Klemm, Ph.D.
Contact Telephone	301-480-5778
Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.			
088457	<a href="#">RFA-CA-20-011 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-011	10-May-2020 [Optional][LOI/Pre-App]	200,000 USD
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	301-480-5778			
	Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.			
088464	<a href="#">RFA-CA-20-013 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-013	10-May-2020 [Optional][LOI/Pre-App]	200,000 USD
	Contact Name	Juli Klemm, Ph.D.			
	Contact Telephone	301-480-5778			
	Contact Email	<a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	10-May-2020 [Optional][LOI/Pre-App], 09-Jun-2020 , 19-Oct-2020 [Optional][LOI/Pre-App], 18-Nov-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U24 resource-related research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.			
081348	<a href="#">Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-242	17-Jun-2020	Not Specified
	Contact Name	Mark Damico, Ph.D., Program Director			
	Contact Telephone	240-276-5630			
	Contact Email	<a href="mailto:damicomw@mail.nih.gov">damicomw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jun-2020 , 17-Jun-2021			
	Synopsis	The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.			
080274	<a href="#">Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-19-198	10-Jun-2020	Not Specified
	Contact Name	Young S. Kim, PhD			
	Contact Telephone	240-276-7115			
	Contact Email	<a href="mailto:yk47s@nih.gov">yk47s@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2020 , 06-Nov-2020 , 10-Jun-2021 , 08-Nov-2021			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.			
080277	<a href="#">Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-19-199	10-Jun-2020	275,000 USD
	Contact Name	Young S. Kim, PhD			
	Contact Telephone	240-276-7115			
	Contact Email	<a href="mailto:yk47s@nih.gov">yk47s@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2020 , 06-Nov-2020 , 10-Jun-2021 , 08-Nov-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.			
082215	<a href="#">Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-275	07-May-2020	275,000 USD
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
082216	<a href="#">Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-19-276	07-May-2020	50,000 USD
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.			
082214	<a href="#">Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-274	07-May-2020	Not Specified
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.			
065701	<a href="#">Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-17-274	16-Jun-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Allowed</a>		Institute/NIH/DHHS	460	
	Contact Name	Ron Johnson, Ph. D.			
	Contact Telephone	240 276 6250			
	Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	<p>National Cancer Institute (NCI) invites applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>			
065699	<a href="#">Biology of Lung, and Head and Neck Preneoplasias (R01 - Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PA-17-459	05-Jun-2020	Not Specified
	Contact Name	Ron Johnson, Ph. D.			
	Contact Telephone	240 276 6250			
	Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	<p>National Cancer Institute (NCI) invites applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies. This FOA will use the NIH Research Project (R01) award mechanism.</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
065733	<a href="#">Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PA-17-460	16-Jun-2020	275,000 USD
	Contact Name	Ron Johnson, Ph. D.			
	Contact Telephone	240 276 6250			
	Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	National Cancer Institute (NCI) invites applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.			
064981	<a href="#">Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)</a>	National Cancer Institute/NIH/DHHS	PA-17-330	07-May-2020	Not Specified
	Contact Name	R. Allan Mufson, Ph.D.			
	Contact Telephone	240-276-6231			
	Contact Email	<a href="mailto:am214t@nih.gov">am214t@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	National Cancer Institute (NCI) offers this funding opportunity with the purpose of stimulating research on the identification of new and novel targets and mechanisms involved in tumor immune evasion, that may be amenable to analysis by small molecule or molecular genetics approaches. This FOA will use the NIH Research Project (R01) award mechanism.			
070783	<a href="#">Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-18-559	07-May-2020	Not Specified
	Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-7048</p> <p>Contact Email <a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences as based on their scientific missions. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
083680	<a href="#">Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-309	07-May-2020	275,000 USD
	<p>Contact Name Tanya Agurs-Collins, Ph.D</p> <p>Contact Telephone 240-276-6956</p> <p>Contact Email <a href="mailto:collinsta@mail.nih.gov">collinsta@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.</p>				
090364	<a href="#">Research Projects to Enhance Applicability of Mammalian Models for</a>	National Cancer	PAR-20-	05-Jun-2020	1,350,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Translational Research (R01 Clinical Trial Not Allowed)</a>	Institute/NIH/DHHS	131		USD
	Contact Name	Joanna Watson, Ph.D.			
	Contact Telephone	240-276-6230			
	Contact Email	<a href="mailto:Joanna.Watson@nih.gov">Joanna.Watson@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>			
068218	<a href="#">NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 No Independent Clinical Trials)</a>	National Cancer Institute/NIH/DHHS	PAR-18-337	12-Jun-2020	Not Specified
	Contact Name	John O. Ojeifo, MD, PhD, MBA.			
	Contact Telephone	240-276-6186			
	Contact Email	<a href="mailto:ojeifojo@mail.nih.gov">ojeifojo@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for the NCI Mentored Clinical Scientist Research Career Development Awards (K08). The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K08 Clinical Investigator Award (CIA) mechanism.</p>				
069273	<a href="#">NCI Mentored Research Scientist Development Award to Promote Diversity (Parent K01 -Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-18-364	12-Jun-2020	650,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.			
	Contact Telephone	240-276-6553			
	Contact Email	<a href="mailto:Abigail.Soyombo@mail.nih.gov">Abigail.Soyombo@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH Mentored Research Scientist Development Award (K01) mechanism.</p>			
070784	<a href="#">National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-18-560	07-May-2020	2,499,995 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Lori A. Henderson, Ph.D.</p> <p>Contact Telephone   240-276-5930</p> <p>Contact Email   <a href="mailto:hendersonlori@mail.nih.gov">hendersonlori@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis   National Cancer Institute (NCI) invites applications for research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD). Applicants are strongly encouraged to consult the NCI DCTD website at <a href="https://dctd.cancer.gov/">https://dctd.cancer.gov/</a> to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
070114	<a href="#">NCI Transition Career Development Award (K22 Independent Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-18-467	12-Jun-2020	450,000 USD
	<p>Contact Name   Sonia Jakowlew, Ph.D., Program Director</p> <p>Contact Telephone   240-276-5630</p> <p>Contact Email   <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021</p> <p>Synopsis   National Cancer Institute (NCI) provides support to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. This program will use the NIH K22 Career Transition Award mechanism.</p>				
068190	<a href="#">NCI Mentored Clinical Scientist Research Career Development Award to Promote</a>	National Cancer	PAR-18-	12-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Diversity (K08 Clinical Trial Required)</a>	Institute/NIH/DHHS	336		Specified
	<p>Contact Name   John O. Ojeifo, MD, PhD, MBA.</p> <p>Contact Telephone   240-276-6186</p> <p>Contact Email   <a href="mailto:ojeifojo@mail.nih.gov">ojeifojo@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2020 , 12-Oct-2020</p> <p>Synopsis   National Cancer Institute (NCI) invites applications for the NCI Mentored Clinical Scientist Research Career Development Awards (K08). The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the NIH K08 Clinical Investigator Award (CIA) mechanism.</p>				
084969	<a href="#">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-350	10-Jun-2020	275,000 USD
	<p>Contact Name   Kelly D. Blake, ScD</p> <p>Contact Telephone   240-281-5934</p> <p>Contact Email   <a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   10-Jun-2020 , 14-Oct-2020 , 09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022</p> <p>Synopsis   Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

084968	<a href="#">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-348	10-Jun-2020	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Kelly D. Blake, ScD
Contact Telephone	240-281-5934
Contact Email	<a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-Jun-2020 , 14-Oct-2020 , 09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022
Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

083834	<a href="#">RFA-OD-19-021 -- Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-OD-19-021	08-Jun-2020 [Optional][LOI/Pre-App]	275,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	-------------

Contact Name	Rachel Grana Mayne, PhD
Contact Telephone	240-276-5899
Contact Email	<a href="mailto:granar@nih.gov">granar@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Jun-2020 [Optional][LOI/Pre-App], 07-Aug-2020 , 07-Jan-2021 [Optional][LOI/Pre-App], 08-Mar-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

070406	<a href="#">Early-life Factors and Cancer Development Later in Life (R03 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PA-18-531	07-May-2020	100,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	Somdat Mahabir, Ph.D., M.PH
Contact Telephone	240-276-6941
Contact Email	<a href="mailto:mahabir@mail.nih.gov">mahabir@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention. This FOA will use the NIH R03 Small Grant Program award mechanism.			
092377	<a href="#">RFA-CA-20-030 -- Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (UG3/UH3 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-030	07-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Joanne Elena, Ph.D., M.P.H.,			
	Contact Telephone	240-276-6818			
	Contact Email	<a href="mailto:elenajw@mail.nih.gov">elenajw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jun-2020 [Optional][LOI/Pre-App], 07-Jul-2020			
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors (i.e., from diagnosis to the end of life). This FOA intends to support research that requires the creation of a new prospective cohort study that addresses a gap in knowledge pertaining to the health of cancer survivors. Applications must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and should include information from all the following five domains in order to cover the full extent of the cancer survivor experience: 1) disease characteristics (e.g., type, stage, tumor biomarkers), 2) individual survivor characteristics (e.g., comorbidities, socioeconomic status [SES], social connections, information seeking, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity, adherence) and 5) quality of life outcomes (health-related quality of life (HRQOL), patient symptom reports). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3/UH3 mechanism has two phases: the UG3 Planning-Exploratory Phase focused on the recruitment of study participants and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 phase should be proposed by the Principal Investigator(s) (PIs), which will require NCI review and approval before the grant is awarded , and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated to ensure that all aims will be completed in the UH3 phase.</p>			
086964	<a href="#">NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-20-052	07-May-2020	100,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 24-Jun-2020 , 07-Sep-2020 , 20-Oct-2020 , 07-Jan-2021 , 24-Feb-2021 , 07-May-2021 , 24-Jun-2021 , 07-Sep-2021 , 20-Oct-2021 , 07-Jan-2022 , 24-Feb-2022 , 07-May-2022 , 24-Jun-2022 , 07-Sep-2022 , 20-Oct-2022 , 07-Jan-2023			
	Synopsis	This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.			
079077	<a href="#">Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-113	05-Jun-2020	2,000,000 USD
	Contact Name	Nastaran Z. Kuhn, Ph.D.			
	Contact Telephone	240-276-7610			
	Contact Email	<a href="mailto:nas.zahir@nih.gov">nas.zahir@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.			
087000	<a href="#">Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-20-053	05-Jun-2020	Not Specified
	Contact Name	Sudhir Srivastava, Ph.D., M.P.H.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-7028</p> <p>Contact Email <a href="mailto:srivasts@mail.nih.gov">srivasts@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.</p>				
067401	<a href="#">Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-307	07-May-2020	1,025,000 USD
	<p>Contact Name Frank Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email <a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. This program will use the NIH R21/R33 Phased Innovation Award award mechanism.</p>				
067494	<a href="#">Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-324	07-May-2020	Not Specified
	<p>Contact Name Frank Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email <a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021

Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This program will use the NIH R01 Research Project Grant award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
070540	<a href="#">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-18-530	07-May-2020	Not Specified

Contact Name Miguel Ossandon MS

Contact Telephone 240-276-5714

Contact Email [ossandom@mail.nih.gov](mailto:ossandom@mail.nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021

Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.			
092626	<a href="#">RFA-CA-20-031 -- Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-031	07-May-2020	1,250,000 USD
	Contact Name	Sudha Sivaram, DrPH, MPH			
	Contact Telephone	240-276-5804			
	Contact Email	<a href="mailto:nciglobaltraining@nih.gov">nciglobaltraining@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the United States (U.S.)-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.			
080324	<a href="#">Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PA-19-201	16-Jun-2020	275,000 USD
	Contact Name	Inna Belfer, M.D., Ph.D.			
	Contact Telephone	301-435-1573			
	Contact Email	<a href="mailto:inna.belfer@nih.gov">inna.belfer@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.			
080314	<a href="#">Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PA-19-200	05-Jun-2020	Not Specified
	Contact Name	Inna Belfer, M.D., Ph.D.			
	Contact Telephone	301-435-1573			
	Contact Email	<a href="mailto:inna.belfer@nih.gov">inna.belfer@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022			
	Synopsis	The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.			
068460	<a href="#">NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18-118	01-Jun-2020	Not Specified
	Contact Name	Lanay Mudd, PhD			
	Contact Telephone	301-594-9346			
	Contact Email	<a href="mailto:lanay.mudd@mail.nih.gov">lanay.mudd@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020 , 29-Jun-2020			
	Synopsis	National Center for Complementary and Integrative Health (NCCIH) invites cooperative agreement applications for			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		investigator-initiated clinical trials of mind and body interventions in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a clinical trial to develop and test adaptive interventions; optimize the intervention by evaluating which element of a complex intervention are critical for changes in outcome; assessing whether the intervention can be delivered with fidelity across sites in preparation for a future multi-site trial; or collect additional preliminary data such as determining the duration or frequency of the intervention to be used in a future multi-site trial. It is important, therefore, to already have sufficient preliminary data that includes: demonstration of feasibility of recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; and evidence that the intervention has promise of clinical benefit. This FOA is not intended to support multi-site efficacy or effectiveness trials, nor will it support trials to test mind and body interventions for the treatment or prevention of cancer. This FOA will use the NIH U01 Research Project – Cooperative Agreements award mechanism.			
072237	<a href="#">Mind and Body Intervention Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18-663	01-Jun-2020	Not Specified
	Contact Name	Robin Boineau, M.D., M.A.			
	Contact Telephone	301-435-6286			
	Contact Email	<a href="mailto:Robin.Boineau@nih.gov">Robin.Boineau@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020 , 29-Jun-2020			
	Synopsis	National Center for Complementary and Integrative Health (NCCIH) invites applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-18-662 The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: ( <a href="http://www.nccih.nih.gov">http://www.nccih.nih.gov</a> ). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA. This FOA will use the NIH U24 Resource-Related Research Projects – Cooperative Agreements award mechanism.			
072236	<a href="#">Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18-662	01-Jun-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Clinical Trial Required](#)

Contact Name Robin Boineau, M.D., M.A.  
 Contact Telephone 301-435-6286  
 Contact Email [Robin.Boineau@nih.gov](mailto:Robin.Boineau@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 01-Jun-2020 , 29-Jun-2020

Synopsis National Center for Complementary and Integrative Health (NCCIH) invites applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of mind and body interventions in NCCIH designated areas of high research priority. Clinical Coordinating Centers should develop and implement the proposed multi-site clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-18-663 proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (<https://nccih.nih.gov/about/plans> ). This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

069919	<a href="#">Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-18-417	07-May-2020	450,000 USD
--------	--	---	------------	-------------	-------------

Contact Name Lanay M. Mudd, Ph.D.  
 Contact Telephone 301-594-9346  
 Contact Email [lanay.mudd@nih.gov](mailto:lanay.mudd@nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020

Synopsis National Center for Complementary and Integrative Health (NCCIH) invites applications for early phase clinical trials of mind and body approaches for conditions that have been identified by NCCIH as high priority research topics. This funding

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; examining acceptability of the intervention and control conditions. This FOA will not support randomized clinical trials to test or determine efficacy or effectiveness. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. The subsequent larger trial should have the potential to make a significant impact on public health. This FOA will use the NIH R34 Planning Grant award mechanism.

067448	<a href="#">Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18-323	07-May-2020	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Wen G. Chen, PhD
Contact Telephone	301-451-3989
Contact Email	<a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021
Synopsis	National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH Research Project (R01) award mechanism.

067449	<a href="#">Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18-322	07-May-2020	275,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Wen G. Chen, PhD
Contact Telephone	301-451-3989
Contact Email	<a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021
Synopsis	National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
091405	<a href="#">Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-154	05-Jun-2020	Not Specified
	Contact Name	Lanay Mudd, Ph.D			
	Contact Telephone	301-594-9346			
	Contact Email	<a href="mailto:lanay.mudd@mail.nih.gov">lanay.mudd@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications must have sufficient preliminary data that includes: demonstration of feasibility of remote recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety of the intervention; and evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>			
070268	<a href="#">Human Subjects Mechanistic and Minimal Risk Studies (R21 Clinical Trial Optional)</a>	National Eye Institute/NIH/DHHS	PA-18-500	07-May-2020	275,000 USD
	Contact Name	Ellen Liberman, Ph.D.			
	Contact Telephone	301-451-2020			
	Contact Email				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Eye Institute (NEI) invites applications that seek to conduct studies of the visual system. Applications that will be supported may be either: those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			

073294	<a href="#">NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)</a>	National Eye Institute/NIH/DHHS	PAR-18-726	11-Jun-2020	Not Specified
--------	--	---------------------------------	------------	-------------	---------------

	Contact Name	Neeraj Agarwal, Ph.D., Training Director			
	Contact Telephone	301-451-2020			
	Contact Email	<a href="mailto:agarwalnee@nei.nih.gov">agarwalnee@nei.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-Jun-2020			
	Synopsis	National Eye Institute (NEI) invites applications from institutions to propose creative and innovative institutional research career development programs which prepare clinically-trained vision scientists for independent research careers. This initiative is intended to expand and strengthen the community of investigators engaged in clinical research. Such an increase in the number of well-trained clinical researchers is necessary to achieve a pool of scientists with contemporary, multidisciplinary expertise able to leverage recent advances in ocular genetics, therapeutics, bioengineering, and bio-behavioral research in order to enhance patient treatment and to increase scientific momentum in these fields. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing a separate ancillary study to an existing trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for either a mechanistic or minimal risk trial. A mechanistic trial is designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. A proposed research career development program that includes a clinical trial that is not a mechanistic trial and/or involves a level of risk beyond that defined as minimal, will not be supported. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

FOA will utilize the Mentored Clinical Scientist Development Program Award (K12) grant mechanism.

090085	<a href="#">RFA-RM-20-010 -- Research Education Program Grants for CryoEM and CryoET Curriculum Development (R25 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	RFA-RM-20-010	25-Jun-2020 [Optional][LOI/Pre-App]	345,000 USD
--------	--	---------------------------------	---------------	-------------------------------------	-------------

Contact Name	Houmam Araj, Ph.D.
Contact Telephone	301-451-2020
Contact Email	<a href="mailto:arajh@nei.nih.gov">arajh@nei.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	25-Jun-2020 [Optional][LOI/Pre-App], 24-Jul-2020
Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this Common Fund R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in cryoelectron microscopy (cryoEM) and cryoelectron tomography (cryoET) for structural and cell biology research. Technical advances in cryoEM have resulted in its expanded use in generating reliable atomic models of complete and fully functional macromolecular complexes. An emerging related cryoEM method, cryoET, can image macromolecular assemblies in intact unstained frozen cells in three dimensions (3-D). Together, these methods enable high-resolution analysis of previously inaccessible levels of biological organization, ranging from below 100 kD to whole cells. Currently, demand for existing training opportunities exceeds capacity. Moreover, this demand is expected to rise as adoption of cryoEM and cryoET technology continues to increase. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on addressing instructional needs for new users of cryoEM and cryoET methods by supporting the development of online and computer-based instructional materials in these technologies.</p>

081084	<a href="#">NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-19-231	07-May-2020	300,000 USD
--------	---	---------------------------------	------------	-------------	-------------

Contact Name	Donald Everett, MA
Contact Telephone	301-451-2020
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.</p>				
081744	<a href="#">NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-19-260	07-May-2020	275,000 USD

Contact Name	Donald Everett, M.A.
Contact Telephone	301-451-2020
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022
Synopsis	This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
079552	<a href="#">Implementation of Shared Decision Making for HLBS Diseases and Conditions (R01 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-19-166	07-May-2020	2,499,995 USD
	Contact Name	Susan T. Shero, BSN, MS			
	Contact Telephone	301-496-1051			
	Contact Email	<a href="mailto:sheros@nih.gov">sheros@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this initiative is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lung, blood, and sleep (HLBS) diseases and conditions; and to address barriers and facilitators related to SDM strategies used to improve quality of care, adherence, and informed consent; reduce health disparities; and deliver treatments best suited for individual patients. Investigators and multidisciplinary research teams with expertise in clinical implementation research, health information technology, behavioral science, behavioral economics, workflow design, and organizational engineering are encouraged to apply.			
074657	<a href="#">The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-18-784	07-May-2020	Not Specified
	Contact Name	Lis Caler, Ph.D.			
	Contact Telephone	301-435-0222			
	Contact Email	<a href="mailto:lis.caler@mail.nih.gov">lis.caler@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Heart, Lung, and Blood Institute (NHLBI) invites applications for functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
072888	<a href="#">RFA-HL-19-016 -- Technologies for Healthy Independent Living for Heart, Lung, Blood and Sleep Disorders (R43 - Clinical Trial Not Allowed) (Temporarily Suspended)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-016	11-May-2020 [Optional][LOI/Pre-App]	225,000 USD
	Contact Name	Erin Iturriaga, RN, BS, MSN			
	Contact Telephone	301-435-0403			
	Contact Email	<a href="mailto:erin.iturriaga@nih.gov">erin.iturriaga@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-May-2020 [Optional][LOI/Pre-App], 10-Jun-2020			
	Synopsis	<p>National Heart, Lung, and Blood Institute (NHLBI) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) for for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. The development of such technologies should incorporate specific human factors for aging adults including disabilities, mild impairments, as well as chronic HLBS conditions. Technology usability for these populations must be incorporated early in the development of the design. Usability considerations include but are not limited to patient-facing displays, hearing and visual impairments, tactile limitations, literacy, and design preferences between men and women. These improvements in technology design could yield more accurate and earlier detection of changes that may interfere with healthy and independent living for older adults. This FOA will utilize the R43 Small Business Innovation Research (SBIR) Grant - Phase I mechanism.</p>			
072487	<a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18-683	04-Jun-2020	Not Specified
	Contact Name	Traci Heath Mondoro, Ph.D.			
	Contact Telephone	301-435-0065			
	Contact Email	<a href="mailto:xxxx@mail.nih.gov">xxxx@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-Jun-2020 , 07-Sep-2020 , 02-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Heart, Lung, and Blood Institute (NHLBI) invites applications for investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award award mechanism.</p>				
084638	<a href="#">Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-329	11-May-2020	Not Specified
	<p>Contact Name Nancy DiFronzo, PhD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email <a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2020 , 10-Jun-2020 , 09-Sep-2020 , 14-Oct-2020 , 14-Jan-2021 , 11-Feb-2021 , 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015) . For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC) ( PAR-19-330 ). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.</p>				
084637	<a href="#">Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial)</a>	National Heart, Lung, and Blood	PAR-19-	11-May-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<a href="#">Required</a>		Institute/NIH/DHHS	328		Specified
--------------------------	--	--------------------	-----	--	-----------

Contact Name	Nahed El Kassar, MD
Contact Telephone	301-435-0065
Contact Email	<a href="mailto:nahed.elkassar@nih.gov">nahed.elkassar@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	11-May-2020 , 10-Jun-2020 , 09-Sep-2020 , 14-Oct-2020 , 14-Jan-2021 , 11-Feb-2021 , 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022
Synopsis	This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.

085482	<a href="#">RFA-HL-20-024 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-024	11-May-2020	500,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Kathleen Rousche, Ph.D.
Contact Telephone	301-827-7981
Contact Email	<a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021
Synopsis	This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.			
085480	<a href="#">RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-022	11-May-2020	600,000 USD
	Contact Name	Margaret Ochocinska, PhD			
	Contact Telephone	301-827-8285			
	Contact Email	<a href="mailto:ochocinm@mail.nih.gov">ochocinm@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.			
085481	<a href="#">RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-023	11-May-2020	700,000 USD
	Contact Name	Kathleen Rousche, Ph.D.			
	Contact Telephone	301-827-7981			
	Contact Email	<a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>			
085485	<a href="#">RFA-HL-20-028 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-028	11-May-2020	500,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				
085483	<a href="#">RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-027	11-May-2020	700,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2020 , 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020 , 11-Aug-2020 , 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.				
086465	<a href="#">RFA-HL-20-029 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23 Recipients (R03 - Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-029	08-May-2020	100,000 USD
	Contact Name	Roya Kalantari, PhD			
	Contact Telephone	301-480-1989			
	Contact Email	<a href="mailto:roya.kalantari@nih.gov">roya.kalantari@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-May-2020 , 08-Jun-2020 , 09-Sep-2020 , 08-Oct-2020 , 08-Jan-2021 , 08-Feb-2021 , 10-May-2021 , 08-Jun-2021 , 08-Sep-2021 , 08-Oct-2021 , 10-Jan-2022			
	Synopsis	<p>The purpose of this FOA is to solicit current or recently completed NHLBI K01, K08, and K23 awardees for grant support to expand their current research objectives or to branch out to a study that resulted from the research conducted under the K award. Active NHLBI K01, K08, and K23 awardees may apply for R03 support to run concurrently with the final two years of their K award. Recently completed NHLBI K01, K08, and K23 awardees are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. Thus, this FOA is intended to enhance the capability of NHLBI K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application.</p>			
072488	<a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18-684	04-Jun-2020	4,545,000 USD
	Contact Name	Traci Heath Mondoro, Ph.D.			
	Contact Telephone	301-435-0065			
	Contact Email	<a href="mailto:xxxx@mail.nih.gov">xxxx@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-Jun-2020 , 07-Sep-2020 , 02-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Heart, Lung, and Blood Institute (NHLBI) invites applications for investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.</p>				
079353	<a href="#">NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-155	07-May-2020	450,000 USD
	<p>Contact Name Patrice Desvigne-Nickens, MD</p> <p>Contact Telephone 301-435-0504</p> <p>Contact Email <a href="mailto:gweinmann@nih.gov">gweinmann@nih.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is to support studies that are scientifically essential, yet also sufficient, for investigators to make definitive decisions that inform the final designs of important Phase II and beyond clinical trials within NHLBI's mission; that is, clinical trials with the primary intent of testing the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and treatment of heart, lung, blood, and sleep disorders. This mechanism may be used to test the feasibility of novel and efficient (pragmatic) trial designs, as well as determine the feasibility of an intervention, intervention parameters, subject availability, or other information essential to complete the design of a trial. Applications should demonstrate that the proposed studies are both necessary and sufficient to permit definitive decisions about the final design of the subsequent clinical trial. Applicants who propose solely to write a protocol or manual of operations, to develop infrastructure for a clinical trial, or implement a fully designed trial will not be considered appropriate for this announcement. Please note that NHLBI supports other funding opportunities for clinical trials- see <a href="https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization">https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization</a> for information on other NHLBI clinical trial funding opportunity announcements. In contrast to the planning or study start up phase of other NHLBI clinical trial FOAs, the R34 mechanism is intended to provide new information that answers a scientific question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial.</p>				
078369	<a href="#">New Research Directions that Advance the NHLBI Strategic Vision Normal</a>	National Heart, Lung, and Blood	PA-19-	16-Jun-2020	275,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Biology (R21 - Clinical Trial Not Allowed)</a>	Institute/NIH/DHHS	049		USD
	Contact Name	Ravi Chandra Balijepalli, Ph.D.			
	Contact Telephone	301-435-0504			
	Contact Email	<a href="mailto:ravi.balijepalli@nih.gov">ravi.balijepalli@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	<p>The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain “resilience” – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.</p>			
084646	<a href="#">Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-330	11-May-2020	Not Specified
	Contact Name	Nancy DiFronzo, PhD			
	Contact Telephone	301-435-0065			
	Contact Email	<a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-May-2020 , 10-Jun-2020 , 09-Sep-2020 , 14-Oct-2020 , 14-Jan-2021 , 11-Feb-2021 , 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA ( PAR-19-329 ) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project</p>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.			
074725	<a href="#">RFA-HL-19-018 -- NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-018	09-Jun-2020 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Gary Robinson, Ph.D.			
	Contact Telephone	301-496-2149			
	Contact Email	<a href="mailto:NHLBI_SBIR@mail.nih.gov">NHLBI_SBIR@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020			
	Synopsis	National Heart, Lung, and Blood Institute (NHLBI) invites applications to provide support to Phase II SBIR or STTR awardees that are developing NHLBI mission-related products that address a rare disease or young pediatric populations. The goal of this FOA is for these products to be further validated so that development can continue with private funding after NHLBI support ends. Applicants must submit a Commercialization Plan that includes details on any independent third-party funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will be equal to or greater than one-third of the NHLBI funds being requested throughout the project period. Projects proposed in response to this FOA must require eventual Federal regulatory approval/clearance, and may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required. This FOA will utilize the NIH R44 Small Business Innovation Research (SBIR) Grant - Phase II only.			
090446	<a href="#">RFA-HL-21-008 -- Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-21-008	08-May-2020 [Optional][LOI/Pre-App]	4,625,000 USD
	Contact Name	Shimian Zou, PhD			
	Contact Telephone	301-827-8301			
	Contact Email	<a href="mailto:shimian.zou@nih.gov">shimian.zou@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-May-2020 [Optional][LOI/Pre-App], 08-Jun-2020			
	Synopsis	This limited competition Funding Opportunity Announcement (FOA) invites an application from the current awardee of the			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sickle Africa Data Coordinating Center (SADaCC) to continue support of the activities of the expanded Sickle Pan-African Research Consortium (SPARCO), including the Clinical Coordinating Center (CCC) in Tanzania, the three established sites in Ghana, Nigeria and Tanzania (and additional satellite sites), as well as up to three new sites located in additional sub-Saharan African nations. The SADaCC is expected to propose a feasible and meritorious plan to provide overall project coordination, administration, data management, and biostatistical support of the SCD in Sub-Saharan Africa Network. A key responsibility of the SADaCC includes effective integration of SADaCC activities with those of SPARCO, Consortium sites, NHLBI, and review/monitoring bodies. This FOA runs in parallel with RFA-HL-21-007, which invites an application from the current awardee institution of the SPARCO CCC, and RFA-HL-21-009, which invites applications for Consortium sites. The SADaCC, CCC, as well as established and new sites of the Consortium will constitute the SCD in Sub-Saharan Africa (SSA) Network. This Network aims to develop a sustainable resource that will advance SCD-related epidemiologic, translational, and clinical research studies.</p>				
073356	<a href="#">RFA-HL-19-015 -- Physician-Scientist (PS) Research Award for Early Stage Investigators (ESIs) (R01 - Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-015	04-Jun-2020	1,125,000 USD
	Contact Name	Henry Chang, MD			
	Contact Telephone	301-435-0050			
	Contact Email	<a href="mailto:changh@nhlbi.nih.gov">changh@nhlbi.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	04-Jun-2020			
	Synopsis	National Heart, Lung, and Blood Institute (NHLBI) invites applications for the Physician-Scientist Research Award for Early Stage Investigators. The award is intended to support the independence of physician-scientist faculty committed to academic careers in heart, lung, and blood diseases and sleep disorders (HLBS) research, and related implementation science. This FOA will use the NIH Research Project (R01) award mechanism.			
090398	<a href="#">RFA-HL-21-007 -- Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (U24 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-21-007	08-May-2020 [Optional][LOI/Pre-App]	2,588,600 USD
	Contact Name	Shimian Zou, PhD			
	Contact Telephone	301-827-8301			
	Contact Email	<a href="mailto:shimian.zou@nih.gov">shimian.zou@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 08-May-2020 [Optional][LOI/Pre-App], 08-Jun-2020</p> <p>Synopsis This limited competition Funding Opportunity Announcement (FOA) invites an application from the current awardee institution of the Sickle Pan-African Research Consortium (SPARCO) Clinical Coordinating Center (CCC) to support activities of the expanded SPARCO Consortium, comprised of three established sites in Ghana, Nigeria and Tanzania (and additional satellite sites), as well as up to three new sites located in additional sub-Saharan African nations. The SPARCO CCC application is expected to propose a feasible and meritorious plan for expanding a sickle hemoglobinopathy registry database to facilitate patient-tracking and follow-up and serve as a backbone for future sickle cell disease (SCD) research. The NHLBI anticipates that the CCC will propose to refine database elements and update plans for harmonization of SCD phenotype definitions and ontologies, and for integration of collaborative Consortium activities. In addition, the CCC will be responsible for enhancing approaches to the development of regionally appropriate standards of SCD care, as well as the organization of research and clinical skill development activities. A primary responsibility of the CCC includes coordination of Consortium sites to allow for development, implementation, and conduct of SCD cohort studies, as well as implementation research of preventive/therapeutic practices. This FOA runs in parallel with RFA-HL-21-008, which invites an application for the Sickle Africa Data Coordinating Center (SADaCC), and RFA-HL-21-009, which invites applications for Consortium sites. The CCC, the SADaCC, as well as established and new sites of the Consortium will constitute the SCD in Sub-Saharan Africa (SSA) Network. This Network aims to develop a sustainable resource that will advance SCD-related epidemiologic, translational, and clinical research studies.</p>				
090453	<a href="#">RFA-HL-21-009 -- Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-21-009	08-May-2020 [Optional][LOI/Pre-App]	850,000 USD

Contact Name	Shimian Zou, PhD
Contact Telephone	301-827-8301
Contact Email	<a href="mailto:shimian.zou@nih.gov">shimian.zou@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-May-2020 [Optional][LOI/Pre-App], 08-Jun-2020
Synopsis	This Funding Opportunity Announcement (FOA) seeks both applications from established sites of the Sickle Pan-African Research Consortium (SPARCO) and applications from other Sub-Saharan African nations to become the Consortium's new sites. The renewed and expanded SPARCO including a Clinical Coordinating Center (CCC), up to three established sites and additional satellite sites, up to three new sites, and the associated Sickle Africa Data Coordinating Center (SADaCC) will together constitute the Sickle Cell Disease (SCD) in Sub-Saharan Africa (SSA) Network. This network aims at developing a sustainable resource that will advance SCD-related epidemiologic, translational, and clinical studies.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
073826	<a href="#">RFA-HG-18-002 -- Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-18-002	26-Jun-2020	400,000 USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	<a href="mailto:smithmw@mail.nih.gov">smithmw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jun-2020 , 10-Sep-2020			
	Synopsis	National Human Genome Research Institute (NHGRI) invites applications to develop novel technologies that will enable substantive (no less than an order of magnitude) improvement in DNA sequencing, and practical methods for direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
073824	<a href="#">RFA-HG-18-001 -- Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-18-001	26-Jun-2020	2,800,000 USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	<a href="mailto:smithmw@mail.nih.gov">smithmw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jun-2020 , 10-Sep-2020			
	Synopsis	National Human Genome Research Institute (NHGRI) invites applications to develop novel technologies that will enable no less than one order of magnitude improvement in DNA sequencing, and practical methods for direct RNA sequencing. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained DNA sequencing throughput increases and cost decreases. The goal now is to improve the quality and efficiency of DNA sequencing and enable direct RNA sequencing (e.g., longer read lengths, faster turn-around time, greater accuracy, and higher-throughput etc.) at reasonable costs with the anticipation that significant advances in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals. This FOA will use the NIH Research Project (R01) award mechanism.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
073828	<a href="#">RFA-HG-18-003 -- Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-18-003	26-Jun-2020	Not Specified
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	<a href="mailto:smithmw@mail.nih.gov">smithmw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jun-2020 , 10-Sep-2020			
	Synopsis	National Human Genome Research Institute (NHGRI) invites applications from small businesses to develop novel technologies that will enable no less than one order of magnitude improvement in DNA sequencing, and practical methods for direct RNA sequencing. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained DNA sequencing throughput increases and cost decreases. The goal now is to improve the quality and efficiency of DNA sequencing and enable direct RNA sequencing (e.g., longer read lengths, faster turn-around time, greater accuracy, and higher-throughput etc.) at reasonable costs with the anticipation that significant advances in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals. This FOA will use the NIH R43/R44 Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track I mechanism.			
073372	<a href="#">Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional)</a>	National Human Genome Research Institute/NIH/DHHS	PAR-18-735	19-Jun-2020	1,999,996 USD
	Contact Name	Christine Chang			
	Contact Telephone	301-480-2255			
	Contact Email	<a href="mailto:christine.chang2@nih.gov">christine.chang2@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	19-Jun-2020 , 21-Sep-2020 , 20-Oct-2020 , 22-Jan-2021			
	Synopsis	National Human Genome Research Institute (NHGRI) invites applications for research that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use. This FOA will use the NIH Research Project (R01) award mechanism.			
073379	<a href="#">Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional)</a>	National Human Genome Research Institute/NIH/DHHS	PAR-18-736	19-Jun-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Christine Chang</p> <p>Contact Telephone   301-480-2255</p> <p>Contact Email   <a href="mailto:christine.chang2@nih.gov">christine.chang2@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   19-Jun-2020 , 21-Sep-2020 , 20-Oct-2020 , 22-Jan-2021</p> <p>Synopsis   National Human Genome Research Institute (NHGRI) invites applications for research that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>				
066539	<a href="#">Comparative Genomics Research Program (R01-Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	PAR-17-482	05-Jun-2020	Not Specified
	<p>Contact Name   Jennifer Troyer, Ph.D</p> <p>Contact Telephone   301-480-3565</p> <p>Contact Email   <a href="mailto:troyerj@mail.nih.gov">troyerj@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2020 , 05-Oct-2020</p> <p>Synopsis   National Human Genome Research Institute (NHGRI) invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076417	<a href="#">Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	PA-18-867	16-Jun-2020	275,000 USD
	<p>Contact Name   Lisa D. Brooks, Ph.D.</p> <p>Contact Telephone   301-547-1387</p> <p>Contact Email   <a href="mailto:Lisa.Brooks@nih.gov">Lisa.Brooks@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021			
	Synopsis	National Human Genome Research Institute (NHGRI) invites applications for the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
076415	<a href="#">Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	PA-18-868	05-Jun-2020	Not Specified
	Contact Name	Lisa D. Brooks, Ph.D.			
	Contact Telephone	301-547-1387			
	Contact Email	<a href="mailto:Lisa.Brooks@nih.gov">Lisa.Brooks@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021			
	Synopsis	National Human Genome Research Institute (NHGRI) invites applications for the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically. This FOA will use the NIH Research Project (R01) award mechanism.			
065298	<a href="#">Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)</a>	National Human Genome Research Institute/NIH/DHHS	PA-17-444	07-May-2020	Not Specified
	Contact Name	Joy Boyer			
	Contact Telephone	301-402-4997			
	Contact Email	<a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. This program will use the NIH Research Project (R01) award			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
065308	<a href="#">Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)</a>	National Human Genome Research Institute/NIH/DHHS	PA-17-446	07-May-2020	275,000 USD
	Contact Name	Joy Boyer			
	Contact Telephone	301-402-4997			
	Contact Email	<a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
065312	<a href="#">Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R03)</a>	National Human Genome Research Institute/NIH/DHHS	PA-17-445	07-May-2020	100,000 USD
	Contact Name	Joy Boyer			
	Contact Telephone	301-402-4997			
	Contact Email	<a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. This program will use the NIH R03 Small Grant Program award mechanism.			
090397	<a href="#">RFA-HG-20-019 -- NHGRI Technology Development Coordinating Center</a>	National Human Genome Research	RFA-HG-	25-May-2020	Not



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">(U24 Clinical Trial Not Allowed)</a>		Institute/NIH/DHHS	20-019 [Optional][LOI/Pre-App]	Specified
	Contact Name	Stephanie A. Morris, Ph.D.			
	Contact Telephone	301-435-5738			
	Contact Email	<a href="mailto:morriss2@mail.nih.gov">morriss2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages applications for the establishment of a Technology Development Coordinating Center for the National Human Genome Research Institute (NHGRI). The Coordinating Center will be responsible for enhancing integration between components of the NHGRI Genome Technology program by facilitating opportunities for collaborations and leading efforts to promote standards in genomic technologies. The Coordinating Center will also disseminate program advances, develop resources and outreach strategies for engaging the broader biomedical research community, and manage an Opportunity Funds program to rapidly fund and support promising small-scale work that advances development of innovative genomic technologies.			
090708	<a href="#">RFA-HG-20-014 -- Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-014	25-May-2020 [Optional][LOI/Pre-App]	2,100,000 USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	<a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 25-Jan-2021 [Optional][LOI/Pre-App], 01-Feb-2021 , 01-Sep-2021 [Optional][LOI/Pre-App], 01-Oct-2021 , 25-May-2022 [Optional][LOI/Pre-App], 24-Jun-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.			
090719	<a href="#">RFA-HG-20-015 -- Novel Synthetic Nucleic Acid Technology Development</a>	National Human Genome Research	RFA-HG-	25-May-2020	400,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">(R21) (Clinical Trial not allowed)</a>	Institute/NIH/DHHS	20-015	[Optional][LOI/Pre-App]	USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	<a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 25-Jan-2021 [Optional][LOI/Pre-App], 01-Feb-2021 , 01-Sep-2021 [Optional][LOI/Pre-App], 01-Oct-2021 , 25-May-2022 [Optional][LOI/Pre-App], 24-Jun-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.			
090720	<a href="#">RFA-HG-20-016 -- Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-016	25-May-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	<a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-May-2020 [Optional][LOI/Pre-App], 24-Jun-2020 , 25-Jan-2021 [Optional][LOI/Pre-App], 01-Feb-2021 , 01-Sep-2021 [Optional][LOI/Pre-App], 01-Oct-2021 , 25-May-2022 [Optional][LOI/Pre-App], 24-Jun-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in commercial synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of commercial nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		magnitude improvement to existing commercial systems. Exploration of methods other than those currently commercially in use is highly encouraged.			
081206	<a href="#">Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-237	07-May-2020	275,000 USD
	Contact Name	Chao Jiang, Ph.D.			
	Contact Telephone	301-761-7802			
	Contact Email	<a href="mailto:chao.jiang@nih.gov">chao.jiang@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.			
073282	<a href="#">Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-724	16-Jun-2020	275,000 USD
	Contact Name	Ryan Ranallo, Ph.D.			
	Contact Telephone	240-627-3351			
	Contact Email	<a href="mailto:ryan.ranallo@nih.gov">ryan.ranallo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
073273	<a href="#">Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-725	05-Jun-2020	Not Specified
	Contact Name	Ryan Ranallo, Ph.D.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-627-3351</p> <p>Contact Email <a href="mailto:ryan.ranallo@nih.gov">ryan.ranallo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021</p> <p>Synopsis National Institute of Allergy and Infectious Diseases (NIAID) invites applications for select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076435	<a href="#">Research to Advance Vaccine Safety (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-872	07-May-2020	275,000 USD
	<p>Contact Name Barbara Mulach, Ph.D.</p> <p>Contact Telephone 240-627-3322</p> <p>Contact Email <a href="mailto:bmulach@niaid.nih.gov">bmulach@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
076434	<a href="#">Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-873	07-May-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Barbara Mulach, Ph.D.</p> <p>Contact Telephone   240-627-3322</p> <p>Contact Email   <a href="mailto:bmulach@niaid.nih.gov">bmulach@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH Research Project (R01) award mechanism.</p>				
084965	<a href="#">Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-347	16-Jun-2020	100,000 USD
	<p>Contact Name   Frosso Voulgaropoulou, Ph.D.</p> <p>Contact Telephone   240-627-3205</p> <p>Contact Email   <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.</p>				
084962	<a href="#">Investigations on Primary Immunodeficiency Diseases/Inborn Errors of</a>	National Institute of Allergy and	PAR-19-	16-Jun-2020	275,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<a href="#">Immunity (R21 Clinical Trial Not Allowed)</a>		Infectious Diseases/NIH/DHHS	346	USD	
	Contact Name	Frosso Voulgaropoulou, Ph.D.				
	Contact Telephone	240-627-3205				
	Contact Email	<a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a>				
	Sponsor Website					
	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022				
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.				
085054	<a href="#">Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)</a>		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-351	07-May-2020	275,000 USD
	Contact Name	Shawn Drew Gaillard, Ph.D				
	Contact Telephone	240-627-3857				
	Contact Email	<a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a>				
	Sponsor Website					
	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020				
	Synopsis	The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.				
085477	<a href="#">NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)</a>		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-371	07-May-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Shawn Drew Gaillard, Ph.D.</p> <p>Contact Telephone   240-627-3857</p> <p>Contact Email   <a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   National Institute of Allergy and Infectious Diseases (NIAID) provides support for the NIAID Research Scholar Development Award (RSDA), which is intended to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) will utilize the NIH Career Transition Award (K22) mechanism.</p>				
078718	<a href="#">Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-078	05-Jun-2020	Not Specified
	<p>Contact Name   Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone   240-627-3205</p> <p>Contact Email   <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.</p>				
078715	<a href="#">Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-082	05-Jun-2020	Not Specified
	<p>Contact Name   Dona Love, Ph.D.</p> <p>Contact Telephone   301-761-7788</p> <p>Contact Email   <a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.			
065199	<a href="#">Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-17-439	07-May-2020	100,000 USD
	Contact Name	Shawn Drew Gaillard, Ph.D.			
	Contact Telephone	240-627-3857			
	Contact Email	<a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This program will use the NIH R03 Small Grant Program grant mechanism.			
078710	<a href="#">Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-077	05-Jun-2020	Not Specified
	Contact Name	Annie Mo, Ph.D.			
	Contact Telephone	240-627-3320			
	Contact Email	<a href="mailto:moa@niaid.nih.gov">moa@niaid.nih.gov</a>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation. This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax.			
078717	<a href="#">Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-083	16-Jun-2020	275,000 USD
	Contact Name	Dona Love, Ph.D.			
	Contact Telephone	301-761-7788			
	Contact Email	<a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.			
078712	<a href="#">Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-080	05-Jun-2020	Not Specified
	Contact Name	Dona Love, Ph.D.			
	Contact Telephone	301-761-7788			
	Contact Email	<a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).			
078719	<a href="#">Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-079	16-Jun-2020	275,000 USD
	Contact Name	Frosso Voulgaropoulou, PhD			
	Contact Telephone	240-627-3205			
	Contact Email	<a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.			
078714	<a href="#">Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-081	16-Jun-2020	275,000 USD
	Contact Name	Dona Love, Ph.D.			
	Contact Telephone	301-761-7788			
	Contact Email	<a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).			
078569	<a href="#">Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-068	16-Jun-2020	275,000 USD
	Contact Name	Ishwar Chandramouliswaran M.S., M.B.A.			
	Contact Telephone	301-761-7822			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:ishwar.chandramouliswaran@nih.gov">ishwar.chandramouliswaran@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases.			
087513	<a href="#">NIAID Investigator Initiated Program Project Applications (P01)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-16-413	07-May-2020	Not Specified
	Contact Name	Mr. Martin Gutierrez, B.S.			
	Contact Telephone	240-292-4844			
	Contact Email	<a href="mailto:mgutierrez@niaid.nih.gov">mgutierrez@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 11-Jun-2020 , 07-Sep-2020 , 11-Jan-2021 , 07-May-2021 , 11-Jun-2021 , 07-Sep-2021 , 11-Jan-2022 , 07-May-2022 , 10-Jun-2022 , 07-Sep-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of healthy immune system development and function across the lifespan; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for proposed research.			
076260	<a href="#">Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-858	16-Jun-2020	275,000 USD
	Contact Name	Diane Post, Ph.D.			
	Contact Telephone	240-627-3348			
	Contact Email	<a href="mailto:postd@niaid.nih.gov">postd@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021</p> <p>Synopsis   National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
076258	<a href="#">Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-859	05-Jun-2020	Not Specified
	<p>Contact Name   Diane Post, Ph.D.</p> <p>Contact Telephone   240-627-3348</p> <p>Contact Email   <a href="mailto:postd@niaid.nih.gov">postd@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis   National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
088593	<a href="#">RFA-AI-19-073 -- Childhood Asthma in Urban Settings -Clinical Research Centers (U01 Clinical Trial Optional)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-19-073	20-May-2020 [Optional][LOI/Pre-App]	2,100,000 USD
	<p>Contact Name   Gang Dong, M.D., Ph.D.</p> <p>Contact Telephone   240-627-3508</p> <p>Contact Email   <a href="mailto:gdong@niaid.nih.gov">gdong@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-May-2020 [Optional][LOI/Pre-App], 19-Jun-2020</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Clinical Research Centers (CAUSE-CRCs). The CAUSE-CRCs will conduct both</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		network-wide and site-specific clinical studies and trials with the ultimate goal of developing effective asthma treatment or prevention approaches applicable to children residing in low-income urban settings. For network-wide clinical research projects and other network functions, the CAUSE-CRCs will work closely with the CAUSE Leadership Center (CAUSE-LC).			
088598	<a href="#">RFA-AI-19-074 -- Childhood Asthma in Urban Settings Clinical Research Network- Leadership Center (UM1 Clinical Trial Required)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-19-074	20-May-2020 [Optional][LOI/Pre-App]	4,300,000 USD
	Contact Name	Gang Dong, M.D., Ph.D.			
	Contact Telephone	240-627-3508			
	Contact Email	<a href="mailto:gdong@niaid.nih.gov">gdong@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-May-2020 [Optional][LOI/Pre-App], 19-Jun-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the NIAID Childhood Asthma in Urban Settings Clinical Research Network Leadership Center (CAUSE-LC). The CAUSE-LC will provide the overall scientific strategy and organizational structure to the CAUSE Clinical Research Network and will interact closely with the CAUSE Clinical Research Centers (CAUSE -CRCs) to support the conduct of multi-site clinical studies and trials with the ultimate goal of developing effective interventions or asthma prevention approaches applicable to children residing in low-income urban settings.			
088841	<a href="#">RFA-AI-20-004 -- Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-004	30-May-2020 [Optional][LOI/Pre-App]	2,000,000 USD
	Contact Name	Cheryl Lapham, Ph.D.			
	Contact Telephone	240-498-1366			
	Contact Email	<a href="mailto:clapham@niaid.nih.gov">clapham@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-May-2020 [Optional][LOI/Pre-App], 29-Jun-2020			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
062665	<a href="#">Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-17-282	07-May-2020	275,000 USD

components for vaccines tailored to specific pathogens. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAID's overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations that will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.

Contact Name	Daniel Frank, Ph.D.
Contact Telephone	301-761-6256
Contact Email	<a href="mailto:Daniel.Frank@nih.gov">Daniel.Frank@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020
Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

062648	<a href="#">Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R01)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-17-283	07-May-2020	Not Specified
Contact Name	Daniel Frank, Ph.D.				
Contact Telephone	301-761-6256				
Contact Email	<a href="mailto:Daniel.Frank@nih.gov">Daniel.Frank@nih.gov</a>				
Sponsor Website					
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020				
Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. This FOA will use the NIH Research Project (R01) award mechanism.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
089595	<a href="#">RFA-AI-20-019 -- Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-019	16-May-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Rajen Koshy, Ph.D.			
	Contact Telephone	240-627-3294			
	Contact Email	<a href="mailto:rkoshy@niaid.nih.gov">rkoshy@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. This information will serve as a guide for the construction of new and improved candidate prophylactic HCV vaccines that will be assessed for immunogenicity and efficacy in appropriate animal models.</p>			
089644	<a href="#">RFA-AI-20-008 -- Multidisciplinary Studies to Improve Understanding of Influenza Transmission (U19 Clinical Trial Optional)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-008	24-May-2020 [Optional][LOI/Pre-App]	10,000,000 USD
	Contact Name	Teresa Hauguel, Ph.D			
	Contact Telephone	240-627-3272			
	Contact Email	<a href="mailto:hauguel@niaid.nih.gov">hauguel@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-May-2020 [Optional][LOI/Pre-App], 23-Jun-2020			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to comprehensively investigate the dynamics and drivers of influenza transmission between humans. This FOA will support research to: (1) improve detection and sampling of influenza viral particles from the air; (2) develop novel assays to assess viability and infectivity of influenza viral particles collected from the air; and (3) comprehensively evaluate the contribution of viral, host, physical, and environmental factors to influenza transmission between humans.</p>			
089797	<a href="#">RFA-AI-20-003 -- Partnerships for the Development of Universal Influenza</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-003	02-Jun-2020	1,175,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Vaccines (R21/R33 Clinical Trial Not Allowed)</a>		Infectious Diseases/NIH/DHHS	20-003	USD
	Contact Name	Michael Schaefer, Ph.D.			
	Contact Telephone	240-627-3364			
	Contact Email	<a href="mailto:mschaefer@niaid.nih.gov">mschaefer@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Jun-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support development of promising universal influenza vaccine candidates that protect against both influenza A and B viruses.			
090127	<a href="#">RFA-AI-20-010 -- Advancing Vaccine Science to Improve Tuberculosis Treatment Outcomes for People Living With or Without HIV (R01 Clinical Trial Not Allowed)</a>		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-010	29-Jun-2020 [Optional][LOI/Pre-App] 4,000,000 USD
	Contact Name	Daniel Frank, Ph.D.			
	Contact Telephone	301-761-6256			
	Contact Email	<a href="mailto:daniel.frank@mail.nih.gov">daniel.frank@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.			
090164	<a href="#">RFA-AI-20-015 -- Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61/R33 Clinical Trial Not Allowed)</a>		National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-015	28-Jun-2020 [Optional][LOI/Pre-App] Not Specified
	Contact Name	Patricia D'Souza, Ph.D.			
	Contact Telephone	240-627-3037			
	Contact Email	<a href="mailto:pdsouza@niaid.nih.gov">pdsouza@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	28-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020			
	Synopsis	The objective of this Funding Opportunity Announcement (FOA) is to pair Bioengineers and Immunologists to leverage emerging innovative knowledge in physical and computational sciences for the design and development of an HIV-1 vaccine.			
081406	<a href="#">Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-248	10-Jun-2020	2,499,995 USD
	Contact Name	M. Chelsea Lane, Ph.D.			
	Contact Telephone	240-627-3741			
	Contact Email	<a href="mailto:lanemc@niaid.nih.gov">lanemc@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2020 , 10-Jun-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.			
081410	<a href="#">Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-247	18-Jun-2020	275,000 USD
	Contact Name	M. Chelsea Lane, Ph.D.			
	Contact Telephone	240-627-3741			
	Contact Email	<a href="mailto:lanemc@niaid.nih.gov">lanemc@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jun-2020 , 18-Jun-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.			
090387	<a href="#">RFA-AI-20-028 -- Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-028	30-May-2020 [Optional][LOI/Pre-App]	3,750,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Michael R. Schaefer, Ph.D.</p> <p>Contact Telephone   240-627-3364</p> <p>Contact Email   <a href="mailto:mschaefer@niaid.nih.gov">mschaefer@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-May-2020 [Optional][LOI/Pre-App], 29-Jun-2020</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.</p>				
090892	<a href="#">RFA-AI-20-024 --Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-024	28-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Marina N Protopopova, PhD</p> <p>Contact Telephone   301-761-7653</p> <p>Contact Email   <a href="mailto:marina.protopopova@nih.gov">marina.protopopova@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020</p> <p>Synopsis   The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.</p>				
072905	<a href="#">Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-18-712	05-Jun-2020	Not Specified
	<p>Contact Name   Frosso Voulgaropoulou, Ph.D.</p> <p>Contact Telephone   240-627-3205</p> <p>Contact Email   <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders. This FOA will use the NIH Research Project (R01) award mechanism.			
091964	<a href="#">RFA-AI-20-026 -- Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-026	17-Jun-2020 [Optional][LOI/Pre-App]	57,500,000 USD
	Contact Name	Nancy Boyd			
	Contact Telephone	240-292-4119			
	Contact Email	<a href="mailto:nboyd@niaid.nih.gov">nboyd@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jun-2020 [Optional][LOI/Pre-App], 17-Jul-2020			
	Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to continue to provide operations support for Biosafety Level 4 (BSL4) facilities to the National Biocontainment Laboratories at the University of Texas Medical Branch (UTMB) in Galveston, Texas and Boston University in Boston, Massachusetts. Operations support is provided in the following areas: facility maintenance and operations; biosecurity; environmental health and safety regulations and requirements; regulatory compliance; and specialized research support services. The NBLs will serve as a national resource for efforts in conducting pre-clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAID's biodefense and emerging infectious diseases research efforts. Additionally, in times of a national biodefense or emerging infectious disease (EID) emergency, the NBLs may be expected to rapidly realign their activities to assist response efforts within the US under the direction of NIAID.			
081513	<a href="#">Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03)</a>	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PAR-19-257	19-Jun-2020	100,000 USD
	Contact Name	Su-Yau Mao, Ph.D.			
	Contact Telephone	301-594-5032			
	Contact Email	<a href="mailto:maos2@mail.nih.gov">maos2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 19-Jun-2020 , 19-Oct-2020 , 19-Feb-2021 , 21-Jun-2021 , 19-Oct-2021 , 21-Feb-2022

Synopsis

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K08 and K23 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$50,000 direct costs per year for each of two years, the NIAMS is seeking to enhance the capability of its clinical scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.

067972	<a href="#">Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R01 Clinical Trial Not Allowed)</a>	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18-409	07-May-2020	275,000 USD
--------	---	--	-----------	-------------	-------------

Contact Name | Gayle E. Lester, Ph.D.

Contact Telephone | 301-594-3511

Contact Email | [lester1@mail.nih.gov](mailto:lester1@mail.nih.gov)

Sponsor Website |

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021

Synopsis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH R01 Research Project Grant award mechanism.

073322	<a href="#">Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21 Clinical Trial Not Allowed)</a>	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18-718	16-Jun-2020	275,000 USD
--------	--	--	-----------	-------------	-------------

Contact Name | Ricardo R. Cibotti, Ph.D.

Contact Telephone | 301-451-5888

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021</p> <p>Synopsis National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
073320	<a href="#">Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)</a>	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18-719	05-Jun-2020	Not Specified
	<p>Contact Name Ricardo R. Cibotti, Ph.D.</p> <p>Contact Telephone 301-451-5888</p> <p>Contact Email <a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
067950	<a href="#">Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R21 Clinical Trial Not Allowed)</a>	National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS	PA-18-408	07-May-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Gayle E. Lester, Ph.D.</p> <p>Contact Telephone   301-594-3511</p> <p>Contact Email   <a href="mailto:lester1@mail.nih.gov">lester1@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
079366	<a href="#">Bioengineering Research Partnerships (U01 Clinical Trial Required)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-157	07-May-2020	Not Specified
	<p>Contact Name   Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone   301-451-4577</p> <p>Contact Email   <a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.</p>				
070281	<a href="#">Synthetic Biology for Engineering Applications (R01 Clinical Trial Optional)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-18-434	07-May-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   David Rampulla, Ph.D.</p> <p>Contact Telephone   301-451-4778</p> <p>Contact Email   <a href="mailto:david.rampulla@nih.gov">david.rampulla@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research to advance the understanding and application of synthetic biology for human health. It will support 1) the development of innovative tools and technologies in synthetic biology and 2) their application in biomedical research and human health. An integrative research plan based on collaborations of synthetic biologists with computational scientists, cell biologists, engineers, and/or physician scientists is strongly recommended. Early Stage Investigators in Synthetic Biology are especially encouraged to apply. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079361	<a href="#">Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-158	07-May-2020	Not Specified
	<p>Contact Name   Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone   301-451-4577</p> <p>Contact Email   <a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis   The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>				
079360	<a href="#">Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-159	07-May-2020	Not Specified
	Contact Name   Seila Selimovic, Ph.D. Program Director				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-451-4577</p> <p>Contact Email   <a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis   The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>				
089682	<a href="#">NIH Technology Accelerator Challenge for Global Health</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS		02-Jun-2020	500,000 USD
	<p>Contact Name   Tiffani Lash Ph.D., Program Director</p> <p>Contact Telephone   301-451-4778</p> <p>Contact Email   <a href="mailto:baileyti@mail.nih.gov">baileyti@mail.nih.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Jun-2020</p> <p>Synopsis   The National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health supports and encourages the development of new diagnostic technologies important for global health. Through this Challenge, NIBIB will offer \$1,000,000 in prizes to reward and spur the development of platform concepts and prototypes of non-invasive, multiplexed diagnostic technologies for sickle cell disease, malaria, and anemia, diseases with high global and public health impact.</p>				
079367	<a href="#">Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-156	07-May-2020	Not Specified
	<p>Contact Name   Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone   301-451-4577</p> <p>Contact Email   <a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021

Synopsis This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

070275	<a href="#">NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-18-433	07-May-2020	275,000 USD
--------	--	--	------------	-------------	-------------

Contact Name Randy King, Ph.D.

Contact Telephone 301-451-0707

Contact Email [randy.king@nih.gov](mailto:randy.king@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021

Synopsis National Institute of Biomedical Imaging and Bioengineering (NIBIB) invites applications for exploratory/developmental research programs of interest to the NIBIB (<https://www.nibib.nih.gov/research-funding>). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

069762	<a href="#">NIBIB Research Project Grant (R01 Clinical Trial Required)</a>	National Institute of Biomedical Imaging and	PA-18-418	07-May-2020	Not Specified
--------	--	--	-----------	-------------	---------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Bioengineering/NIH/DHHS

Contact Name	Steven H. Krosnick, M.D.
Contact Telephone	301-594-3009
Contact Email	<a href="mailto:krosnics@mail.nih.gov">krosnics@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021
Synopsis	NIH invites applications for discrete, specified, circumscribed projects in areas representing the specific interests and competencies of the investigator(s). This NIBIB Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of the NIBIB. For this Funding Opportunity Announcement, NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern. This FOA will use the NIH Research Project (R01) award mechanism.

088092	<a href="#">NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-20-084	07-May-2020	400,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Randy King, Ph.D.
Contact Telephone	301-451-0707
Contact Email	<a href="mailto:Randy.King@nih.gov">Randy.King@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators ( <a href="https://grants.nih.gov/policy/early-investigators/index.htm">https://grants.nih.gov/policy/early-investigators/index.htm</a> ) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.			
065329	<a href="#">Pregnancy in Women with Disabilities (R01)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-452	05-Jun-2020	Not Specified
	Contact Name	Maurice Davis, DHA, MPA, MHSA			
	Contact Telephone	301-435-6887			
	Contact Email	<a href="mailto:Maurice.Davis@mail.nih.gov">Maurice.Davis@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research. This FOA will use the NIH Research Project (R01) award mechanism.			
065330	<a href="#">Pregnancy in Women with Disabilities (R03)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-451	16-Jun-2020	100,000 USD
	Contact Name	Maurice Davis, DHA, MPA, MHSA			
	Contact Telephone	301-435-6887			
	Contact Email	<a href="mailto:Maurice.Davis@mail.nih.gov">Maurice.Davis@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for small research project grants (R03) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Applicants are encouraged to			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

include women with disabilities and members of the community in the design and conduct of their research. This FOA will use the NIH Research Project (R01) award mechanism.

070455	<a href="#">Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-511	07-May-2020	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Ekaterini Tsilou, MD
Contact Telephone	301-496-6287
Contact Email	<a href="mailto:tsiloue@mail.nih.gov">tsiloue@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021
Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications that will identify molecular targets for pregnancy associated/induced disorders and will lead to the development of new safer and more effective medications for use in pregnancy. This FOA will use the NIH Research Project (R01) award mechanism.

070412	<a href="#">Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-506	07-May-2020	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Ekaterini Tsilou. MD
Contact Telephone	301-496-6287
Contact Email	<a href="mailto:tsiloue@mail.nih.gov">tsiloue@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021
Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations. This FOA will use the NIH Research Project (R01) award mechanism.

070172	<a href="#">Studies in Neonatal and Pediatric Resuscitation (R01 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-485	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Marion Koso-Thomas, M.D, MPH
--------------	------------------------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-6873</p> <p>Contact Email <a href="mailto:kosomari@mail.nih.gov">kosomari@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Applications can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
074138	<a href="#">Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-766	07-May-2020	Not Specified
	<p>Contact Name Tracy King, MD, MPH</p> <p>Contact Telephone 301-402-1822</p> <p>Contact Email <a href="mailto:tracy.king@nih.gov">tracy.king@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications focusing on identification and management of behavioral symptoms and mental health conditions in individuals with intellectual disabilities (ID). Specific areas of interest for this funding opportunity are (1) applications to develop and validate assessment tools that reliably identify behavioral symptoms or diagnose mental health conditions in individuals with ID, and (2) applications studying the pharmacokinetics, safety and efficacy of specific psychotropic medications for treatment of behavioral symptoms or mental health conditions in individuals with ID. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
072576	<a href="#">Developmental Pharmacodynamics and Models of Drug Effects in</a>	National Institute of Child Health and	PA-18-	07-May-2020	100,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Pediatrics (R03 Clinical Trial Optional)</a>	Human Development/NIH/DHHS	687		USD
	Contact Name	George P. Giacoia MD			
	Contact Telephone	301-496-5589			
	Contact Email	<a href="mailto:giacoia@exchange.nih.gov">giacoia@exchange.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH R03 Small Grant Program award mechanism.			
072575	<a href="#">Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R01 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-688	07-May-2020	Not Specified
	Contact Name	George P. Giacoia MD			
	Contact Telephone	301-496-5589			
	Contact Email	<a href="mailto:giacoia@exchange.nih.gov">giacoia@exchange.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH Research Project (R01) award mechanism.			
072588	<a href="#">Innovative Therapies and Tools for Screenable Disorders in Newborns (R03 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-690	07-May-2020	100,000 USD
	Contact Name	Melissa Parisi, MD, PhD			
	Contact Telephone	301-435-6880			
	Contact Email	<a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R03 Small Grant Program award mechanism.			
072577	<a href="#">Innovative Therapies and Tools for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-689	07-May-2020	Not Specified
	Contact Name	Melissa Parisi, MD, PhD			
	Contact Telephone	301-435-6880			
	Contact Email	<a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH Research Project (R01) award mechanism.			
073287	<a href="#">Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-728	07-May-2020	275,000 USD
	Contact Name	Della B. White, PhD			
	Contact Telephone	301-435-2712			
	Contact Email	<a href="mailto:whitede@mail.nih.gov">whitede@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>				
074832	<a href="#">Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-790	07-May-2020	Not Specified
	<p>Contact Name Marion Koso-Thomas, M.D, MPH</p> <p>Contact Telephone 301-435-6873</p> <p>Contact Email <a href="mailto:kosomari@mail.nih.gov">kosomari@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
075836	<a href="#">Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-838	07-May-2020	2,499,995 USD
	<p>Contact Name Ravi Ravindranath, PhD</p> <p>Contact Telephone 301-435-6889</p> <p>Contact Email <a href="mailto:ravindr@nih.gov">ravindr@nih.gov</a></p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH Research Project (R01) award mechanism.			
074839	<a href="#">Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-791	07-May-2020	100,000 USD
	Contact Name	Marion Koso-Thomas, M.D, MPH			
	Contact Telephone	301-435-6873			
	Contact Email	<a href="mailto:kosomari@mail.nih.gov">kosomari@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH R03 Small Grant Program award mechanism.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
075841	<a href="#">Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-839	07-May-2020	275,000 USD
	Contact Name	Ravi Ravindranath, PhD			
	Contact Telephone	301-435-6889			
	Contact Email	<a href="mailto:ravindr@nih.gov">ravindr@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
085590	<a href="#">Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19-375	07-May-2020	200,000 USD
	Contact Name	James N. Coulombe, Ph.D.			
	Contact Telephone	301-451-1390			
	Contact Email	<a href="mailto:CoulombeJ@mail.nih.gov">CoulombeJ@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The goal of the Gabriella Miller Kids First Pediatric Data Resource is to build a collection of curated genomic and phenotypic data from childhood cancer and birth defects cohorts and provide a central portal where data and analysis tools will be readily accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

087243	<a href="#">Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-065	16-Jun-2020	150,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Reiko Toyama, PhD
Contact Telephone	301-435-2723
Contact Email	<a href="mailto:toyamar@mail.nih.gov">toyamar@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician-scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects.

087240	<a href="#">Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-064	07-May-2020	100,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Regina Bures, Ph.D.
Contact Telephone	301-496-9485

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.			
070065	<a href="#">NICHD Exploratory/Developmental Research Grant (R21 - Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-482	07-May-2020	275,000 USD
	Contact Name	NICHD Referral Office			
	Contact Telephone				
	Contact Email	<a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications for exploratory and developmental research projects that fall within the NICHD mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
070064	<a href="#">NICHD Small Grant Program (R03 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-481	07-May-2020	100,000 USD
	Contact Name	NICHD Referral Office			
	Contact Telephone				
	Contact Email	<a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for small research projects that can be carried out in a short period of time with limited resources. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
070059	<a href="#">NICHD Research Project Grant (R01 - Clinical Trial Required)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-480	07-May-2020	Not Specified
	<p>Contact Name NICHD Referral Office</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:NICHDReferral@mail.nih.gov">NICHDReferral@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for clinical trials that fall within the NICHD mission. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
062078	<a href="#">Promoting NICHD Areas of Research for HIV/AIDS in Maternal and Child Health (R01)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-17-262	07-May-2020	Not Specified
	<p>Contact Name Samantha C. Calabrese, MPH</p> <p>Contact Telephone 301-827-7568</p> <p>Contact Email <a href="mailto:samantha.calabrese@nih.gov">samantha.calabrese@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for HIV/AIDS research by addressing scientific areas of primary interest to NICHD, Maternal and Pediatric Infectious Disease Branch (MPIDB) and the Office of AIDS Research (OAR). This FOA will further explain our interests over the next three years. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
073285	<a href="#">Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-729	07-May-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Della B. White, PhD</p> <p>Contact Telephone 301-435-2712</p> <p>Contact Email <a href="mailto:whitede@mail.nih.gov">whitede@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
070178	<a href="#">Studies in Neonatal and Pediatric Resuscitation (R01 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-491	07-May-2020	Not Specified
	<p>Contact Name Marion Koso-Thomas, M.D, MPH</p> <p>Contact Telephone 301-435-6873</p> <p>Contact Email <a href="mailto:kosomari@mail.nih.gov">kosomari@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Applications can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
079181	<a href="#">Academic Research Enhancement Award for Undergraduate-Focused</a>	National Institute of Child Health and	PAR-19-	07-May-2020	300,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Institutions (R15 - Clinical Trial Required)</a>	Human Development/NIH/DHHS	133		USD
	Contact Name	Mahua Mukhopadhyay, PhD			
	Contact Telephone	301-435-6886			
	Contact Email	<a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 25-Jun-2020 , 07-Sep-2020 , 25-Oct-2020 , 07-Jan-2021			
	Synopsis	The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.			
091775	<a href="#">RFA-HD-21-017 -- Child Health Research Career Development Award (CHRCDA) Program [K12 Clinical Trials Not Allowed]</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-017	30-Jun-2020 [Optional][LOI/Pre-App]	2,125,000 USD
	Contact Name	Andrew A Bremer, MD, PhD			
	Contact Telephone	301-402-7886			
	Contact Email	<a href="mailto:andrew.bremer@nih.gov">andrew.bremer@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 30-Jul-2020			
	Synopsis	This funding opportunity announcement (FOA) invites applications for institutional research career development (K12) programs from applicant organizations that propose to support a program of mentored institutional career development programs for junior faculty investigators who have recently completed postgraduate clinical training in a subspecialty area of Pediatrics and are committed to launching an independent research career. The program provides supervised biomedical research training to assist the transition of junior faculty investigators into productive and independent physician-scientists. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.			
092506	<a href="#">RFA-HD-21-007 -- Development of Fertility Regulation Methods by</a>	National Institute of Child Health and	RFA-HD-	30-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Small Business (R43/R44 Clinical Trial Optional)</a>		Human Development/NIH/DHHS	21-007 [Optional][LOI/Pre-App]	Specified
	Contact Name	Christopher C. Lindsey, Ph.D.			
	Contact Telephone	301-435-6907			
	Contact Email	<a href="mailto:chris.lindsey@mail.nih.gov">chris.lindsey@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 30-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved non-hormonal contraceptive products for men and women.			
072586	<a href="#">Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-691	07-May-2020	275,000 USD
	Contact Name	Melissa Parisi, MD, PhD			
	Contact Telephone	301-435-6880			
	Contact Email	<a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
083076	<a href="#">Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-292	07-May-2020	Not Specified
	Contact Name	Kathryn Stein, Ph.D.			
	Contact Telephone	301-827-4653			
	Contact Email	<a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic investigation of the interplay of genes/gene networks and environmental factors in dental, oral, craniofacial (DOC), and other diseases and conditions.			

070589	<a href="#">NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-547	07-May-2020	Not Specified
--------	--	---	------------	-------------	---------------

	Contact Name	J Dena Fischer, DDS, MSD, MS			
	Contact Telephone	301-594-4876			
	Contact Email	<a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 08-Jun-2020 , 07-Sep-2020 , 06-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit the Program Director/Principal Investigator to finalize the study team and will support activities to develop: the final clinical protocol; the Clinical Investigator's Brochure (or equivalent), if needed; the data management system and other tools for data collection and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UG3 planning phase is not designed for pre-clinical studies with animals, the collection of preliminary data on the efficacy of the intervention (such as pilot testing), or the collection of observational data from humans to support the rationale for a clinical trial. Evaluation of the potential subject population to determine individuals' eligibility for participation in the future UH3 trial is allowed in the UG3 phase but not required. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
053538	<a href="#">Precision Imaging of Oral Lesions (R21-Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-788	07-May-2020	275,000 USD
	Contact Name	Chiayeng Wang, Ph.D.			
	Contact Telephone	301-827-4647			
	Contact Email	<a href="mailto:chiayeng.wang@nih.gov">chiayeng.wang@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
072634	<a href="#">Basic and Translational Oral Health Research Related to HIV/AIDS (R21 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-18-695	07-May-2020	275,000 USD
	Contact Name	Gallya Gannot, DMD, Ph.D.			
	Contact Telephone	301-451-5096			
	Contact Email	<a href="mailto:gallya.gannot@nih.gov">gallya.gannot@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for innovative basic and translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
083077	<a href="#">Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-293	07-May-2020	275,000 USD
	Contact Name	Kathryn Stein, Ph.D.			
	Contact Telephone	301-827-4653			
	Contact Email	<a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications to develop novel and robust experimental systems that offer approaches complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.			
076575	<a href="#">Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 - Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-18-874	07-May-2020	275,000 USD
	Contact Name	Darien Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	<a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
074728	<a href="#">Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-787	07-May-2020	Not Specified
	Contact Name	Chiayeng Wang, Ph.D.			
	Contact Telephone	301-827-4647			
	Contact Email	<a href="mailto:chiayeng.wang@nih.gov">chiayeng.wang@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				2021	
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH Research Project (R01) award mechanism.			
076573	<a href="#">Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 - Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-875	07-May-2020	Not Specified
	Contact Name	Darren Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	<a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH Research Project (R01) award mechanism.			
085470	<a href="#">NIDCR Small Grant Program for New Investigators (R03)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-370	07-May-2020	200,000 USD
	Contact Name	R. Dwayne Lunsford, PhD			
	Contact Telephone	301-827-4635			
	Contact Email	<a href="mailto:lunsfordr@nidcr.nih.gov">lunsfordr@nidcr.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Small Grant Program for New Investigators. The program supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application. This FOA will utilize the NIH R03 Small Grant Program.			
072035	<a href="#">NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-656	07-May-2020	Not Specified
	Contact Name	Melissa W. Riddle, PhD			
	Contact Telephone	301-451-3888			
	Contact Email	<a href="mailto:riddleme@mail.nih.gov">riddleme@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 08-Jun-2020 , 07-Sep-2020 , 06-Oct-2020 , 07-Jan-2021			
	Synopsis	<p>National Institute of Dental and Craniofacial Research (NIDCR) invites research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include traditional clinical trials to develop and test behavior change interventions for preventing and treating dental, oral, or craniofacial conditions, as well as interventions that are used as tools to understand mechanisms of behavior change. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UH3 phase of the award will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stage 0 &amp; I) through implementation and cost-effectiveness research (Stages IV/V). This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.</p>			
087115	<a href="#">Improving Oral Health and Reducing Disparities in Adolescents (R21 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-059	07-May-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone   301-594-5394</p> <p>Contact Email   <a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</p>				
087114	<a href="#">Improving Oral Health and Reducing Disparities in Adolescents (R01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-058	07-May-2020	Not Specified
	<p>Contact Name   Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone   301-594-5394</p> <p>Contact Email   <a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</p>				
087123	<a href="#">NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-060	07-May-2020	Not Specified
	<p>Contact Name   Dena Fischer, DDS, MSD, MS</p> <p>Contact Telephone   301-594-4876</p> <p>Contact Email   <a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 This Funding Opportunity Announcement (FOA) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected as part of a previous NIDCR award.			
079337	<a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-151	07-May-2020	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should apply to the companion ‘Clinical Trial Required’ FOA (PAR-18-360). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-152).			
079378	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-160	07-May-2020	Not Specified
	Contact Name	Lynn Mertens King, Ph.D.			
	Contact Telephone	301-594-5006			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:lynn.king@nih.gov">lynn.king@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor . This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-18-359).</p>				
079343	<a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-152	07-May-2020	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion ‘Clinical Trial Required’ FOA (PAR-18-360). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Studies with Humans FOA (PAR-19-151).					
079322	<a href="#">NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-145	07-May-2020	200,000 USD
	Contact Name	Darlen Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	<a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.			
079369	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-161	07-May-2020	Not Specified
	Contact Name	Lynn Mertens King, Ph.D.			
	Contact Telephone	301-594-5006			
	Contact Email	<a href="mailto:lynn.king@nih.gov">lynn.king@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trial Required' NIDCR K01 PAR-18-359). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NIDCR K01 PAR-19-160 Clinical Trial Not Allowed.</p>			
086959	<a href="#">NIDCR Research Grants for Analyses of Existing Genomics Data (R01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-045	07-May-2020	Not Specified
	Contact Name	Lu Wang, Ph.D.			
	Contact Telephone	301-594-4846			
	Contact Email	<a href="mailto:wanglu@nidcr.nih.gov">wanglu@nidcr.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023			
	Synopsis	<p>The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.</p>			
086963	<a href="#">NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-046	07-May-2020	200,000 USD
	Contact Name	Lu Wang, Ph.D.			
	Contact Telephone	301-594-4846			
	Contact Email	<a href="mailto:wanglu@nidcr.nih.gov">wanglu@nidcr.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML).			
069107	<a href="#">NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-359	07-May-2020	625,000 USD
	Contact Name	Lynn Mertens King, PhD			
	Contact Telephone	301-594-5006			
	Contact Email	<a href="mailto:lynn.king@nih.gov">lynn.king@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K01 Research Scientist Development Award - Research & Training award mechanism.			
069114	<a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-360	07-May-2020	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	<a href="mailto:leslie.frieden@mail.nih.gov">leslie.frieden@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program. provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K22 Career Transition Award mechanism.</p>				
070273	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00-Clinical Trial Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-432	07-May-2020	Not Specified
	<p>Contact Name Leslie A. Frieden, Ph.D.</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the Pathway to Independence Award (K99/R00). The primary purpose of the Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical specialty training at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K99/R00 Career Transition Award/Research Transition Award mechanism.</p>				
079225	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-144	07-May-2020	Not Specified
	Contact Name Leslie A. Frieden, PhD				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone 301-496-4263  
Contact Email [leslie.frieden@nih.gov](mailto:leslie.frieden@nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022  
Synopsis This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19- 141). The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.

079632	<a href="#">Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-172	05-Jun-2020	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name Preethi Chander, PhD  
Contact Telephone 301-827-4620  
Contact Email [preethi.chander@nih.gov](mailto:preethi.chander@nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022  
Synopsis This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

specific manner across the lifespan.

079633	<a href="#">Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-173	16-Jun-2020	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Preethi Chander, PhD
Contact Telephone	301-827-4620
Contact Email	<a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022
Synopsis	This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.

079222	<a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Basic Experimental Studies with Humans Required)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-141	07-May-2020	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
Contact Telephone	301-496-4263
Contact Email	<a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022
Synopsis	The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ FOA (PAR-18-432). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ( PAR-19-144 ).

081272	<a href="#">Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-240	07-May-2020	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Darien Weatherspoon, DDS, MPH
Contact Telephone	301-594-5394
Contact Email	<a href="mailto:darien.weatherspoon@mail.nih">darien.weatherspoon@mail.nih</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.

072628	<a href="#">Basic and Translational Oral Health Research Related to HIV/AIDS (R01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-18-699	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Gallya Gannot, DMD, Ph.D.
Contact Telephone	301-451-5096
Contact Email	<a href="mailto:gallya.gannot@nih.gov">gallya.gannot@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis National Institute of Dental and Craniofacial Research (NIDCR) invites applications for innovative basic and translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity. This FOA will use the NIH Research Project (R01) award mechanism.

090419	<a href="#">RFA-DE-20-007 -- Defining Lineage Plasticity and Endogenous Regeneration Capacity of Dental, Oral, and Craniofacial Tissues (R21 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-20-007	08-Jun-2020 [Optional][LOI/Pre-App]	275,000 USD
--------	--	---	---------------	-------------------------------------	-------------

Contact Name Nadya Lumelsky, PhD  
Contact Telephone 301-594-7703  
Contact Email [nadyal@nidcr.nih.gov](mailto:nadyal@nidcr.nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 08-Jun-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 31-Jul-2020  
Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage high risk high reward studies that will interrogate the capacity of cells residing in the postnatal Dental, Oral, and Craniofacial tissues to acquire developmental plasticity to undergo lineage reprogramming in vivo in response to injury and other types of environmental stress, and to generate functionally-competent cells of alternative lineage(s). The end goal of this initiative is to develop approaches that will explore new opportunities for capitalizing on this developmental plasticity for obtaining needed cells to promote endogenous regeneration of DOC tissues affected by disease or injury and to achieve the goals of regenerative medicine. This Initiative will aid in building a basic science foundation for developing clinically relevant, minimally invasive strategies for overcoming limitations of the currently available regenerative medicine methodologies.

090417	<a href="#">RFA-DE-20-006 -- Defining Lineage Plasticity and Endogenous Regeneration Capacity of Dental, Oral, and Craniofacial Tissues (R01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-20-006	08-Jun-2020 [Optional][LOI/Pre-App]	Not Specified
--------	--	---	---------------	-------------------------------------	---------------

Contact Name Nadya Lumelsky, PhD  
Contact Telephone 301-594-7703  
Contact Email [nadyal@nidcr.nih.gov](mailto:nadyal@nidcr.nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 08-Jun-2020 [Optional][LOI/Pre-App], 08-Jul-2020 , 31-Jul-2020  
Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage studies that will interrogate the capacity of cells residing in the postnatal Dental, Oral, and Craniofacial tissues to acquire developmental plasticity to undergo lineage



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		reprogramming in vivo in response to injury and other types of environmental stress, and to generate functionally-competent cells of alternative lineage(s). The end goal of this initiative is to develop approaches for capitalizing on this developmental plasticity for obtaining needed cells to promote endogenous regeneration of Dental, Oral, and Craniofacial tissues affected by disease or injury for? achieving the goals of regenerative medicine. This Initiative will build a basic science foundation for developing clinically relevant, minimally invasive strategies for overcoming limitations of the currently available regenerative medicine methodologies.			
081212	<a href="#">Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-238	07-May-2020	Not Specified
	Contact Name	Lynn Mertens King, PhD			
	Contact Telephone	301-594-5006			
	Contact Email	<a href="mailto:Lynn.King@nih.gov">Lynn.King@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial (DOC) research with a focus on behavioral and social sciences, and on genetics, genomics, bioinformatics and computational biology research. The intent of this program is to provide mid-career and senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field, in order to enrich their existing DOC research program; and (b) established investigators in other fields who seek training with DOC research investigators in order to facilitate the introduction of DOC research into an existing research program. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.			
081268	<a href="#">Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-239	07-May-2020	Not Specified
	Contact Name	Darren Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	<a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines "older adults" as those individuals age 65 years and older.			
079182	<a href="#">Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-134	07-May-2020	300,000 USD
	Contact Name	Alicia Dombroski, Ph.D.			
	Contact Telephone	301-594-4805			
	Contact Email	<a href="mailto:adombroski@mail.nih.gov">adombroski@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 25-Jun-2020 , 07-Sep-2020 , 25-Oct-2020 , 07-Jan-2021			
	Synopsis	The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than \$6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this FOA, a college is a stand-alone entity and not a component of a university system.			
081339	<a href="#">Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-19-241	05-Jun-2020	Not Specified
	Contact Name	Tamara G. Bavendam, MD, MS			
	Contact Telephone	301-594-4733			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:tamara.bavendam@nih.gov">tamara.bavendam@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational and clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. Specific research topic areas supported by the SUITOR program, as outlined below, will change over time and will be updated annually through the NIH Guide to Grants and Contracts.</p>				
076879	<a href="#">Elucidating the Role of the Autonomic Nervous System in Peripheral Metabolism and Metabolic Disease through the Application of Novel Tools and Methodologies (RC2 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-898	02-Jun-2020	Not Specified
	<p>Contact Name Karen Teff, Ph.D.</p> <p>Contact Telephone 301-594-8803</p> <p>Contact Email <a href="mailto:karen.teff@nih.gov">karen.teff@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 02-Jun-2020 , 03-Nov-2020 , 01-Jun-2021</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for scientific advancements addressing the role of the autonomic nervous system in the regulation of peripheral metabolism and its role in diabetes, obesity and related metabolic disease. Interdisciplinary teams may propose to develop resources in the form of novel tools or methodologies that when applied to the autonomic nervous system will contribute to elucidating its functional role in metabolism. Alternatively, teams may focus on novel approaches to address specific knowledge gaps or scientific questions that will significantly contribute to our understanding of role of the autonomic nervous system in metabolism with the goal of accelerating scientific progress in the treatment and prevention of metabolic disease. This FOA will use the NIH RC2 High Impact Research and Research Infrastructure Programs award mechanism.</p>				
073342	<a href="#">New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-18-730	07-May-2020	600,000 USD
	Contact Name Terry Rogers Bishop, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-7726</p> <p>Contact Email <a href="mailto:terry.bishop@nih.gov">terry.bishop@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications in nonmalignant hematology research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build and promote research activities in nonmalignant hematology. Innovative research project applications that will steer the field in new directions are invited. Each project will propose proof of principle research that is tightly focused into one specific aim and is directed at validating novel concepts and approaches that promise to open up new pathways for discovery. Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
073411	<a href="#">Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-741	07-May-2020	275,000 USD
	<p>Contact Name Aynur Unalp-Arida, MD, MSc, PhD</p> <p>Contact Telephone 301-594-8879</p> <p>Contact Email <a href="mailto:aynur.unalp-arida@nih.gov">aynur.unalp-arida@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
076166	<a href="#">Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney	PAR-18-854	11-May-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Diseases/NIH/DHHS

Contact Name	Mary Evans, Ph.D.
Contact Telephone	301-594-4578
Contact Email	<a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	11-May-2020 , 10-Jun-2020 , 10-Jul-2020 , 11-Aug-2020 , 10-Sep-2020 , 14-Oct-2020 , 10-Nov-2020 , 11-Dec-2020 , 11-Jan-2021 , 10-Feb-2021 , 10-Mar-2021 , 09-Apr-2021 , 10-May-2021 , 11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.

076238	<a href="#">Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-856	07-May-2020	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Mary Evans, Ph.D.
Contact Telephone	301-594-4578
Contact Email	<a href="mailto:evansmary@nidk.nih.gov">evansmary@nidk.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH Research Project (R01) award mechanism.			
084473	<a href="#">NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-319	30-Jun-2020	Not Specified
	Contact Name	Lisa M. Spain, Ph.D			
	Contact Telephone	301-451-9871			
	Contact Email	<a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 , 27-Oct-2020 , 02-Mar-2021 , 29-Jun-2021 , 26-Oct-2021 , 01-Mar-2022 , 28-Jun-2022			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at <a href="http://www.niddkrepository.org">www.niddkrepository.org</a> . Applicants must provide information from the NIDDK Central Repositories documenting sample availability. This FOA will utilize the NIH X01 Resource Access Award mechanism.			
085472	<a href="#">Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-365	07-May-2020	150,000 USD
	Contact Name	Lisa M. Spain, Ph.D.			
	Contact Telephone	301-451-9871			
	Contact Email	<a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to provide NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08,			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This program will use the NIH Small Research Grant (R03) award mechanism.</p>			
085595	<a href="#">RFA-DK-19-005--NIDDK Cooperative Centers of Excellence in Hematology (U54 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-19-005	30-May-2020 [Optional][LOI/Pre-App]	3,250,000 USD
	Contact Name	Terry Rogers Bishop, MD, PhD			
	Contact Telephone	301-594-7726			
	Contact Email	<a href="mailto:terry.bishop@nih.gov">terry.bishop@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-May-2020 [Optional][LOI/Pre-App], 30-Jun-2020			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement is to invite U54 cooperative agreement applications for Cooperative Centers of Excellence in Hematology (CCEH). The NIDDK Hematology Centers Program is designed to increase access to critical research resources and collaboration in the national multidisciplinary research effort to combat nonmalignant hematologic diseases and to study normal hematopoiesis. In addition, it aims to improve cost-effectiveness of preparing critical reagents, maintaining state-of-the-art resources, and running multi-step molecular biologic assays. Each CCEH will support a minimum of three Biomedical Research Cores, an Administrative Core, and an Enrichment Program. The CCEH are expected to work collaboratively with the NIDDK Hematology Central Coordinating Center -- together comprising the NIDDK Hematology Centers Program. By providing state-of-the-art equipment, resources, and expertise to the greater nonmalignant hematology research community, the program will serve as a national hub for nonmalignant hematology research, supporting career development of scientists just beginning their careers in the field and attracting established investigators from other domains. Funded Centers will cooperate with the NIDDK to facilitate research collaborations and interactions within and among Centers and with the wider research community.</p>			
079079	<a href="#">Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-19-105	05-Jun-2020	Not Specified
	Contact Name	Terry Rogers Bishop, Ph.D.			
	Contact Telephone	301-594-7726			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:terry.bishop@nih.gov">terry.bishop@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.</p>				
067709	<a href="#">Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-330	07-May-2020	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for investigator-initiated clinical trials within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to be conducted at no more than two clinical research centers. NIDDK is committed to improving the health of people with diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic and hematologic diseases. Applications for clinical trials submitted under this FOA should be hypothesis driven, have clearly described aims and objectives, and have a high likelihood that the trial findings will improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
087233	<a href="#">RFA-DK-19-017 -- The Physiology of the Weight Reduced State Clinical Trial Consortium (UG3/UH3 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-19-017	11-May-2020 [Optional][LOI/Pre-App]	3,285,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Maren R Laughlin, Ph.D.				
Contact Telephone	301-594-8802				
Contact Email	<a href="mailto:maren.laughlin@nih.gov">maren.laughlin@nih.gov</a>				
Sponsor Website					
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	11-May-2020 [Optional][LOI/Pre-App], 11-Jun-2020				
Synopsis	<p>Following intentional weight loss, physiological processes including altered appetite and decreased energy expenditure create a tendency toward regain of lost weight. This Funding Opportunity Announcement (FOA) invites UG3/UH3 cooperative agreement applications from multi-disciplinary teams that propose to conduct collaborative mechanistic clinical trials focused on elucidation of the physiological mechanisms underlying individual variability in maintenance of reduced weight over time. This FOA will not support studies with a goal to evaluate the efficacy of interventions for weight loss or maintenance of reduced weight. Participants must be studied before and after a successful behavioral/lifestyle weight loss intervention to determine the extent, durability, and mechanisms for physiologic adaptations to weight loss, including metabolic and biobehavioral mechanisms. It is expected that tissue biospecimens will be collected that can be used to identify potential metabolic pathways that are altered after weight loss and may render it more difficult to maintain the reduced weight. This Funding Opportunity Announcement (FOA) will use the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism in parallel with a companion FOA, RFA DK-19-018 , Physiology of the Weight Reduced State Data Coordinating Center (U24 Clinical Trial Not Allowed). Awards made under this FOA will initially support a planning/preparation phase (UG3) for approximately one year with possible transition to a study (UH3) phase of up to four additional years once planning milestones are met. Applications submitted in response to this FOA must propose activities for both phases and are expected to include plans for project management and performance milestones for each phase.</p>				

087236	<a href="#">RFA-DK-19-018 -- The Physiology of the Weight Reduced State Data Coordinating Center (U24 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-19-018	11-May-2020 [Optional][LOI/Pre-App]	2,180,000 USD
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Maren R Laughlin, Ph.D.				
Contact Telephone	301-594-8802				
Contact Email	<a href="mailto:maren.laughlin@nih.gov">maren.laughlin@nih.gov</a>				
Sponsor Website					
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	11-May-2020 [Optional][LOI/Pre-App], 11-Jun-2020				
Synopsis	This Funding Opportunity Announcement (FOA) invites U24 cooperative agreement applications for a Data Coordination Center to participate in a clinical trial focused on elucidation of the physiological mechanisms underlying individual variability				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		in maintenance of reduced weight over time. A companion FOA (RFA DK-19-017, The Physiology of the Weight Reduced State Clinical Trial Consortium (UG3/UH3 Clinical Trial Required) invites Clinical Centers (CC) to recruit and study participants before and after a behavioral/lifestyle weight loss intervention to determine the extent, durability and mechanisms for physiologic adaptations to weight loss, including metabolic and biobehavioral mechanisms. It is expected that tissue biospecimens will be collected that can be used to identify potential metabolic pathways that are altered after weight loss and may render it more difficult to maintain the reduced weight.			
071705	<a href="#">Pilot and Feasibility Studies of HIV and Animal Models for HIV Infection within the Mission of NIDDK (R21 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-615	07-May-2020	275,000 USD
	Contact Name	Peter J. Perrin, Ph.D.			
	Contact Telephone	301-451-3759			
	Contact Email	<a href="mailto:Peter.Perrin@nih.gov">Peter.Perrin@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational research projects examining HIV infection, persistence, and comorbidities as they relate to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that are consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.			
072688	<a href="#">High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-18-698	07-May-2020	Not Specified
	Contact Name	Peter J. Perrin, Ph.D.			
	Contact Telephone	301-451-3759			
	Contact Email	<a href="mailto:Peter.Perrin@nih.gov">Peter.Perrin@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

069922	<a href="#">NIDDK Mentored Research Scientist Development Award (K01 - Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-419	07-May-2020	575,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Lisa M. Spain, Ph.D.
Contact Telephone	301-451-9871
Contact Email	<a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021
Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for Mentored Research Scientist Development Awards (K01). The awards provide support and protected time for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. The NIDDK invites K01 applications from experienced postdoctoral (two years minimum) and/or recently appointed junior faculty (usually with a Ph.D. degree) in biomedical, behavioral, or clinical sciences who are pursuing careers in research areas supported by the NIDDK. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial that is itself comprised of a clinical trial intervention(s). Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

090031	<a href="#">RFA-DK-20-001 -- Urological Epidemiology (UroEpi) Institutional Research Career Development Program [K12-Independent Clinical Trial Not Allowed]</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-001	18-May-2020 [Optional][LOI/Pre-App]	3,000,000 USD
--------	--	---	---------------	-------------------------------------	---------------

Contact Name	Kevin C. Abbott, MD, MPH
Contact Telephone	301-594-7714
Contact Email	<a href="mailto:Kevin.abbott@nih.gov">Kevin.abbott@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	18-May-2020 [Optional][LOI/Pre-App], 18-Jun-2020
Synopsis	This Funding Opportunity Announcement (FOA) invites institutional career development program (K12) applications in the

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

area of epidemiology of benign urological conditions. This institutional program will provide scholars with research and/or clinical doctoral degrees (including MD, PhD, MD/PhD, DrPH) with the skills and resources necessary to initiate an independent research career in the epidemiology of benign urological conditions within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

090389	<a href="#">RFA-DK-20-006 -- Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-006	22-Jun-2020 [Optional][LOI/Pre-App]	650,000 USD
--------	--	---	---------------	-------------------------------------	-------------

Contact Name	Daniel Gossett, Ph.D.
Contact Telephone	301-594-7723
Contact Email	<a href="mailto:daniel.gossett@nih.gov">daniel.gossett@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	22-Jun-2020 [Optional][LOI/Pre-App], 22-Jul-2020
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences This FOA encourages applications from institutions that propose to establish research experiences in kidney technology development. Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. Applications must include plans to recruit undergraduate students as participants and to engage students from engineering and other quantitative scientific and technical backgrounds, but applicants may also propose the inclusion of medical students, graduate students and/or dual-degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.

080282	<a href="#">High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-202	02-Jun-2020	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Corinne M. Silva, Ph.D.
Contact Telephone	301-451-7335
Contact Email	<a href="mailto:silvacm@mail.nih.gov">silvacm@mail.nih.gov</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Jun-2020 , 03-Nov-2020 , 01-Jun-2021 , 02-Nov-2021			
	Synopsis	The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of NIDDK.			
069889	<a href="#">NIDDK Multi-Center Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-415	07-May-2020	Not Specified
	Contact Name	Marva Moxey-Mims, M.D			
	Contact Telephone	301-594-7717			
	Contact Email	<a href="mailto:mimsm@mail.nih.gov">mimsm@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for investigator-initiated, multi-center clinical trials involving three or more clinical centers. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-18-423). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This program use the the NIH U01 grant mechanism.			
080578	<a href="#">RFA-DK-19-002 -- Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-19-002	03-May-2020 [Optional][LOI/Pre-App]	3,750,000 USD
	Contact Name	Mary E. Evans, Ph.D.			
	Contact Telephone	301-594-4578			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-May-2020 [Optional][LOI/Pre-App], 02-Jun-2020</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of research in nutrition and obesity. The NIDDK Nutrition Obesity Research Centers program consists of 12 Centers, each located at outstanding research institutions with documented programs of excellence in nutrition and/or obesity research.</p>				
069904	<a href="#">NIDDK Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-414	07-May-2020	Not Specified
	<p>Contact Name Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone 301-594-4748</p> <p>Contact Email <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for investigator-initiated, multi-center clinical trials involving three or more clinical centers. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-18-423). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application. This program use the the NIH U01 grant mechanism.</p>				
090534	<a href="#">Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20-140	16-Jun-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Daniel Gossett, Ph.D.			
	Contact Telephone	301-594-7723			
	Contact Email	<a href="mailto:daniel.gossett@nih.gov">daniel.gossett@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.			
078518	<a href="#">Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-19-065	07-May-2020	Not Specified
	Contact Name	Jose Serrano, M.D., Ph.D.			
	Contact Telephone	301-594-8871			
	Contact Email	<a href="mailto:serranoj@mail.nih.gov">serranoj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop “virtual coaches” by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate).			
069920	<a href="#">NIDDK Mentored Research Scientist Development Award (K01 - Clinical</a>	National Institute of Diabetes and	PAR-18-	07-May-2020	575,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Trial Required</a>		Digestive and Kidney Diseases/NIH/DHHS		418 USD
	Contact Name	Lisa M. Spain, Ph.D.			
	Contact Telephone	301-451-9871			
	Contact Email	<a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for Mentored Research Scientist Development Awards (K01). The awards provide support and protected time for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. The NIDDK invites K01 applications from experienced postdoctoral (two years minimum) and/or recently appointed junior faculty (usually with a Ph.D. degree) in biomedical, behavioral, or clinical sciences who are pursuing careers in research areas supported by the NIDDK. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. The ancillary study must also meet the NIH clinical trial definition. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.			
091518	<a href="#">Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-20-160	05-Jun-2020	600,000 USD
	Contact Name	Susan Mendley, M.D.			
	Contact Telephone	301- 827-1861			
	Contact Email	<a href="mailto:susan.mendley@nih.gov">susan.mendley@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023			
	Synopsis	This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.			
069548	<a href="#">Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21 Clinical Trial Required)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-405	07-May-2020	275,000 USD
	Contact Name	Yan Li			
	Contact Telephone	301-435-3721			
	Contact Email	<a href="mailto:liy7@mail.nih.gov">liy7@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites pilot and feasibility therapeutic trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diabetes or selected endocrine and genetic metabolic diseases within the mission of NIDDK. The program will support short-term clinical trials in humans to acquire preliminary data and/or refine power calculations that would lead to a larger, more definitive study impacting clinical care or health outcomes. This FOA is not appropriate for mechanistic clinical trials. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			
073445	<a href="#">Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-743	07-May-2020	275,000 USD
	Contact Name	Ziya Kirkali, M.D.			
	Contact Telephone	301-594-7717			
	Contact Email	<a href="mailto:ziya.kirkali@nih.gov">ziya.kirkali@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			
073449	<a href="#">Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-744	07-May-2020	275,000 USD
	Contact Name	Tracy L. Rankin, Ph.D., M.P.H.			
	Contact Telephone	301-594-4748			
	Contact Email	<a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			
080703	<a href="#">Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-222	07-May-2020	375,000 USD
	Contact Name	Lawrence Agodoa, M.D.			
	Contact Telephone	301-594-1932			
	Contact Email	<a href="mailto:SmallGrant4Diversity@nidk.nih.gov">SmallGrant4Diversity@nidk.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators: (1) from diverse backgrounds, including from groups nationally underrepresented in biomedical and behavioral research to conduct			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Human Genome Research Institute (NHGRI) and (2) who at the time of award under this FOA will have/have had less than \$125,000 direct cost of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

073219	<a href="#">Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-720	07-May-2020	275,000 USD
--------	---	---	-----------	-------------	-------------

Contact Name	Robert J. Kuczmariski, Dr.P.H.
Contact Telephone	301-451-8354
Contact Email	<a href="mailto:kuczmariskir@mail.nih.gov">kuczmariskir@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.

076246	<a href="#">Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-857	07-May-2020	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Mary Evans, Ph.D.
Contact Telephone	301-594-4578
Contact Email	<a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
076910	<a href="#">Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21 Clinical Trial Optional)</a>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-903	07-May-2020	275,000 USD
	Contact Name	Edward Doo, MD			
	Contact Telephone	301-451-4524			
	Contact Email	<a href="mailto:dooe@niddk.nih.gov">dooe@niddk.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	<p>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for research concepts for clinical pilot and feasibility research studies; and translational research studies in digestive diseases and nutrition. Specifically, this FOA is inviting two types of studies: Clinical Pilot and Feasibility study proposals; and Clinical Translational Science proposals that will promote exploratory and novel science through the use of human subjects biospecimens. The following studies will not be supported by this FOA: those that have obesity as a component of the study proposal (please refer to the Office of Extramural Research Grants and Funding to search for multiple obesity related Funding Opportunity Announcements at <a href="https://grants.nih.gov/grants/oer.htm">https://grants.nih.gov/grants/oer.htm</a> ); and translational studies that utilize animal models. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>			
068838	<a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-18-291	12-Jun-2020	375,000 USD
	Contact Name	Carol Shreffler, Ph.D.			
	Contact Telephone	919-541-1445			
	Contact Email	<a href="mailto:Shreffl1@niehs.nih.gov">Shreffl1@niehs.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021

Synopsis National Institute of Environmental Health Sciences (NIEHS) invites applications for the Transitions to Independent Environmental Health Research (TIEHR) Career Development Award. This award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

068837	<a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-18-261	12-Jun-2020	375,000 USD
--------	--	--	------------	-------------	-------------

Contact Name Carol Shreffler, Ph.D.  
 Contact Telephone 919-541-1445  
 Contact Email [Shreffl1@niehs.nih.gov](mailto:Shreffl1@niehs.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021

Synopsis National Institute of Environmental Health Sciences (NIEHS) invites applications for the Transitions to Independent Environmental Health Research (TIEHR) Career Development Award. This award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. his Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial a feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
080739	<a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-19-225	07-May-2020	375,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Carol Shreffler, PhD</p> <p>Contact Telephone   984-287-3322</p> <p>Contact Email   <a href="mailto:shreffl1@niehs.nih.gov">shreffl1@niehs.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion ‘Independent Clinical Trial Required’ PAR 18-261.</p>				
091110	<a href="#">RFA-ES-20-009 -- Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-20-009	19-May-2020 [Optional][LOI/Pre-App]	6,000,000 USD
	<p>Contact Name   Jennifer B. Collins</p> <p>Contact Telephone   984-287-3247</p> <p>Contact Email   <a href="mailto:collins6@niehs.nih.gov">collins6@niehs.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   19-May-2020 [Optional][LOI/Pre-App], 18-Jun-2020</p> <p>Synopsis   The NIEHS Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program is intended to provide support for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award to support the majority of their</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

independent environmental health sciences research program.

084593	<a href="#">RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)</a>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	01-May-2020	275,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name	Martha I. Barnes, MS
Contact Telephone	919-541-3335
Contact Email	<a href="mailto:barnes@niehs.nih.gov">barnes@niehs.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-May-2020 , 01-Jun-2020 , 01-Jul-2020 , 03-Aug-2020 , 01-Sep-2020 , 01-Oct-2020 , 02-Nov-2020 , 01-Dec-2020 , 04-Jan-2021 , 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021 , 01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022
Synopsis	This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

081443	<a href="#">Exploratory Research for Technology Development (R21 - Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-254	16-Jun-2020	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Paul Sammak, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:paul.sammak@nih.gov">paul.sammak@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022
Synopsis	This Funding Opportunity Announcement (FOA) will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high-risk approaches with potential for

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been developed in the literature or with preliminary data. Published data can be used to establish the current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely-available preprints that have a Digital Object Identifier (DOI) are acceptable.

082561	<a href="#">RFA-RM-19-004 -- Sponsored Programs Administration Development (SPAD) Program (UC2 Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	RFA-RM-19-004	26-Jun-2020	600,000 USD
--------	--	---	---------------	-------------	-------------

Contact Name	Luis A. Cubano, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:luis.cubano@nih.gov">luis.cubano@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	26-Jun-2020
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that propose to establish Offices of Sponsored Programs (OSPs) or enhance the services of existing OSPs or similar entities at domestic institutions of higher learning. Program priorities include funding primarily undergraduate institutions with emerging biomedical research and/or undergraduate research training programs. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative through the NIH Office of the Director, Office of Strategic Coordination. All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of General Medical Sciences (NIGMS) on behalf of the NIH

083122	<a href="#">Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences (R01 - Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-295	05-Jun-2020	1,250,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Michael A. Sesma, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:msema@mail.nih.gov">msema@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that propose research designed to test training, mentoring, and networking interventions intended to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the design and implementation of interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.</p>				
083521	<a href="#">Limited Competition: NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-301	15-Jun-2020	3,750,000 USD
	<p>Contact Name Peter C. Preusch, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:preuschp@nigms.nih.gov">preuschp@nigms.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2020 , 15-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for support of national or regional resources that will provide access to state-of-the-art facilities, equipment, technologies, research tools, software, and/or service to a substantial user base at institutions across multiple states (regional) or the country (national). These resources should already be established, although new resources formed through consolidation of multiple local or regional facilities are also eligible. They should be poised to achieve or already have achieved significant economies of scale and should be able to significantly increase access to the supported technologies or services for researchers across one or more regions or the country. Major new research and development efforts should not be included. For this FOA, a resource is defined as an activity that provides research capabilities and expertise to a large number of investigators and is available to any qualified investigator as a service. The intent is to provide access to investigators without regard to the particular biomedical focus of their research, but not to duplicate or replace resources supported by other NIH Institutes and Centers (ICs) or host institutions. Only those resources whose technical capabilities fall within the program areas supported by NIGMS will be supported. It is expected that the resource will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support. Stand-alone data resources and databases are not eligible for funding through this FOA. This FOA is limited to applications requesting support for resources that have been developed through previous NIGMS funding.</p>				
081442	<a href="#">Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-253	05-Jun-2020	Not Specified
	Contact Name Paul Sammak, Ph.D.				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email <a href="mailto:paul.sammak@nih.gov">paul.sammak@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact. The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. Proof of concept for the technology must have already been demonstrated, but there should still be significant technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three-year R01 application with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four-year duration (five years for Early Stage Investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive.</p>				
072936	<a href="#">Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Not Allowed)</a>	National Institute of General Medical Sciences/NIH/DHHS	PAR-18-714	07-May-2020	300,000 USD
	<p>Contact Name Alexandra M. Ainsztein, PhD.</p> <p>Contact Telephone 301-594-0943</p> <p>Contact Email <a href="mailto:Alexandra.Ainsztein@nih.gov">Alexandra.Ainsztein@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 25-Jun-2020 , 07-Sep-2020 , 25-Oct-2020 , 07-Jan-2021 , 25-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of General Medical Sciences (NIGMS) invites applications for the Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions. The purpose of the award is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees, and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This FOA will use the NIH R15 Academic Research Enhancement Award (AREA) mechanism.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
078035	<a href="#">Basic Neurodevelopmental Biology of Brain Circuits and Behavior (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-028	16-Jun-2020	275,000 USD
	Contact Name	Bettina Buhring			
	Contact Telephone	301-443-1576			
	Contact Email	<a href="mailto:neurodevelopmentpar@mail.nih.gov">neurodevelopmentpar@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change during pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity seeks R01 grant applications.</p>			
081132	<a href="#">Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-236	05-Jun-2020	Not Specified
	Contact Name	Susan T. Azrin, Ph.D.			
	Contact Telephone	301-443-3267			
	Contact Email	<a href="mailto:susan.azrin@nih.gov">susan.azrin@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022			
	Synopsis	<p>Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP in the U.S. by eliminating bottlenecks or closing gaps in the pathway to CSC services. Alternatively, applicants whose work in this area is at a developmental stage should consider applying to the companion R34 FOA PAR-19-235.			
063784	<a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R21)</a>	National Institute of Mental Health/NIH/DHHS	PAR-17-310	16-Jun-2020	275,000 USD
	Contact Name	David Panchision			
	Contact Telephone	301-443-5288			
	Contact Email	<a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020			
	Synopsis	National Institute of Mental Health (NIMH) invites research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
082860	<a href="#">Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-289	05-Jun-2020	Not Specified
	Contact Name	Lois Winsky, Ph.D.			
	Contact Telephone	301-443-5288			
	Contact Email	<a href="mailto:lwinsky@mail.nih.gov">lwinsky@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses. The objectives of the FOA will be accomplished by supporting basic and translational neuroscientists who are committed to			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivophysiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. As such, this FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.			
070086	<a href="#">Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-430	05-Jun-2020	Not Specified
	Contact Name	Adam Haim, Ph.D.			
	Contact Telephone	301-435-3593			
	Contact Email	<a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This FOA encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA will use the NIH Research Project (R01) award mechanism.			
070076	<a href="#">Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-428	05-Jun-2020	2,500,000 USD
	Contact Name	Denise Pintello, Ph.D., M.S.W.			
	Contact Telephone	301-451-1481			
	Contact Email	<a href="mailto:dpintell@mail.nih.gov">dpintell@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and test the navigator model's ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as symptoms are detected. Of interest are navigator models that coordinate needed care strategies, determine the "personalized match" to the level of needed service amount, frequency and intensity, and harness novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
073671	<a href="#">NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 Independent Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-755	12-Jun-2020	900,000 USD
	<p>Contact Name Ashlee Van't Veer, PhD</p> <p>Contact Telephone 301-443-3107</p> <p>Contact Email <a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) provides support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (DIRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields. This FOA will utilize the NIH Career Transition (K22) award mechanism.</p>				
071668	<a href="#">Mentored Career Transition Award for Intramural Fellows (K22 No Independent Clinical Trials)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-614	12-Jun-2020	Not Specified
	<p>Contact Name Ashlee Van't Veer</p> <p>Contact Telephone 301-443-3107</p> <p>Contact Email <a href="mailto:dnbstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K22 Career Transition Award mechanism.</p>				
076934	<a href="#">Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-904	05-Jun-2020	Not Specified
	<p>Contact Name Anjené Addington</p> <p>Contact Telephone 301-443-6653</p> <p>Contact Email <a href="mailto:anjene.addinton@nih.gov">anjene.addinton@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for projects that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
083168	<a href="#">Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-297	07-May-2020	Not Specified
	<p>Contact Name Anjené Addington</p> <p>Contact Telephone 301-443-6653</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:anjene.addington@nih.gov">anjene.addington@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.</p>				
077196	<a href="#">New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 (Collab) Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-907	07-May-2020	Not Specified
	<p>Contact Name Alexander Arguello, PhD</p> <p>Contact Telephone 301-827-3547</p> <p>Contact Email <a href="mailto:alexander.arguello@nih.gov">alexander.arguello@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA should be used when two or more sites are needed to complete the study. For a linked set of collaborative R01s, each site must have its own</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Program Director/Principal Investigator and the set of linked applications provide a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA will use the NIH Research Project (R01) award mechanism.			
076937	<a href="#">Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 (Collab) Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-905	05-Jun-2020	Not Specified
	Contact Name	Anjené Addington			
	Contact Telephone	301-443-6653			
	Contact Email	<a href="mailto:anjene.addinton@nih.gov">anjene.addinton@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for collaborative R01 projects from multidisciplinary teams that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address research projects that go beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions. This FOA will use the NIH Research Project (R01) award mechanism.			
077195	<a href="#">New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-908	07-May-2020	Not Specified
	Contact Name	Alexander Arguello, PhD			
	Contact Telephone	301-827-3547			
	Contact Email	<a href="mailto:alexander.arguello@nih.gov">alexander.arguello@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA will use the NIH Research Project (R01) award mechanism.			
069759	<a href="#">Research on Autism Spectrum Disorders (R21-Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-400	16-Jun-2020	275,000 USD
	Contact Name	Lisa Gilotty, Ph.D.			
	Contact Telephone	301-443-3825			
	Contact Email	<a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
069760	<a href="#">Research on Autism Spectrum Disorders (R03-Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-399	16-Jun-2020	100,000 USD
	Contact Name	Lisa Gilotty, Ph.D.			
	Contact Telephone	301-443-3825			
	Contact Email	<a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). This program will use the NIH R03 Small Grant Program award mechanism.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
069757	<a href="#">Research on Autism Spectrum Disorders (R01-Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-401	05-Jun-2020	Not Specified
	Contact Name	Lisa Gilotty, Ph.D.			
	Contact Telephone	301-443-3825			
	Contact Email	<a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). This program will use the NIH Research Project Grant (R01) award mechanism.			
070136	<a href="#">Detecting and Preventing Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-479	05-Jun-2020	500,000 USD
	Contact Name	Denise Juliano-Bult, M.S.W.			
	Contact Telephone	301-443-1638			
	Contact Email	<a href="mailto:djuliano@mail.nih.gov">djuliano@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system. Opportunities for detection and prevention start at early points of contact (e.g., police interaction, the intake interview) and continue through many juvenile justice settings (e.g., pre-trial detention, juvenile or family court activities, court disposition, placement and on-going care in either residential or multiple community settings.) This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population. This FOA will use the NIH R01 Research Project Grant award mechanism.			
069255	<a href="#">Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R34 Clinical Trial Required) (Defunct)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-228	16-Jun-2020	450,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Denise Juliano-Bult, M.S.W.			
	Contact Telephone	301-443-1638			
	Contact Email	<a href="mailto:djuliano@mail.nih.gov">djuliano@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system. Opportunities for detection and prevention start at early points of contact (e.g., police interaction, the intake interview) and continue through many juvenile justice settings (e.g., pre-trial detention, juvenile or family court activities, court disposition, placement and on-going care in either residential or multiple community settings.) This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population. The purpose of this FOA is to provide resources for evaluating the feasibility, tolerability, acceptability and safety of novel approaches to improving outcomes, modifying health risk behavior, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale (efficacy or effectiveness) services study. This FOA will use the NIH R34 Planning Grant award mechanism.			

070073	<a href="#">First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-427	07-May-2020	Not Specified
--------	--	--	------------	-------------	---------------

	Contact Name	Lois Winsky, Ph.D.			
	Contact Telephone	301-443-5288			
	Contact Email	<a href="mailto:lwinsky@mail.nih.gov">lwinsky@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

079331	<a href="#">Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-146	07-May-2020	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Enrique Michelotti, PhD
Contact Telephone	301-443-5415
Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism ( PAR-19-147)

079325	<a href="#">Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-147	07-May-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Enrique Michelotti, PhD
Contact Telephone	301-443-5415
Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.			

078784	<a href="#">Emotion Regulation, Aging and Mental Disorder (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-19-094	05-Jun-2020	Not Specified
--------	--	--	-----------	-------------	---------------

	Contact Name	Jovier Evans, PhD			
	Contact Telephone	301-443-1369			
	Contact Email	<a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.			

077725	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-942	05-Jun-2020	Not Specified
--------	--	--	------------	-------------	---------------

	Contact Name	David McMullen, M.D.			
	Contact Telephone	301-451-0180			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [david.mcmullen@nih.gov](mailto:david.mcmullen@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021

Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA may propose hypothesis-driven research , but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA.

077665	<a href="#">Development and Optimization of Tasks and Measures for Functional Domains of Behavior (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-930	05-Jun-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name Sarah Morris, Ph.D.

Contact Telephone 301-443-9233

Contact Email [sarah.morris@nih.gov](mailto:sarah.morris@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021

Synopsis National Institute of Mental Health (NIMH) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for the development and optimization of tasks and/or measures for constructs pertaining to functional aspects of behavior or cognitive/affective processes, for use in laboratory or population-based studies, clinical trials outcomes, or related research. This FOA encourages research that will result in the availability of tasks and measures that demonstrate: (1) good validity as a measure of a specific construct; (2) robust measurement properties; and (3) suitability for use across

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

diverse participants. This FOA will use the NIH Research Project (R01) award mechanism.

080146	<a href="#">Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-189	16-Jun-2020	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Denise Juliano-Bult, M.S.W.
Contact Telephone	301-443-1638
Contact Email	<a href="mailto:djuliano@mail.nih.gov">djuliano@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021
Synopsis	The purpose of this funding announcement is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials. These areas include: 1) studies to identify mutable factors that impact access, continuity, utilization, quality, value, outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future intervention development 2) development and testing of new research tools, measures, or methods 3) testing the feasibility of integrating existing data sets to understand factors affecting access, quality or outcomes of care 4) pilot work on the learning mental health care system model as a means to enable practical studies of the value and effectiveness of services and treatments Studies focused on the development or preliminary testing of services interventions should be submitted under RFA-MH-18-706 (SPIN # 68982).

062237	<a href="#">Innovative Mental Health Services Research Not Involving Clinical Trials (R01)</a>	National Institute of Mental Health/NIH/DHHS	PAR-17-264	05-Jun-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Michael C. Freed, Ph.D.
Contact Telephone	301-443-3747
Contact Email	<a href="mailto:michael.freed@nih.gov">michael.freed@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2020
Synopsis	National Institute of Mental Health (NIMH) invites applications for innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research (see <a href="http://www.nimh.nih.gov/about/strategic-">http://www.nimh.nih.gov/about/strategic-</a>



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>planning-reports/strategic-research-priorities/srp-objective-4/index.shtml). Proposed research should seek to: 1) Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services in the United States, which may serve as targets in future service delivery intervention development; 2) Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues; 3) Integrate and analyze large data sets to understand factors affecting mental health services outcomes using sophisticated computational and predictive analytic approaches; 4) Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
077664	<a href="#">High-Priority Areas for Research Leveraging EHR and Large-Scale Data (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-929	05-Jun-2020	Not Specified
	Contact Name	Farris Tuma, ScD			
	Contact Telephone	301-443-9232			
	Contact Email	<a href="mailto:ftuma@mail.nih.gov">ftuma@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers, along with Department of Veterans Affairs (VA) invite applications to leverage large-scale, real-world data from electronic health records (EHRs) from a variety of systems (e.g., the Department of Defense (DOD), Department of Veterans Affairs (VA), Centers for Medicare and Medicaid Services administrative claims, as well as public or private health care systems and networks) to understand risk, onset, course, and impact of treatments and services for mental and neurological disorders and to identify promising new mental health and neurological disorders research. There is particular interest in leveraging EHRs and administrative data to 1) understand and improve the treatment of post traumatic psychopathology, including posttraumatic stress disorder, depression, traumatic brain injury (TBI), and risk for suicide; and 2) characterize post-trauma multi-symptom recovery trajectory patterns of TBI, that may include post traumatic stress disorder, depression, cognitive impairment, pain, substance abuse disorder and risk for suicide. NIMH also invites innovative approaches to use EHR and administrative data to understand risk, onset, course, and impact of treatments and services for mental disorders more broadly. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
068701	<a href="#">NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-350	07-May-2020	275,000 USD
	Contact Name	Pim Brouwers, Ph.D.			
	Contact Telephone	240-627-3863			
	Contact Email	<a href="mailto:ebrouwer@mail.nih.gov">ebrouwer@mail.nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			
071667	<a href="#">Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-613	12-Jun-2020	Not Specified
	Contact Name	Ashlee Van't Veer			
	Contact Telephone	301-443-3107			
	Contact Email	<a href="mailto:dnbbsstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K22 Career Transition Award mechanism.			
065058	<a href="#">Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21)</a>	National Institute of Mental Health/NIH/DHHS	PAR-17-335	07-May-2020	275,000 USD
	Contact Name	Enrique L. Michelotti, Ph.D.			
	Contact Telephone	301-443 5415			
	Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIA, and/or NIDCD; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be in the discovery of cell-based chemical probes. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
065054	<a href="#">Discovery of in vivo Chemical Probes for Novel Brain Targets (R01)</a>	National Institute of Mental Health/NIH/DHHS	PAR-17-336	07-May-2020	Not Specified
	<p>Contact Name Enrique L. Michelotti, Ph.D.</p> <p>Contact Telephone 301-443 5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NEI, NIAAAA, NIDA, NIA and/or NIDCD and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
063781	<a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R01)</a>	National Institute of Mental Health/NIH/DHHS	PAR-17-309	05-Jun-2020	Not Specified
	Contact Name David Panchision				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-443-5288			
	Contact Email	<a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020			
	Synopsis	National Institute of Mental Health (NIMH) invites research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. This FOA will use the NIH Research Project (R01) award mechanism.			
070684	<a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-554	07-May-2020	275,000 USD
	Contact Name	Bettina D. Buhring, Ph.D.			
	Contact Telephone	301-443-1576			
	Contact Email	<a href="mailto:bettina.buhring@mail.nih.gov">bettina.buhring@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Mental Health's (NIMH) invites applications for projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
070409	<a href="#">Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-505.	07-May-2020	Not Specified
	Contact Name	Jamie Driscoll			
	Contact Telephone	301-443-5288			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:jdrisco1@mail.nih.gov">jdrisco1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to develop novel, robust assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function into phenotypic assays, with the intent to probe mechanisms or perturbations in an unbiased and efficient manner. These novel assays would provide opportunities to measure neurobiological endpoints to accelerate basic discovery and support target identification and therapeutic development efforts. This FOA will use the NIH Research Project (R01) award mechanism.			
081133	<a href="#">Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-235	16-Jun-2020	450,000 USD
	Contact Name	Susan T. Azrin, Ph.D.			
	Contact Telephone	301-443-3267			
	Contact Email	<a href="mailto:susan.azrin@nih.gov">susan.azrin@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022			
	Synopsis	Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. Alternatively, applicants who have already completed significant developmental or pilot work in this area are encouraged to apply to the companion R01 FOA PAR-19-236.			
070089	<a href="#">Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize</a>	National Institute of Mental	PAR-18-	16-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Longer-term Outcomes (R34 Clinical Trial Required)</a>		Health/NIH/DHHS	431	Specified
	Contact Name	Adam Haim, Ph.D.			
	Contact Telephone	301-435-3593			
	Contact Email	<a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	<p>National Institute of Mental Health (NIMH) invites applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA will use the NIH R34 Planning Grant award mechanism.</p>			
078030	<a href="#">Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-027	05-Jun-2020	2,500,000 USD
	Contact Name	Bettina Buhring			
	Contact Telephone	301-443-1576			
	Contact Email	<a href="mailto:neurodevelopmentpar@mail.nih.gov">neurodevelopmentpar@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion funding opportunity seeks shorter, higher-risk R21</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| grant applications.

070683	<a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-555	07-May-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Bettina D. Buhring, Ph.D.
Contact Telephone	301-443-1576
Contact Email	<a href="mailto:bettina.buhring@mail.nih.gov">bettina.buhring@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021
Synopsis	National Institute of Mental Health's (NIMH) invites applications for projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA will use the NIH Research Project (R01) award mechanism.

080474	<a href="#">Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-214	19-Jun-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Lois Winsky, Ph.D.
Contact Telephone	301-443-5288
Contact Email	<a href="mailto:lwinsky@mail.nih.gov">lwinsky@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	19-Jun-2020 , 20-Oct-2020 , 19-Feb-2021 , 21-Jun-2021 , 20-Oct-2021 , 21-Feb-2022
Synopsis	The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to specific chemical, physiological, or behavioral manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.

070081	<a href="#">Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-429	16-Jun-2020	450,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Denise Pintello, Ph.D., M.S.W.
Contact Telephone	301-451-1481
Contact Email	<a href="mailto:dpintell@mail.nih.gov">dpintell@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020
Synopsis	National Institute of Mental Health (NIMH) invites applications research applications to develop and pilot test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and pilot test the navigator model's ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as symptoms are detected. Of interest are navigator models that coordinate needed care strategies, determine the "personalized match" to the level of needed service amount, frequency and intensity, and harness novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

achieving intended services outcomes. This FOA will use the NIH R34 Planning Grant award mechanism.

071755	<a href="#">Research to Support the Reduction and Elimination of Mental Health Disparities (Admin Supp Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PA-18-621	01-Jun-2020	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name	Andrea Horvath Marques, M.D., Ph.D, M.P.H.
Contact Telephone	301-646-7320
Contact Email	<a href="mailto:andrea.horvathmarques@nih.gov">andrea.horvathmarques@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2020
Synopsis	National Institute of Mental Health (NIMH) invites applications for Administrative Supplements to active NIMH grants to foster research across the NIMH Strategic Objectives that target the reduction and elimination of mental health disparities by race and ethnicity, geography, and socioeconomic status in the United States. This initiative aims to generate research within the scientific scope of the parent grant that identifies mechanisms underlying disparities or differences in mental health status and/or enhances optimal delivery of mental health interventions among diverse groups. This program will use the NIH Administrative Supplement award mechanism.

078787	<a href="#">Emotion Regulation, Aging and Mental Disorder (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-19-095	16-Jun-2020	275,000 USD
--------	--	--	-----------	-------------	-------------

Contact Name	Jovier Evans, PhD
Contact Telephone	301-443-1369
Contact Email	<a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021
Synopsis	This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

068963	<a href="#">RFA-MH-18-700 -- Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 - Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-700	16-May-2020 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	<a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020
Synopsis	National Institute of Mental Health (NIMH) invites applications to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA will use the NIH R01 Research Project Grant award mechanism.

068973	<a href="#">RFA-MH-18-701 -- Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-701	16-May-2020 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	<a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020			
	Synopsis	<p>National Institute of Mental Health (NIMH) invites applications to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA will use the NIH R01 Research Project Grant award mechanism.</p>			
077729	<a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	PAR-18-941	16-Jun-2020	275,000 USD
	Contact Name	David McMullen, M.D.			
	Contact Telephone	301-451-0180			
	Contact Email	<a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021			
	Synopsis	<p>National Institute of Mental Health (NIMH) invites applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA will utilize the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
068980	<a href="#">RFA-MH-18-704--Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-704	16-May-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Ann Wagner, Ph.D.			
	Contact Telephone	301-443-3633			
	Contact Email	<a href="mailto:awagner@mail.nih.gov">awagner@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020			
	Synopsis	<p>National Institute of Mental Health (NIMH) invites applications to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention's impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting "go/no-go" milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.</p>			
068981	<a href="#">RFA-MH-18-705--Development of Psychosocial Therapeutic and Preventive</a>	National Institute of Mental	RFA-MH-	16-May-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Interventions for Mental Disorders (R33 Clinical Trial Required)</a>		Health/NIH/DHHS	18-705 [Optional][LOI/Pre-App]	Specified
	<p>Contact Name   Ann Wagner, Ph.D.</p> <p>Contact Telephone   301-443-3633</p> <p>Contact Email   <a href="mailto:awagner@mail.nih.gov">awagner@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020</p> <p>Synopsis   National Institute of Mental Health (NIMH) invites applications to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.</p>				
068977	<a href="#">RFA-MH-18-702 -- Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required)</a>		National Institute of Mental Health/NIH/DHHS	RFA-MH-18-702 16-May-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Margaret Grabb, Ph.D.</p> <p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high risk applications. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.</p>				
068979	<a href="#">RFA-MH-18-703 -- Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-703	16-May-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Margaret Grabb, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.</p>				
068983	<a href="#">RFA-MH-18-707 -- Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-707	16-May-2020 [Optional][LOI/Pre-App]	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Sarah Morris, Ph.D</p> <p>Contact Telephone 301-443-9233</p> <p>Contact Email <a href="mailto:sarah.morris@nih.gov">sarah.morris@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. This FOA will use the NIH R01 Research Project Grant award mechanism.</p>				
068982	<a href="#">RFA-MH-18-706 -- Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-706	16-May-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Joel Sherrill, Ph.D.</p> <p>Contact Telephone 301-443-2477</p> <p>Contact Email <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-May-2020 [Optional][LOI/Pre-App], 15-Jun-2020 , 15-Sep-2020 [Optional][LOI/Pre-App], 15-Oct-2020</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability,</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study. In this pilot phase of effectiveness research, NIMH places highest priority on approaches that can be justified in terms of their potential to substantially impact practice and public health and approaches that are empirically grounded. Adaptations or augmentations of efficacious interventions should only be undertaken if there is an empirical rationale for the adaptation target and for the corresponding mechanism by which the adapted intervention or augmentation is expected to substantially enhance outcomes. This FOA is intended to support pilot effectiveness trials that are designed to explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects. This FOA will use the NIH R34 Planning Grant award mechanism.

092121	<a href="#">RFA-MH-20-525 -- NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-20-525	21-May-2020 [Optional][LOI/Pre-App]	2,500,000 USD
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Eric R. Murphy, Ph.D.
Contact Telephone	301-443-9230 ?
Contact Email	<a href="mailto:eric.murphy@nih.gov">eric.murphy@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	21-May-2020 [Optional][LOI/Pre-App], 20-Jun-2020 , 21-May-2021 [Optional][LOI/Pre-App], 20-Jun-2021 , 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022
Synopsis	The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders. The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.

072892	<a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-710	12-Jun-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Stephen Korn, Ph.D.
Contact Telephone	301-496-4188
Contact Email	<a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL) Synopsis				
072904	<a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-711	12-Jun-2020	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis				
070232	<a href="#">RFA-NS-18-018 -- BRAIN Initiative: Biology and Biophysics of Neural Stimulation (R01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-018	05-May-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone Contact Email				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-May-2020 [Optional][LOI/Pre-App], 04-Jun-2020 , 06-Sep-2020 [Optional][LOI/Pre-App], 06-Oct-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation. Development of new technologies and therapies, as well as of disease models are outside the scope of this FOA. However, activities related to combining multiple recording modalities are allowed. As part of this program, investigators will be required to participate in a consortium to develop standards and model systems for the evaluation of current and next generation neuromodulation technologies. This FOA will use the NIH Research Project (R01) award mechanism.			
070123	<a href="#">NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-No Independent Clinical Trials)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-469	07-May-2020	Not Specified
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	<a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity is designed to enhance the participation of highly trained early career investigators from underrepresented groups in neuroscience research. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K22 Career Transition Award mechanism.			
070119	<a href="#">NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-Clinical Trial Required)</a>	National Institute of Neurological Disorders and	PAR-18-468	07-May-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Stroke/NIH/DHHS					
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	<a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021			
	Synopsis	<p>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial that also meets the definition of a clinical trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS Scientific/Research contact prior to submitting an application with human subjects to determine the appropriate funding opportunity. This FOA will utilize the NIH K22 Career Transition Award mechanism.</p>			
070862	<a href="#">NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-561	05-Jun-2020	Not Specified
	Contact Name	Claudia Scala Moy, PhD			
	Contact Telephone	301-496-9135			
	Contact Email	<a href="mailto:moyc@ninds.nih.gov">moyc@ninds.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	<p>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. Successful applicants will</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

collaborate and conduct the trial within the NIH StrokeNet. Following peer review, NINDS will prioritize trials among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. NINDS intends that all multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet and that only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this program. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this FOA. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

070137	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-486	07-May-2020	975,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Michelle Jones-London, Ph.D.
Contact Telephone	301-451-7966
Contact Email	<a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
070493	<a href="#">NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-528	05-Jun-2020	Not Specified
	<p>Contact Name: Codrin Lungu, MD</p> <p>Contact Telephone: 301-496-9135</p> <p>Contact Email: <a href="mailto:lunguci@ninds.nih.gov">lunguci@ninds.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 05-Jun-2020 , 05-Oct-2020</p> <p>Synopsis: National Institute of Neurological Disorders and Stroke (NINDS) invites applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (<a href="http://www.ninds.nih.gov/funding/areas/index.htm">www.ninds.nih.gov/funding/areas/index.htm</a>). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>				
070628	<a href="#">RFA-NS-18-021 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-021	23-May-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Nick Langhals, PhD</p> <p>Contact Telephone: 301-496-1447</p> <p>Contact Email: <a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 23-May-2020 [Optional][LOI/Pre-App], 22-Jun-2020 , 21-Sep-2020 [Optional][LOI/Pre-App], 21-Oct-2020</p> <p>Synopsis: National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical trial (e.g., Early Feasibility Study). The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement mechanism.</p>			
070629	<a href="#">RFA-NS-18-022 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-022	23-May-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Nick Langhals, PhD			
	Contact Telephone	301-496-1447			
	Contact Email	<a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-May-2020 [Optional][LOI/Pre-App], 22-Jun-2020 , 21-Sep-2020 [Optional][LOI/Pre-App], 21-Oct-2020			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications from small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain. The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical trial (e.g., Early Feasibility Study). Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-Track mechanism.</p>			
070636	<a href="#">RFA-NS-18-023 -- BRAIN Initiative: Clinical Studies to Advance Next-Generation</a>	National Institute of	RFA-NS-	22-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Required)</a>	Neurological Disorders and Stroke/NIH/DHHS	18-023		Specified
	<p>Contact Name   Nick Langhals, PhD</p> <p>Contact Telephone   301-496-1447</p> <p>Contact Email   <a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   22-Jun-2020 , 21-Oct-2020</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study). Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device. This FOA will use the NIH UH3 Exploratory Phased Award Cooperative Agreement mechanism.</p>				
073884	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-761	07-May-2020	750,000 USD
	<p>Contact Name   Mary Ann Pellemounter, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 17-Jun-2020 , 07-Sep-2020 , 20-Oct-2020 , 07-Jan-2021 , 17-Feb-2021 , 07-May-2021</p> <p>Synopsis   National Institute of Neurological Disorders and Stroke (NINDS) invites applications to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs. This FOA will utilize the R61/R33 Phased Innovation Award mechanism.

071757	<a href="#">Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (R21 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-623	07-May-2020	275,000 USD
--------	---	--	-----------	-------------	-------------

Contact Name	Jill A. Morris, Ph.D.
Contact Telephone	301-496-5745
Contact Email	<a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications that propose to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. The primary objective of this FOA is to remove barriers to hydrocephalus research that are due to scarcity of tools to investigate both the disease mechanisms and alternative therapies (non-shunt) in a rigorous manner. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

073885	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-762	07-May-2020	750,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	<a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 17-Jun-2020 , 07-Sep-2020 , 20-Oct-2020 , 07-Jan-2021 , 17-Feb-2021 , 07-May-2021



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. This FOA will utilize the NIH R61/R33 Phased Innovation Award mechanism.			
071756	<a href="#">Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (R01 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-622	07-May-2020	Not Specified
	Contact Name	Jill A. Morris, Ph.D.			
	Contact Telephone	301-496-5745			
	Contact Email	<a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus. This FOA will use the NIH Research Project (R01) award mechanism.			
077714	<a href="#">Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-939	16-Jun-2020	275,000 USD
	Contact Name	Michael L. Oshinsky, Ph.D.			
	Contact Telephone	301-451-4460			
	Contact Email	<a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

077707	<a href="#">Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-937	05-Jun-2020	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name Michael L. Oshinsky, Ph.D.  
Contact Telephone 301-451-4460  
Contact Email [michael.oshinsky@nih.gov](mailto:michael.oshinsky@nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021

Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions. This FOA will use the NIH Research Project (R01) award mechanism.

086471	<a href="#">NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-021	07-May-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Stephen Korn, Ph.D.
Contact Telephone	301-496-4188
Contact Email	<a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 09-Jun-2020 , 07-Sep-2020 , 14-Oct-2020 , 07-Jan-2021 , 11-Feb-2021 , 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

086932	<a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 - Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-050	07-May-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Stephen Korn, PhD
Contact Telephone	
Contact Email	<a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a>
Sponsor Website	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049).</p>				
086929	<a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 - No Independent Clinical Trial Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-049	07-May-2020	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent small clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent small clinical trial as lead investigator, should apply to the companion FOA (PAR-20-050).

069923	<a href="#">NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-420	07-May-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Peter R. Gilbert, Sc.M.
Contact Telephone	301-496-0870
Contact Email	<a href="mailto:pgilbert@nih.gov">pgilbert@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website ( <a href="https://www.ninds.nih.gov/">https://www.ninds.nih.gov/</a> ). This FOA will use the NIH Research Project (R01) award mechanism.

069928	<a href="#">NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-422	07-May-2020	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Peter R. Gilbert, ScM
Contact Telephone	301-496-0870
Contact Email	<a href="mailto:pgilbert@nih.gov">pgilbert@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<https://www.ninds.nih.gov/>). This FOA will utilize the Cooperative Agreement (U01) grant mechanism.

073889	<a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-763	07-May-2020	750,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	<a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 17-Jun-2020 , 07-Sep-2020 , 20-Oct-2020 , 07-Jan-2021 , 17-Feb-2021 , 07-May-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery. This FOA will utilize the NIH R61/R33 Phased Innovation Award mechanism.

079593	<a href="#">Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-171	07-May-2020	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Adam L. Hartman, MD
Contact Telephone	301-496-9135
Contact Email	<a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2020 , 18-Jun-2020 , 07-Sep-2020 , 14-Oct-2020 , 07-Jan-2021 , 18-Feb-2021 , 07-May-2021 , 18-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered)). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>				
068924	<a href="#">RFA-NS-18-012 -- Translational Neural Devices (U44 Clinical Trial Required) (Defunct)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-012	23-May-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Nick Langhals, PhD</p> <p>Contact Telephone 301-496-1447</p> <p>Contact Email <a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-May-2020 [Optional][LOI/Pre-App], 22-Jun-2020 , 21-Sep-2020 [Optional][LOI/Pre-App], 21-Oct-2020</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design. This FOA will use the NIHU44 Small Business Innovation Research (SBIR) Cooperative Agreements - Fast-Track award mechanism.</p>				
088962	<a href="#">RFA-NS-20-016 -- Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA CWOW) (U54 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-20-016	27-May-2020 [Optional][LOI/Pre-App]	10,000,000 USD
	<p>Contact Name Patrick SF Bellgowan, Ph.D.</p> <p>Contact Telephone 301-496-1447</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:psfb@mail.nih.gov">psfb@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 27-May-2020 [Optional][LOI/Pre-App], 26-Jun-2020</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is to promote the development and initial clinical validation of objective biological measures to be used for prognosing, and monitoring recovery of adolescents who either clinically present with or are at risk for developing prolonged/persistent concussive symptoms following exposure to repetitive head impacts and/or concussion. Resultant biological measures should be incorporated into risk stratification algorithms to inform clinical care and patient stratification for future clinical trials. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data to further advance research in the area of persistent concussive symptoms in early and middle adolescent (EMA; ages 11-17 years old) populations.</p>				
077189	<a href="#">RFA-NS-19-001-- BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-19-001	19-May-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name James Gnad, Ph.D.</p> <p>Contact Telephone 301-496-9964</p> <p>Contact Email <a href="mailto:BRAINResOppHu@ninds.nih.gov">BRAINResOppHu@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 19-May-2020 [Optional][LOI/Pre-App], 19-Jun-2020 , 19-Sep-2020 [Optional][LOI/Pre-App], 19-Oct-2020</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to brain recording and stimulating from invasive surgical procedures. Projects should employ approaches guided by specified theoretical constructs and quantitative, mechanistic models where appropriate. Awardees will join a consortium work group, coordinated by the NIH, to identify consensus standards of practice, including neuroethical considerations, to collect and provide data for ancillary studies, and to aggregate and standardize data for dissemination among the wider scientific community. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.</p>				
070144	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-490	07-May-2020	975,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Michelle Jones-London, Ph.D.</p> <p>Contact Telephone   301-451-7966</p> <p>Contact Email   <a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021</p> <p>Synopsis   National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research &amp; Training mechanism.</p>				
069085	<a href="#">NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-358	07-May-2020	275,000 USD
	<p>Contact Name   Timothy LaVaute, PHD</p> <p>Contact Telephone   301-496-1447</p> <p>Contact Email   <a href="mailto:lavautetm@mail.nih.gov">lavautetm@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis   National Institute of Neurological Disorders and Stroke (NINDS) invites applications for exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
068913	<a href="#">RFA-NS-18-011 -- Translational Neural Devices (UG3/UH3 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-011	22-Jun-2020	Not Specified
	<p>Contact Name: Nick Langhals, PhD</p> <p>Contact Telephone: 301-496-1447</p> <p>Contact Email: <a href="mailto:nick.langhals@nih.gov">nick.langhals@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 22-Jun-2020 , 21-Oct-2020</p> <p>Synopsis: National Institute of Neurological Disorders and Stroke (NINDS) invites applications for translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical trial to collect safety and effectiveness data required to support a marketing application or to inform final device design. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.</p>				
070148	<a href="#">Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAS-18-483	07-May-2020	Not Specified
	<p>Contact Name: Robert Riddle, PhD</p> <p>Contact Telephone: 301-496-5745</p> <p>Contact Email: <a href="mailto:rr260c@nih.gov">rr260c@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis: National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related. This FOA will use the NIH Research</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Project (R01) award mechanism.			
067277	<a href="#">NIH SIREN Neurologic Clinical Trials (U01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-304	05-Jun-2020	Not Specified
	Contact Name	Jeremy Brown, MD			
	Contact Telephone	301-594-4481			
	Contact Email	<a href="mailto:jeremy.brown@nih.gov">jeremy.brown@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.			
076050	<a href="#">Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-850	07-May-2020	275,000 USD
	Contact Name	Mary C. Roary, Ph.D.			
	Contact Telephone	301-594-2154			
	Contact Email	<a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

illness and disability in later years. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

069482	<a href="#">Family-Centered Self-Management of Chronic Conditions (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-383	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI
Contact Telephone	301-594-5970
Contact Email	<a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021
Synopsis	National Institute of Nursing Research (NINR) invites applications for research to build the science of family-centered self-management (FCSM) in chronic conditions. This FOA will use the NIH Research Project (R01) award mechanism.

065708	<a href="#">Symptom Cluster Characterization in Chronic Conditions (R01)</a>	National Institute of Nursing Research/NIH/DHHS	PA-17-462	07-May-2020	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Michelle R.J. Hamlet, PhD
Contact Telephone	301-496-9623
Contact Email	<a href="mailto:Michelle.hamlet@nih.gov">Michelle.hamlet@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021
Synopsis	National Institute of Nursing Research (NINR) invites applications for preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions. This FOA will use the NIH Research Project (R01) award mechanism.

066699	<a href="#">New Onset Depressive Symptoms in Acute Illness (R01 Clinical Trial Not Allowed)</a>	National Institute of Nursing Research/NIH/DHHS	PA-17-488	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Martha Matocha, PhD
Contact Telephone	301-594-2775
Contact Email	<a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute of Mental Health (NIMH) invite applications for research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness. This FOA will use the NIH Research Project (R01) award mechanism.			
070260	<a href="#">End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-498	07-May-2020	Not Specified
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	<a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH Research Project (R01) award mechanism.			
070262	<a href="#">End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-499	07-May-2020	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	<a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021

Synopsis National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

070314	<a href="#">Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-348	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name Lois A. Tully, Ph.D.

Contact Telephone 301-594-5968

Contact Email [tullyla@mail.nih.gov](mailto:tullyla@mail.nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021

Synopsis National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invites applications for clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer's disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers. This FOA will use the NIH Research Project (R01) award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

069491	<a href="#">mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-386	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name | Augie Diana, Ph.D.  
Contact Telephone | 301-402-6423  
Contact Email | [dianaa@mail.nih.gov](mailto:dianaa@mail.nih.gov)  
Sponsor Website |  
Program URL | [Link to program URL](#)  
Deadline Dates (ALL) | 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021

Synopsis | National Institute of Nursing Research (NINR) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. This FOA will use the NIH Research Project (R01) award mechanism.

070340	<a href="#">Community Partnerships to Advance Research (CPAR) (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-377	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name | Augie Diana, Ph.D.  
Contact Telephone | 301-402-6423  
Contact Email | [dianaa@mail.nih.gov](mailto:dianaa@mail.nih.gov)  
Sponsor Website |  
Program URL | [Link to program URL](#)  
Deadline Dates (ALL) | 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021

Synopsis | National Institute of Nursing Research (NINR) invites applications for researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. This FOA will use the NIH Research Project (R01) award mechanism.

070051	<a href="#">Obesity and Asthma: Awareness and Self- Management (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-379	07-May-2020	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name | Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-594-5970			
	Contact Email	<a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for research that examines the relationship between asthma, obesity and self-management. It seeks to build the science of obesity, asthma, and self-management awareness. This FOA will use the NIH Research Project (R01) award mechanism.			
067124	<a href="#">Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R01- Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-17-491	07-May-2020	Not Specified
	Contact Name	Rebecca Henry, PhD, RN			
	Contact Telephone	301-594-5976			
	Contact Email	<a href="mailto:rebecca.henry@nih.gov">rebecca.henry@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. This FOA will use the NIH Research Project (R01) award mechanism.			
067107	<a href="#">Addressing Chronic Wound Trajectories Through Social Genomics Research (R21- Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-17-493	07-May-2020	275,000 USD
	Contact Name	Lois Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	<a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>			
	Sponsor Website				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) invites applications for clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
070320	<a href="#">Self-Management for Health in Chronic Conditions (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-376	07-May-2020	Not Specified
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
070317	<a href="#">Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-347	07-May-2020	275,000 USD
	<p>Contact Name Lois A. Tully, Ph.D.</p> <p>Contact Telephone 301-594-5968</p> <p>Contact Email <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invites applications for clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer's disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.			
069458	<a href="#">Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-354	07-May-2020	275,000 USD
	Contact Name	Mary C. Roary, Ph.D.			
	Contact Telephone	301-594-2154			
	Contact Email	<a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	The sponsors invite applications that employ innovative research to identify mechanisms of influence and/or promote positive sustainable health behavior(s) in children and youth (birth to age 21). Positive health behaviors may include: developing healthy sleep patterns, developing effective self-regulation strategies, adaptive decision-making in risk situations, practicing proper dental hygiene, eating a balanced and nutritious diet, engaging in age-appropriate physical activity and/or participating in healthy relationships. Applications to promote positive health behavior(s) should target social and cultural factors, including, but not limited to: schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include: effective, sustainable processes for influencing young people to make healthy behavior choices; identification of the appropriate stage of influence for learning sustainable lifelong health behaviors; the role of technology and new media in promoting healthy behavior; identification of factors that support healthy behavior development in vulnerable populations, identification of barriers to healthy behaviors; and, identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors. Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary teams are strongly encouraged. The ultimate goal of this FOA is to promote research that identifies and enhances processes that promote sustainable positive behavior or changes social and cultural			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		norms that influence health and future health behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
069486	<a href="#">Family-Centered Self-Management of Chronic Conditions (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-380	07-May-2020	275,000 USD
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI			
	Contact Telephone	301-594-5970			
	Contact Email	<a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for research to build the science of family-centered self-management (FCSM) in chronic conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
084550	<a href="#">Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-320	07-May-2020	275,000 USD
	Contact Name	Karen A. Kehl, PhD, RN, FPCN			
	Contact Telephone	301-594-8010			
	Contact Email	<a href="mailto:karen.kehl@mail.nih.gov">karen.kehl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.			
084549	<a href="#">Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-321	07-May-2020	Not Specified
	Contact Name	Karen A. Kehl, PhD, RN, FPCN			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-594-8010</p> <p>Contact Email <a href="mailto:karen.kehl@mail.nih.gov">karen.kehl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.</p>				
085700	<a href="#">Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-377	07-May-2020	Not Specified
	<p>Contact Name Lois A. Tully, PhD</p> <p>Contact Telephone 301-594-5968</p> <p>Contact Email <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.</p>				
085884	<a href="#">Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-382	16-Jun-2020	400,000 USD
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></p> <p>Sponsor Website</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 07-Sep-2020 , 16-Feb-2021 , 16-Mar-2021 , 07-May-2021 , 16-Jun-2021 , 16-Jul-2021 , 07-Sep-2021 , 16-Feb-2022 , 16-Mar-2022 , 07-May-2022 , 16-Jun-2022 , 16-Jul-2022 , 07-Sep-2022 , 16-Feb-2023 , 16-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.			
085882	<a href="#">Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-381	05-Jun-2020	Not Specified
	Contact Name	Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI			
	Contact Telephone	301-594-5970			
	Contact Email	<a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 07-Sep-2020 , 05-Feb-2021 , 05-Mar-2021 , 07-May-2021 , 05-Jun-2021 , 05-Jul-2021 , 07-Sep-2021 , 05-Feb-2022 , 05-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.			
079344	<a href="#">End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-153	07-May-2020	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	<a href="mailto:lynn.adams@nih.gov">lynn.adams@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
078362	<a href="#">End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-044	07-May-2020	Not Specified
	Contact Name	Karen A. Kehl, Ph.D.			
	Contact Telephone	301-594-8010			
	Contact Email	<a href="mailto:kehlka@nih.gov">kehlka@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.			
077785	<a href="#">Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-944	07-May-2020	Not Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	<a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.			
077972	<a href="#">Addressing Caregiver Symptoms through Technological Tools (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-19-023	07-May-2020	Not Specified
	Contact Name	Augie Diana, Ph.D.			
	Contact Telephone	301-402-6423			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.</p>				
077789	<a href="#">Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-946	07-May-2020	275,000 USD
	<p>Contact Name Martha Matocha, PhD</p> <p>Contact Telephone 301-594-2775</p> <p>Contact Email <a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.</p>				
078345	<a href="#">End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-045	07-May-2020	Not Specified
	<p>Contact Name Karen A. Kehl, Ph.D.</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email <a href="mailto:kehlka@nih.gov">kehlka@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	2021 , 05-Oct-2021 , 07-Jan-2022 The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.			
077788	<a href="#">Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-945	07-May-2020	Not Specified
	Contact Name	Martha Matocha, PhD			
	Contact Telephone	301-594-2775			
	Contact Email	<a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.			
077974	<a href="#">Addressing Caregiver Symptoms through Technological Tools (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-19-024	07-May-2020	275,000 USD
	Contact Name	Augie Diana, Ph.D.			
	Contact Telephone	301-402-6423			
	Contact Email	<a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.			
078635	<a href="#">Telomeres in Wellness and Disease: A Biobehavioral Approach (R01)</a>	National Institute of Nursing	PA-19-074	07-May-2020	Not



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Clinical Trial Optional</a>		Research/NIH/DHHS		Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	<a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.			
079185	<a href="#">End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-136	07-May-2020	Not Specified
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	<a href="mailto:lynn.adams@nih.gov">lynn.adams@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.			
078414	<a href="#">Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-058	07-May-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Lynn S. Adams, Ph.D.</p> <p>Contact Telephone   301-594-8911</p> <p>Contact Email   <a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.</p>				
078411	<a href="#">Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-057	07-May-2020	Not Specified
	<p>Contact Name   Lynn S. Adams, Ph.D.</p> <p>Contact Telephone   301-594-8911</p> <p>Contact Email   <a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.</p>				
077787	<a href="#">Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-943	07-May-2020	275,000 USD
	<p>Contact Name   Lois A. Tully, PhD</p> <p>Contact Telephone   301-594-5968</p> <p>Contact Email   <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.			
078636	<a href="#">Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-19-073	07-May-2020	Not Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	<a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.			
068622	<a href="#">Mechanisms, Models, Measurement, &amp; Management in Pain Research (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-159	07-May-2020	275,000 USD
	Contact Name	Martha Matocha, PhD			
	Contact Telephone	301-594-2775			
	Contact Email	<a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
068621	<a href="#">Mechanisms, Models, Measurement, &amp; Management in Pain Research (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-141	07-May-2020	Not Specified
	Contact Name	Martha Matocha, PhD			
	Contact Telephone	301-594-2775			
	Contact Email	<a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH Research Project (R01) award mechanism.			
065717	<a href="#">Symptom Cluster Characterization in Chronic Conditions (R21)</a>	National Institute of Nursing Research/NIH/DHHS	PA-17-461	07-May-2020	275,000 USD
	Contact Name	Michelle R.J. Hamlet, PhD			
	Contact Telephone	301-496-9623			
	Contact Email	<a href="mailto:Michelle.hamlet@nih.gov">Michelle.hamlet@nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
076049	<a href="#">Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-849	07-May-2020	Not Specified
	Contact Name	Mary C. Roary, Ph.D.			
	Contact Telephone	301-594-2154			
	Contact Email	<a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH Research Project (R01) award mechanism.			
070341	<a href="#">Community Partnerships to Advance Research (CPAR) (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-381	07-May-2020	275,000 USD
	Contact Name	Augie Diana, Ph.D.			
	Contact Telephone	301-402-6423			
	Contact Email	<a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| mechanism.

069457	<a href="#">Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-355	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Mary C. Roary, Ph.D.
Contact Telephone	301-594-2154
Contact Email	<a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021
Synopsis	The sponsors invite applications that employ innovative research to identify mechanisms of influence and/or promote positive sustainable health behavior(s) in children and youth (birth to age 21). Positive health behaviors may include: developing healthy sleep patterns, developing effective self-regulation strategies, adaptive decision-making in risk situations, practicing proper dental hygiene, eating a balanced and nutritious diet, engaging in age-appropriate physical activity and/or participating in healthy relationships. Applications to promote positive health behavior(s) should target social and cultural factors, including, but not limited to: schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include: effective, sustainable processes for influencing young people to make healthy behavior choices; identification of the appropriate stage of influence for learning sustainable lifelong health behaviors; the role of technology and new media in promoting healthy behavior; identification of factors that support healthy behavior development in vulnerable populations, identification of barriers to healthy behaviors; and, identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors. Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary teams are strongly encouraged. The ultimate goal of this FOA is to promote research that identifies and enhances processes that promote sustainable positive behavior or changes social and cultural norms that influence health and future health behaviors. This FOA will use the NIH Research Project (R01) award mechanism.

067106	<a href="#">Addressing Chronic Wound Trajectories Through Social Genomics Research (R01- Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-17-492	07-May-2020	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Lois Tully, PhD
Contact Telephone	301-594-5968
Contact Email	<a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life. This FOA will use the NIH Research Project (R01) award mechanism.			
067127	<a href="#">Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R21- Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-17-490	07-May-2020	275,000 USD
	Contact Name	Rebecca Henry, PhD, RN			
	Contact Telephone	301-594-5976			
	Contact Email	<a href="mailto:rebecca.henry@nih.gov">rebecca.henry@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
066276	<a href="#">Symptom Cluster Characterization in Chronic Conditions (R21)</a>	National Institute of Nursing Research/NIH/DHHS	PA-17-461	07-May-2020	275,000 USD
	Contact Name	Michelle R.J. Hamlet, PhD			
	Contact Telephone	301-496-9623			
	Contact Email	<a href="mailto:Michelle.hamlet@nih.gov">Michelle.hamlet@nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
066708	<a href="#">New Onset Depressive Symptoms in Acute Illness (R21 Clinical Trial Not Allowed)</a>	National Institute of Nursing Research/NIH/DHHS	PA-17-487	07-May-2020	275,000 USD
	Contact Name	Martha Matocha, PhD			
	Contact Telephone	301-594-2775			
	Contact Email	<a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute of Mental Health (NIMH) invite applications for research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
069494	<a href="#">mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-389	07-May-2020	275,000 USD
	Contact Name	Augie Diana, Ph.D.			
	Contact Telephone	301-402-6423			
	Contact Email	<a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
070322	<a href="#">Self-Management for Health in Chronic Conditions (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-384	07-May-2020	275,000 USD
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
079184	<a href="#">Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-135	07-May-2020	300,000 USD
	<p>Contact Name Michelle R.J. Hamlet, PhD</p> <p>Contact Telephone 301-496-9623</p> <p>Contact Email <a href="mailto:hamletm@mail.nih.gov">hamletm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 25-Jun-2020 , 07-Sep-2020 , 25-Oct-2020 , 07-Jan-2021 , 25-Feb-2021 , 07-May-2021 , 25-Jun-2021 , 07-Sep-</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>2021 , 25-Oct-2021 , 07-Jan-2022</p> <p>The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions (e.g., the university or college with a unique Employee Identification Number [EIN]) must award NIH-relevant baccalaureate or advanced degrees in health professions and have received no more than \$6 million per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by the institution as a whole (meaning all schools and colleges within an institution). In other words, the funding for all the institution's health professional schools, graduate schools, and colleges and all the institution's non-health professional schools and colleges that are part of the institution are considered together and summed as total NIH funding when determining institutional eligibility. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.</p>			
081010	<a href="#">Pragmatic Clinical Trial on Efficacy of Managing Reduced Iron Stores on Risk of Clinically Important Events in Older Adults with Heart Failure and Anemia (U01 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PA-19-230	05-Jun-2020	Not Specified
	Contact Name	Sergei Romashkan, MD, Ph.D.			
	Contact Telephone	301-435-3047			
	Contact Email	<a href="mailto:romashks@nia.nih.gov">romashks@nia.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	This FOA invites applications for a pragmatic clinical trial to establish efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia.			
082123	<a href="#">Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-19-269	05-Jun-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Marilyn Miller, Ph.D.</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.</p>				
070587	<a href="#">Basic and Translational Research on Decision Making in Aging and Alzheimer's Disease (R01 - Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-544	08-Jun-2020	Not Specified
	<p>Contact Name   Lis Nielsen, Ph.D.</p> <p>Contact Telephone   301-402-4156</p> <p>Contact Email   <a href="mailto:nielsenli@nia.nih.gov">nielsenli@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jun-2020</p> <p>Synopsis   National Institute on Aging (NIA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). This FOA will use the NIH Research Project (R01) award mechanism.</p>				
083316	<a href="#">Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional)</a>	National Institute on	PAR-19-	05-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Aging/NIH/DHHS	298		Specified
	Contact Name	Kristina McLinden			
	Contact Telephone	301-827-2563			
	Contact Email	<a href="mailto:kristina.mclinden@nih.gov">kristina.mclinden@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination interventions are allowed, provided the focus and innovative component is neurostimulation. Applications that seek to develop devices, tools, or invasive techniques are outside the scope of this FOA.			
070482	<a href="#">Sensory and motor system changes as predictors of preclinical Alzheimer's disease (R01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-18-519	08-Jun-2020	Not Specified
	Contact Name	Coryse St. Hillaire-Clarke, Ph.D.			
	Contact Telephone	301-827-6944			
	Contact Email	<a href="mailto:coryse.sthillaire-clarke@nih.gov">coryse.sthillaire-clarke@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jun-2020 , 08-Oct-2020			
	Synopsis	National Institute on Aging (NIA) invites applications for either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimer's disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including cellular, molecular, imaging, physiological and genetic, to address this need. For clinical studies, leveraging of existing longitudinal cohorts already collecting sensory and motor assessments is highly encouraged. This FOA will use the NIH Research Project (R01) award mechanism.			
070284	<a href="#">Sleep Disorders and Circadian Clock Disruption in Alzheimer's Disease and Other Dementias of Aging (R01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-18-497	08-Jun-2020	2,500,000 USD
	Contact Name	Miroslaw Mackiewicz, Ph.D.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone 301-496-9350  
 Contact Email [mackiewicz2@mail.nih.gov](mailto:mackiewicz2@mail.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 08-Jun-2020 , 08-Oct-2020  
 Synopsis National Institute on Aging (NIA) invites applications for molecular, cellular, genetic, epigenetic, and systems biology approaches to advance basic and clinical research on the causes and consequences of sleep deficiency and circadian clock dysfunction in Alzheimer's disease, and the roles of sleep and the circadian clock as modifiers of the progression of neurodegeneration. This FOA will use the NIH Research Project (R01) award mechanism.

070550	<a href="#">Basic and Translation Research on Decision Making in Aging and Alzheimer's Disease (R21 - Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-538	22-Jun-2020	275,000 USD
--------	--	--------------------------------------	------------	-------------	-------------

Contact Name Lis Nielsen, Ph.D.  
 Contact Telephone 301-402-4156  
 Contact Email [nielsenli@nia.nih.gov](mailto:nielsenli@nia.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 22-Jun-2020  
 Synopsis National Institute on Aging (NIA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.

083523	<a href="#">NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-19-302	05-Jun-2020	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name Sergei Romashkan, M.D., Ph.D.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-3047</p> <p>Contact Email <a href="mailto:romashks@mail.nih.gov">romashks@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</p>				
083551	<a href="#">Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-19-305	16-Jun-2020	Not Specified
	<p>Contact Name Chhanda Dutta, Ph.D.</p> <p>Contact Telephone 301-496-4161</p> <p>Contact Email <a href="mailto:duttac@nia.nih.gov">duttac@nia.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. This FOA provides support for up to two years (R21, milestone-driven exploratory phase) for preliminary, proof-of-concept studies, which is followed by up to three years of support (R33 phase) for further/expanded preclinical development of the candidate therapeutic. Applicants may request funds for the development of assays and other methodologies required for translational studies in the project budget for the R21 and/or R33 phases. Funding for the R33 phase will be contingent on successful completion of established milestones in the R21 phase. The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement. Applications using only the R21 mechanism will not be accepted under this FOA.</p>				
083550	<a href="#">Early-Stage T1 Translational Aging Research (Bench to Bedside) for the</a>	National Institute on	PAR-19-	16-Jun-2020	1,500,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Development of Novel Therapeutics (R33 Clinical Trial Optional)</a>	Aging/NIH/DHHS	304		USD
	<p>Contact Name   Chhanda Dutta, Ph.D.</p> <p>Contact Telephone   301-496-4161</p> <p>Contact Email   <a href="mailto:duttac@nia.nih.gov">duttac@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets. The R33 mechanism is intended to provide milestone-driven support (up to 5 years) for innovative exploratory and developmental research activities originally initiated under the R21 mechanism. Awardees from NIA's R21 T1 translational aging research program are encouraged to apply to this FOA to expand upon the translation of their candidate pharmacological interventions from prior studies. Other applicants with sufficient and strong preliminary/proof-of-concept data (equivalent to that achievable under a R21) for a novel drug target, new compound(s), or for a potential new clinical indication for an FDA-approved drug for age-related conditions are also eligible to apply to this FOA. The scope of early-stage T1 translational research activities to be conducted under the R33 is expected to vary with the stage of translation of the candidate therapeutic. Nevertheless, the R33 support should advance the experimental intervention closer to human testing (if warranted). The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement.</p>				
070904	<a href="#">Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PA-18-570	07-May-2020	Not Specified
	<p>Contact Name   Marcel E. Salive, MD</p> <p>Contact Telephone   301-496-6761</p> <p>Contact Email   <a href="mailto:saliveme@mail.nih.gov">saliveme@mail.nih.gov</a></p> <p>Sponsor Website  </p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
070905	<a href="#">Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PA-18-572	07-May-2020	275,000 USD
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email <a href="mailto:saliveme@mail.nih.gov">saliveme@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
073071	<a href="#">NIA Limited Competition: Renewals of, and Revisions to, Existing Alzheimer's Disease Patient Registry Cooperative Agreement Awards (U01 - Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-18-715	05-Jun-2020	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Robin A. Barr</p> <p>Contact Telephone 301-496-9322</p> <p>Contact Email <a href="mailto:BarrR@mail.nih.gov">BarrR@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021</p> <p>Synopsis National Institute on Aging (NIA) invites invites existing Alzheimer's Disease Patient Registry cooperative agreements to submit revision and or renewal applications. The Alzheimer's Disease (AD) Patient Registry is a population-based longitudinal cohort study of AD and dementia that is linked to an HMO-medical record system or a similar record system. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>				
070906	<a href="#">Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PA-18-571	07-May-2020	100,000 USD
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email <a href="mailto:saliveme@mail.nih.gov">saliveme@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) invites pilot/feasibility projects that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
075524	<a href="#">Analyses of Adherence Strategies and Data Sets from CALERIE to Explore Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PA-18-825	05-Jun-2020	Not Specified
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-6240</p> <p>Contact Email <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
075525	<a href="#">Exploratory Analyses of Adherence Strategies and Data Sets from CALERIE to Investigate Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R21 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PA-18-826	16-Jun-2020	275,000 USD
	<p>Contact Name Giovanna Zappalà, Ph.D., M.P.H.</p> <p>Contact Telephone 301-827-6240</p> <p>Contact Email <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) invites applications for exploratory research projects (R21) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076718	<a href="#">Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-18-889	05-Jun-2020	2,500,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Marilyn Miller, Ph.D.</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis   National Institute on Aging (NIA) invites the NIA Alzheimer's Disease Genetics Consortium to submit revision and/or renewal applications in the area of the genetics of Alzheimer's Disease. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.</p>				
075498	<a href="#">Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-820	07-May-2020	5,000,000 USD
	<p>Contact Name   Lorenzo M. Refolo, Ph.D.</p> <p>Contact Telephone   301-594-7576</p> <p>Contact Email   <a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   National Institute on Aging's (NIA) invites applications for pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>				
076587	<a href="#">Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-877	05-Jun-2020	Not Specified
	Contact Name   Laurie Ryan				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement early stage (Phase I or II) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) to stimulate studies to enhance trial design and methods. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076719	<a href="#">Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project: Opportunity for Revision Requests for Active Cooperative Agreements (U01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-18-890	05-Jun-2020	2,500,000 USD
	<p>Contact Name Marilyn Miller, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.</p>				
076590	<a href="#">Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-18-878	05-Jun-2020	Not Specified
	<p>Contact Name Laurie Ryan</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021			
	Synopsis	National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism.			
084767	<a href="#">Limited Competition: Renewals of, and Revisions and Resubmissions to, the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-19-338	05-Jun-2020	Not Specified
	Contact Name	John K. Hsiao, M.D.			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:jhsiao@mail.nih.gov">jhsiao@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	This FOA invites revision, resubmission, or renewal applications to the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cooperative Agreement. Revision applications may not request funding beyond the project end date of the Parent award.			
086469	<a href="#">Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-19-394	07-May-2020	Not Specified
	Contact Name	Shahrooz Vahedi, Ph.D.			
	Contact Telephone	301-496-9322			
	Contact Email	<a href="mailto:shahrooz.vahedi@nih.gov">shahrooz.vahedi@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA's strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

aging-related health conditions.

086244	<a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAS-19-391	16-Jun-2020	200,000 USD
--------	--	--------------------------------------	------------	-------------	-------------

Contact Name	Partha Bhattacharyya, Ph.D.
Contact Telephone	301-496-3136
Contact Email	<a href="mailto:bhattacharyyap@mail.nih.gov">bhattacharyyap@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

086248	<a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Basic Science (R03 Clinical Trials Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAS-19-392	16-Jun-2020	200,000 USD
--------	--	--------------------------------------	------------	-------------	-------------

Contact Name	Lisa Opanashuk, Ph.D.
Contact Telephone	301-807-5422
Contact Email	<a href="mailto:lisa.opanashuk@nih.gov">lisa.opanashuk@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

086252	<a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAS-19-393	16-Jun-2020	200,000 USD
--------	---	--------------------------------------	------------	-------------	-------------

Contact Name	Alison Yao, Ph.D.
Contact Telephone	301-496-9350
Contact Email	<a href="mailto:alison.yao@nih.gov">alison.yao@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

086966	<a href="#">RFA-AG-21-007 -- Leadership Award for Alzheimer's Disease and Related Dementias Research (R35 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-21-007	19-May-2020 [Optional][LOI/Pre-App]	3,000,000 USD
--------	---	--------------------------------------	---------------	-------------------------------------	---------------

Contact Name	Cerise Elliott, Ph.D.
Contact Telephone	301-496-9350
Contact Email	<a href="mailto:elliottce@nih.gov">elliottce@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	19-May-2020 [Optional][LOI/Pre-App], 19-Jun-2020
Synopsis	NIA invites applications for the Leadership Award for Alzheimer's Disease and Related Dementias Research (R35). Applicants

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		will be supported to develop and implement innovative multidisciplinary research and mentoring programs through an interchange of ideas that enable individuals and their institutions to strengthen existing programs and the development of new research programs that are specific to the goals/milestones of the NIH Alzheimer's Disease and Alzheimer's Disease Related Dementias Summits.			
069778	<a href="#">Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-189	07-May-2020	Not Specified
	Contact Name	Basil A. Eldadah, MD, PhD			
	Contact Telephone	301-496-6761			
	Contact Email	<a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137. This FOA will use the NIH Research Project (R01) award mechanism.			
069782	<a href="#">Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-190	07-May-2020	275,000 USD
	Contact Name	Basil A. Eldadah, MD, PhD			
	Contact Telephone	301-496-6761			
	Contact Email	<a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.

087500	<a href="#">Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-20-071	16-Jun-2020	2,495,000 USD
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Winifred K. Rossi
Contact Telephone	301-496-3836
Contact Email	<a href="mailto:rossiw@mail.nih.gov">rossiw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

087474	<a href="#">Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-20-070	16-Jun-2020	1,775,000 USD
--------	---	--------------------------------------	------------	-------------	---------------

Contact Name	Winifred K. Rossi
Contact Telephone	301-496-3836
Contact Email	<a href="mailto:rossiw@mail.nih.gov">rossiw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
087731	<a href="#">RFA-AG-21-002 -- Mechanisms of Rejuvenation and Age-Acceleration in Heterochronic Blood Exchange (R01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-21-002	17-May-2020 [Optional][LOI/Pre-App]	1,500,000 USD
	Contact Name	Ronald A. Kohanski, Ph.D.			
	Contact Telephone	240-687-0644			
	Contact Email	<a href="mailto:ronald.kohanski@nih.gov">ronald.kohanski@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020			
	Synopsis	This FOA will support research on aspects of rejuvenation and accelerated aging observed specifically in heterochronic blood exchange (HBE) experiments. The objectives are to identify the multiple factors involved, the multiple cell types involved, and the mechanisms underlying rejuvenation or accelerated aging that is observed in the transfer of phenotypes between young and old laboratory animals. It is also anticipated that molecular signatures of rejuvenation or accelerated aging will be obtained from research supported under this FOA.			
087732	<a href="#">RFA-AG-21-010 -- Glial Plasticity in the Aging Brain (R01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-21-010	17-May-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Amanda M. DiBattista, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:amanda.dibattista@nih.gov">amanda.dibattista@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020			
	Synopsis	Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could contribute to vulnerability and resilience to brain aging.			
088223	<a href="#">RFA-AG-21-005 -- Limited Competition: National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) (U24 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-21-005	17-Jun-2020	20,000,000 USD
	Contact Name	Cerise Elliott, Ph.D.			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:elliottce@mail.nih.gov">elliottce@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jun-2020			
	Synopsis	The National Institute on Aging invites applications to renew an ongoing NIA-supported cooperative agreement, the National Centralized Repository for Alzheimer's Disease and Related Dementias.			
088523	<a href="#">RFA-AG-21-012 -- Resource Networks for Protein Polymorphisms in Alzheimer's Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-21-012	17-May-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Austin Yang, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:austin.yang@nih.gov">austin.yang@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020			
	Synopsis	This Funding Opportunity Announcement (FOA) invites U24 Cooperative Agreement applications aiming to establish several mis-folded protein polymorphisms resource networks in the area of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The central goal of these resource networks is to standardize and distribute seed, oligomers, and fibrils to other investigators in order to clarify and improve the reproducibility of experiments in AD/ADRD. For the past several years, many studies have developed assays and reagents to understand the biophysical properties of various tau and Aβ structural variants such as oligomers, protofibrils, and fibrils. As a result, many imaging, chemical, and immunological tools have been developed to detect different types of Aβ and tau polymorphs. Establishing standards, understanding the pathological roles of these protein polymorphs, and using newly developed analytic tools to address the direct correlation between patient-to-patient variations in Aβ and tau polymorphs are the long-term goals of the resource networks supported by this FOA.			
088618	<a href="#">RFA-AG-21-014 -- National Alzheimer's Coordinating Center (U24 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-21-014	17-May-2020 [Optional][LOI/Pre-App]	26,000,000 USD
	Contact Name	Nina Silverberg			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:silverbergn@nih.gov">silverbergn@nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020 Synopsis This FOA invites applications for a National Alzheimer's Coordinating Center (NACC) whose purpose is to serve NIA and the Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) field as 1) a national data resource, collecting data from the Alzheimer's Disease Research Centers (ADRCs), affiliated data, and sample repositories; 2) a facilitator of current and future AD/ADRD research; and 3) the central hub for organizing and enabling communication within and outside the ADRC program, including annual meetings and steering committees.				
075522	<a href="#">Exploratory Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R21 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PA-18-824	16-Jun-2020	275,000 USD
	Contact Name Giovanna Zappalà, Ph.D., M.P.H. Contact Telephone 301-827-6240 Contact Email <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 Synopsis National Institute on Aging (NIA) invites applications for exploratory research projects (R21) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.				
062697	<a href="#">NIA Academic Leadership Career Award (K07)</a>	National Institute on Aging/NIH/DHHS	PAR-17-287	07-May-2020	625,000 USD
	Contact Name Robin A. Barr, D. Phil. Contact Telephone 301-402-7715 Contact Email <a href="mailto:BarrR@mail.nih.gov">BarrR@mail.nih.gov</a> Sponsor Website Program URL <a href="#">Link to program URL</a>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute on Aging (NIA) invites applications for the NIA Research Leadership Career Award (K07). The award is intended to provide support for more senior investigators who have the expertise and leadership skills to enhance the aging and geriatric research capacity within their academic institution. This FOA will use the NIH K07 Academic/Teacher Award (ATA) mechanism.			
089645	<a href="#">RFA-AG-21-006 -- Alzheimer's Disease Sequencing Project Functional Genomics Consortium (U01 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	RFA-AG-21-006	01-Jun-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Alison Yao, Ph.D.			
	Contact Telephone	301-827-7264			
	Contact Email	<a href="mailto:alison.yao@nih.gov">alison.yao@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020 [Optional][LOI/Pre-App], 01-Jul-2020			
	Synopsis	This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer's disease and related dementias (AD/ADRD).			
070464	<a href="#">Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)</a>	National Institute on Aging/NIH/DHHS	PAR-18-513	05-Jun-2020	Not Specified
	Contact Name	Laurie Ryan, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	National Institute on Aging (NIA) invites applications to develop and implement Phase I to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. This FOA will use the NIH Research Project (R01) award mechanism.			
075519	<a href="#">Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of</a>	National Institute on	PA-18-823	05-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Caloric Restriction (CR)-Induced Effects in Humans (R01 Clinical Trial Not Allowed)</a>	Aging/NIH/DHHS			Specified
	<p>Contact Name: Giovanna Zappalà, Ph.D., M.P.H.</p> <p>Contact Telephone: 301-827-6240</p> <p>Contact Email: <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis: National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long- term Effects of Reducing Intake of Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
073851	<a href="#">In Vivo Synaptic Function in Alzheimer's Disease and Related Dementias (R21 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-18-760	16-Jun-2020	275,000 USD
	<p>Contact Name: John K. Hsiao, M.D.</p> <p>Contact Telephone: 301-496-9350</p> <p>Contact Email: <a href="mailto:jhsiao@nia.nih.gov">jhsiao@nia.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 16-Jun-2020 , 16-Oct-2020</p> <p>Synopsis: National Institute on Aging (NIA) invites applications to study in vivo synaptic structure and function in Alzheimer's and related dementia; and to advance development of methods to study synapses in animal models and humans. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
081131	<a href="#">Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed) Activity Code</a>	National Institute on Aging/NIH/DHHS	PAR-19-234	05-Jun-2020	Not Specified
	<p>Contact Name: Marilyn Miller, Ph.D.</p> <p>Contact Telephone: 301-496-9350</p> <p>Contact Email: <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 Synopsis This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.				
091505	<a href="#">Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease (R01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-20-156	05-Jun-2020	Not Specified
	Contact Name Jean Yuan, Ph.D. Contact Telephone 301-496-9350 Contact Email <a href="mailto:yuanx4@mail.nih.gov">yuanx4@mail.nih.gov</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 Synopsis This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.				
070269	<a href="#">Advancing the Science of Geriatric Palliative Care (R01 - Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PA-18-502	05-Jun-2020	Not Specified
	Contact Name Basil Eldadah, MD, PhD Contact Telephone 301-496-6761 Contact Email <a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies. This FOA will use the NIH Research Project (R01) award mechanism.			
070272	<a href="#">Advancing the Science of Geriatric Palliative Care (R21 - Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PA-18-503	16-Jun-2020	275,000 USD
	Contact Name	Basil Eldadah, MD, PhD			
	Contact Telephone	301-496-6761			
	Contact Email	<a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and limited interventional studies where feasible for this R21 mechanism. This FOA will use the NIH Research Project (R01) award mechanism.			
072233	<a href="#">Genetics of Alcohol Sensitivity and Tolerance (R01 Clinical Trial Not Allowed)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-660	07-May-2020	Not Specified
	Contact Name	Hemin R. Chin, Ph.D.			
	Contact Telephone	301-443-1282			
	Contact Email	<a href="mailto:chinh@mail.nih.gov">chinh@mail.nih.gov</a>			
	Sponsor Website				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel genetic mechanisms underlying the development of tolerance and the progression to alcohol use disorder. Alcohol use disorders is complex, multifactorial, and influenced both by genetic and environmental factors. The purpose of this FOA is to stimulate and support efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
071743	<a href="#">Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R21 - Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-620	16-Jun-2020	275,000 USD
	<p>Contact Name Brett T. Hagman</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email <a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism.</p>				
071738	<a href="#">Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R01 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-619	07-May-2020	Not Specified
	<p>Contact Name Brett T. Hagman</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email <a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that seek to examine processes of recovery</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD. This FOA will use the NIH Research Project (R01) award mechanism.			
072235	<a href="#">Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Not Allowed)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	/PAR-18-659	07-May-2020	Not Specified
	Contact Name	Elizabeth M Powell, PhD			
	Contact Telephone	Elizabeth M Powell, PhD			
	Contact Email	<a href="mailto:elizabeth.powell3@nih.gov">elizabeth.powell3@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications on sensitivity and tolerance mechanisms underlying the development of alcohol use disorders. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol dependence. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. This FOA will use the NIH R21/R33 Phased Innovation Award mechanism.			
083915	<a href="#">Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-311	07-May-2020	1,775,000 USD
	Contact Name	Elizabeth M Powell, PhD			
	Contact Telephone	301-443-0786			
	Contact Email	<a href="mailto:elizabeth.powell3@nih.gov">elizabeth.powell3@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660).

076324	<a href="#">Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R21 - Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-862	07-May-2020	275,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Robert Freeman, Ph.D.
Contact Telephone	301-443-8820
Contact Email	<a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021
Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.

076327	<a href="#">Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-861	07-May-2020	100,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Robert Freeman, Ph.D.
Contact Telephone	301-443-8820
Contact Email	<a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021
Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R03 Small Grant Program award mechanism.			
076319	<a href="#">Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R01 - Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-863	07-May-2020	Not Specified
	Contact Name	Robert Freeman, Ph.D.			
	Contact Telephone	301-443-8820			
	Contact Email	<a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a>			
	Sponsor Website				
	Program URL				
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.			
063268	<a href="#">Alcohol-Induced Effects on Tissue Injury and Repair (R01)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-297	07-May-2020	Not Specified
	Contact Name	Bill Dunty, Ph.D.			
	Contact Telephone	301-443-7351			
	Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol's effects on complex mechanisms of injury and repair that are either common or specific to each			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		organ system. This FOA also encourages the study of alcohol's effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage. This FOA will use the NIH Research Project (R01) award mechanism.			
066094	<a href="#">Secondary Analyses of Existing Alcohol Research Data (R03)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-468	07-May-2020	100,000 USD
	Contact Name	Wenxing Zha, Ph.D.			
	Contact Telephone	301-443-0633			
	Contact Email	<a href="mailto:zhaw@mail.nih.gov">zhaw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that propose to conduct the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest. This FOA will use the NIH R03 Small Grant Program award mechanism.			
066088	<a href="#">Secondary Analyses of Existing Alcohol Research Data (R01)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-467	07-May-2020	Not Specified
	Contact Name	Wenxing Zha, Ph.D.			
	Contact Telephone	301-443-0633			
	Contact Email	<a href="mailto:zhaw@mail.nih.gov">zhaw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that propose to conduct the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest. This FOA will use the NIH Research Project (R01) award mechanism.

063269	<a href="#">Alcohol-Induced Effects on Tissue Injury and Repair (R21)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-296	07-May-2020	275,000 USD
--------	---	---	-----------	-------------	-------------

Contact Name	Bill Dunty, Ph.D.
Contact Telephone	301-443-7351
Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020
Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol's effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol's effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

070392	<a href="#">Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-508	07-May-2020	275,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Bill Dunty, Ph.D.
Contact Telephone	301-443-7351
Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website					
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021				
Synopsis	<p>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use. This FOA will use the NIH R21 Research Project Grant award mechanism.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
060837	<a href="#">Mechanisms of Alcohol-associated Cancers (R21)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-219	07-May-2020	275,000 USD

Contact Name	Bill Dunty, Ph.D.				
Contact Telephone	301-443-7351				
Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>				
Sponsor Website					
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020				
Synopsis	<p>National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute (NCI) invite applications for research investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
060834	<a href="#">Mechanisms of Alcohol-associated Cancers (R01)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-220	07-May-2020	Not Specified
	Contact Name	Bill Dunty, Ph.D.			
	Contact Telephone	301-443-7351			
	Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	<p>National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute (NCI) invite applications for research investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. Alcohol consumption is classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC; 2010, 2012) and the National Toxicology Program (NTP; 2014) of the US Department of Health and Human Services. Target sites for alcohol-related carcinogenesis include the upper aerodigestive tract, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk for certain tissues and organs could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
070391	<a href="#">Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01 Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-507	07-May-2020	Not Specified
	Contact Name	Bill Dunty, Ph.D.			
	Contact Telephone	301-443-7351			
	Contact Email	<a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	<p>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may</p>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use. This FOA will use the NIH Research Project (R01) award mechanism.
059893	<a href="#">Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-132	07-May-2020	275,000 USD
	Contact Name	Gregory Bloss, M.A.			
	Contact Telephone	301-443-3865			
	Contact Email	<a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.			
059896	<a href="#">Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R01)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-135	07-May-2020	Not Specified
	Contact Name	Gregory Bloss, M.A.			
	Contact Telephone	301-443-3865			
	Contact Email	<a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes. This FOA will use the NIH R01 Research Project Grant award mechanism.</p>			
059895	<a href="#">Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-17-134	07-May-2020	100,000 USD
	Contact Name	Gregory Bloss, M.A.			
	Contact Telephone	301-443-3865			
	Contact Email	<a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	<p>National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes. This FOA will use the NIH Small Research Grant (R03) award mechanism.</p>			
070546	<a href="#">NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18-533	18-Jun-2020	Not Specified
	Contact Name	Roger L. Miller, Ph.D.			
	Contact Telephone	301-402-3458			
	Contact Email	<a href="mailto:millerr@nidcd.nih.gov">millerr@nidcd.nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jun-2020 , 22-Feb-2021			
	Synopsis	National Institute on Deafness and Other Communication Disorders (NIDCD) offers support for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact. This program will use the NIH Research Project (R01) award mechanism.			
067708	<a href="#">Typical and Atypical Patterns of Language &amp; Literacy in Dual Language Learners (R21-Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-18-328	16-Jun-2020	275,000 USD
	Contact Name	Judith A. Cooper, Ph.D			
	Contact Telephone	301-496-5061			
	Contact Email	<a href="mailto:cooperj@mail.nih.gov">cooperj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	National Institute on Deafness and Other Communication Disorders (NIDCD) and National Institute of Child Health and Human Development (NICHD) invite applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
069078	<a href="#">NIDCD Clinical Trials in Communication Disorders (R01Clinical Trial Required)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-18-334	07-May-2020	2,499,995 USD
	Contact Name	Trinh T. Ly, M.D.			
	Contact Telephone	301-496 5061			
	Contact Email	<a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. This FOA will use the NIH Research Project (R01) award mechanism.			
070829	<a href="#">Hearing Health Care for Adults: Improving Access and Affordability (R21 Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-18-382	16-Jun-2020	275,000 USD
	Contact Name	Kelly King, Au.D., Ph.D.			
	Contact Telephone	301-402-3458			
	Contact Email	<a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020			
	Synopsis	National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
070868	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18-564	07-May-2020	Not Specified
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 08-Jun-2020 , 07-Sep-2020 , 08-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Research Career Enhancement Award for Established Investigators (K18) program to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K18 Career Enhancement Award mechanism.			
079193	<a href="#">NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-19-137	08-Jun-2020	7,500,000 USD
	Contact Name	Lana Shekim, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	<a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jun-2020 , 06-Oct-2020 , 08-Feb-2021 , 06-Jun-2021 , 06-Oct-2021			
	Synopsis	The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a clinical trial but are not required to (optional).			
079239	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-19-142	07-May-2020	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	<a href="mailto:riverara@mail.nih.gov">riverara@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 18-Jun-2020 , 07-Sep-2020 , 15-Oct-2020 , 07-Jan-2021			
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical,			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			<p>behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Independent Clinical Trial Required’ (PAR-18-435). Applicants not planning an independent clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion ‘Independent Clinical Trial Not Allowed’ (PAR-18-436) FOA.</p>		
079241	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-19-143	07-May-2020	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p> <p><a href="mailto:riverara@mail.nih.gov">riverara@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2020 , 08-Jun-2020 , 07-Sep-2020 , 08-Oct-2020 , 07-Jan-2021</p>			
	Synopsis				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
FOA PAR-18-564 'Independent Clinical Trial Not Allowed' FOA.					
078368	<a href="#">Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-19-046	07-May-2020	275,000 USD
	Contact Name	Lana Shekim, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	<a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	This funding opportunity announcement (FOA) solicits Research Project Grants (R21) applications on augmentative and alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.			
078310	<a href="#">Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-19-047	07-May-2020	Not Specified
	Contact Name	Lana Shekim, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	<a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational.			
069082	<a href="#">NIDCD Cooperative Agreement for Clinical Trials in Communication</a>	National Institute on Deafness & Other	PAR-18-	22-Jun-2020	Not



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Disorders (U01 - Clinical Trial Required)</a>	Communication Disorders/NIH/DHHS	340		Specified
	Contact Name	Trinh T. Ly, M.D.			
	Contact Telephone	301-496 5061			
	Contact Email	<a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Jun-2020 , 21-Oct-2020			
	Synopsis	National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, has annual direct costs equal to or greater than \$500,000, that is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application. This FOA will use the NIH U01 Research Project – Cooperative Agreements award mechanism.			
070828	<a href="#">Hearing Health Care for Adults: Improving Access and Affordability (R01 Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-18-438	05-Jun-2020	Not Specified
	Contact Name	Kelly King, Au.D., Ph.D.			
	Contact Telephone	301-402-3458			
	Contact Email	<a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020			
	Synopsis	National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults. This FOA will use the NIH Research Project (R01) award mechanism.			
070865	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18-562	07-May-2020	Not Specified
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 07-May-2020 , 08-Jun-2020 , 07-Sep-2020 , 08-Oct-2020 , 07-Jan-2021 Synopsis National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Research Career Enhancement Award for Established Investigators (K18) program to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K18 Career Enhancement Award mechanism.				
067706	<a href="#">Typical and Atypical Patterns of Language &amp; Literacy in Dual Language Learners (R01-Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PA-18-316	05-Jun-2020	Not Specified
	Contact Name Judith A. Cooper, Ph.D Contact Telephone 301-496-5061 Contact Email <a href="mailto:cooperj@mail.nih.gov">cooperj@mail.nih.gov</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 Synopsis National Institute on Deafness and Other Communication Disorders (NIDCD) and National Institute of Child Health and Human Development (NICHD) invite applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations. This FOA will use the NIH Research Project (R01) award mechanism.				
070854	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18-435	07-May-2020	315,000 USD
	Contact Name Alberto L. Rivera-Rentas, Ph.D. Contact Telephone 301-496-1804 Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a> Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 18-Jun-2020 , 07-Sep-2020 , 15-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists. This award is designed to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K01 Research Scientist Development Award - Research &amp; Training award mechanism.</p>				
070859	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18-436	07-May-2020	315,000 USD
	<p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 18-Jun-2020 , 07-Sep-2020 , 15-Oct-2020 , 07-Jan-2021</p> <p>Synopsis National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists. This award is designed to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K01 Research Scientist Development Award - Research &amp; Training award mechanism.</p>				
070187	<a href="#">NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	PAR-18-487	26-Jun-2020	300,000 USD
	<p>Contact Name Bracie Watson, Jr.</p> <p>Contact Telephone 301-402-3458</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [watsonb@nidcd.nih.gov](mailto:watsonb@nidcd.nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 26-Jun-2020 , 27-Oct-2020

Synopsis National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for support of basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

090894	<a href="#">RFA-DC-20-001 -- Special Topic Research Education Course: Exploring Auditory and Vestibular Biology (R25 - Clinical Trial Not Allowed)</a>	National Institute on Deafness & Other Communication Disorders/NIH/DHHS	RFA-DC-20-001	26-Jun-2020	2,500,000 USD
--------	--	---	---------------	-------------	---------------

Contact Name Nancy Freeman, Ph.D.  
Contact Telephone 301-402-3458  
Contact Email [freemann@mail.nih.gov](mailto:freemann@mail.nih.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 26-Jun-2020

Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDCD R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical research needs, and to encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in auditory and vestibular research. To accomplish the stated over-arching goal, this NIDCD FOA will support creative educational activities with a primary focus on courses for skills development, research experiences, mentoring activities, and dissemination/outreach.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
071562	<a href="#">Women &amp; Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-601	07-May-2020	100,000 USD
	Contact Name	Cora Lee Wetherington, Ph.D.			
	Contact Telephone	301-435-1319			
	Contact Email	<a href="mailto:cwetheri@mail.nih.gov">cwetheri@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021			
	Synopsis	National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R03 Small Grant Program award mechanism.			
071788	<a href="#">Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAS-18-625	07-May-2020	Not Specified
	Contact Name	Vani Pariyadath, Ph.D.			
	Contact Telephone	301-443-3209			
	Contact Email	<a href="mailto:vani.pariyadath@nih.gov">vani.pariyadath@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institute on Drug Abuse (NIDA) invites applications for innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
071556	<a href="#">Women &amp; Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-603	07-May-2020	Not Specified
	Contact Name	Cora Lee Wetherington, Ph.D.			
	Contact Telephone	301-435-1319			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:cwetheri@mail.nih.gov">cwetheri@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
073554	<a href="#">NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-18-746	11-Jun-2020	750,000 USD
	<p>Contact Name Aria Davis Crump, Sc.D.</p> <p>Contact Telephone 301-435-0881</p> <p>Contact Email <a href="mailto:acrump@nida.nih.gov">acrump@nida.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jun-2020 , 28-Aug-2020</p> <p>Synopsis National Institute on Drug Abuse (NIDA) invites applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research. This FOA allows appointment of scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. For this FOA, clinician scientists may include (but are not limited to) physicians, clinical psychologists, epidemiologists, doctoral level social workers, pharmacists, and behavioral scientists. Scholars are expected to be supported for 3-5 years on consecutive 12-month appointments. Candidates selected for support as scholars must hold a doctorate and commit a minimum of 9 person-months (equivalent to 75% of full-time professional effort) to conducting clinical research and career development activities associated with the proposed program. This FOA will use the NIH K12 Clinician Scientist Award (Program) (PSA) mechanism.</p>				
071560	<a href="#">Women &amp; Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-602	07-May-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Cora Lee Wetherington, Ph.D.</p> <p>Contact Telephone   301-435-1319</p> <p>Contact Email   <a href="mailto:cwetheri@mail.nih.gov">cwetheri@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis   National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>				
072241	<a href="#">RFA-DA-19-003 -- Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-19-003	17-Jun-2020 [Optional][LOI/Pre-App]	2,650,000 USD
	<p>Contact Name   John Satterlee Ph.D.</p> <p>Contact Telephone   301-435-1020</p> <p>Contact Email   <a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   17-Jun-2020 [Optional][LOI/Pre-App], 17-Jul-2020</p> <p>Synopsis   National Institute on Drug Abuse (NIDA) invites applications for projects that exploit Omics assays to address outstanding questions regarding molecular regulation of persistent HIV (e.g. latency or reservoirs) in the context of chronic substance use or substance use disorder (SUD). This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award award mechanism.</p>				
074542	<a href="#">Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34-Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-780	07-May-2020	450,000 USD
	<p>Contact Name   Richard A. Jenkins, PhD</p> <p>Contact Telephone   301-443-1923</p> <p>Contact Email   <a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021			
	Synopsis	National Institute on Drug Abuse (NIDA) invites applications for formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected. This FOA will use the NIH R34 Planning Grant award mechanism.			
077321	<a href="#">Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-917	07-May-2020	Not Specified
	Contact Name	David Thomas, PhD			
	Contact Telephone	301-435-1313			
	Contact Email	<a href="mailto:dthomas1@nida.nih.gov">dthomas1@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. This FOA will use the NIH Research Project (R01) award mechanism.			
074442	<a href="#">International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-773	07-May-2020	Not Specified
	Contact Name	Steven Gust, Ph.D., Director			
	Contact Telephone	301-443-6480			
	Contact Email	<a href="mailto:ipdirector@nida.nih.gov">ipdirector@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021			
	Synopsis	National Institute on Drug Abuse (NIDA) solicits collaborative research applications on drug abuse and addiction that: Take			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery; Describe how the research will significantly advance U.S. health sciences; Demonstrate specific relevance to the NIDA mission and objectives. To determine whether your research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (<https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan>). Where feasible, applications should address NIDA's international scientific priority areas (<https://www.drugabuse.gov/international/research-priorities>); and Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country. This FOA will use the NIH Research Project (R01) award mechanism.

074449	<a href="#">Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-774	07-May-2020	450,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Sarah Q. Duffy, Ph.D.
Contact Telephone	301-451- 4998
Contact Email	<a href="mailto:duffys@nida.nih.gov">duffys@nida.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021
Synopsis	National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities. This FOA will use the NIH R34 Planning Grant grant mechanism.

074451	<a href="#">Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-18-775	07-May-2020	450,000 USD
--------	---	---	-----------	-------------	-------------

Contact Name	Jacqueline Lloyd, Ph.D.
Contact Telephone	301-443-8892
Contact Email	<a href="mailto:lloydj2@nida.nih.gov">lloydj2@nida.nih.gov</a>
Sponsor Website	



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, prevent suicide attempts (nonfatal and fatal), and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems. This FOA will utilize the NIH Planning Grant (R34) award mechanism.</p>				
071785	<a href="#">Mechanistic investigations of Psychosocial Stress Effects on Opioid Use Patterns (R01- Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAS-18-624	07-May-2020	Not Specified
	<p>Contact Name Vani Pariyadath, Ph.D.</p> <p>Contact Telephone 301-443-3209</p> <p>Contact Email <a href="mailto:vani.pariyadath@nih.gov">vani.pariyadath@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020</p> <p>Synopsis National Institute on Drug Abuse (NIDA) invites applications for innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
078460	<a href="#">Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-064	08-Jun-2020	275,000 USD
	<p>Contact Name Marsha F. Lopez, PhD, MHS</p> <p>Contact Telephone 301-443-6504</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:lopezmar@mail.nih.gov">lopezmar@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Jun-2020 , 06-Oct-2020 , 08-Feb-2021 , 08-Jun-2021 , 08-Oct-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service; 6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis). It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline)</p>				
082221	<a href="#">Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-278	24-Jun-2020	Not Specified
	<p>Contact Name John Satterlee Ph.D.</p> <p>Contact Telephone 301-435-1020</p> <p>Contact Email <a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 24-Jun-2020 , 18-Dec-2020 , 24-Jun-2021 , 17-Dec-2021</p> <p>Synopsis The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.</p>				
079380	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-163	07-May-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<a href="#">(R21-Clinical Trial Not Allowed)</a>					
	Contact Name	Karen Sirocco			
	Contact Telephone	301-451-8661			
	Contact Email	<a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page ( <a href="http://www.abcdstudy.org">www.abcdstudy.org</a> ).			
089603	<a href="#">RFA-DA-21-004 -- Exploring the Roles of Biomolecular Condensates (BMCs) in HIV Replication, Latency, or Pathogenesis in the Context of Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-004	20-Jun-2020 [Optional][LOI/Pre-App]	1,000,000 USD
	Contact Name	John Satterlee, Ph.D.			
	Contact Telephone	301-435-1020			
	Contact Email	<a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Jun-2020 [Optional][LOI/Pre-App], 20-Jul-2020			
	Synopsis	To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances.			
085474	<a href="#">Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-368	07-May-2020	2,499,995 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Marsha F. Lopez, Ph.D., M.H.S.
Contact Telephone	301-443-6504
Contact Email	<a href="mailto:marsha.lopez@nih.gov">marsha.lopez@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.

079379	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-162	07-May-2020	1,250,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Karen Sirocco
Contact Telephone	301-451-8661
Contact Email	<a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page ( <a href="http://www.abcdstudy.org">www.abcdstudy.org</a> ).

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
090993	<a href="#">NIDA Small Research Grant Program (R03 Clinical Trial Required)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-20-146	16-Jun-2020	100,000 USD
	Contact Name	Katrina L Foster, PhD			
	Contact Telephone	301-827-5815			
	Contact Email	<a href="mailto:fosterkl@nih.gov">fosterkl@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.			
077343	<a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-18-918	07-May-2020	150,000 USD
	Contact Name	Steven Grant, Ph.D.			
	Contact Telephone	301-443-4877			
	Contact Email	<a href="mailto:sgrant@nida.nih.gov">sgrant@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute on Drug Abuse (NIDA) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources. This program will use the NIH Small Research Grant (R03) award mechanism.			
083682	<a href="#">Behavioral Science Track Award for Rapid Transition (B/Start)(R03)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-	07-May-2020	75,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Clinical Trial Optional</a>	Abuse/NIH/DHHS	310		
	Contact Name	Holly Moore, Ph.D.			
	Contact Telephone	301-827-7376			
	Contact Email	<a href="mailto:holly.moore@nih.gov">holly.moore@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	<p>This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.</p>			
073605	<a href="#">Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)</a>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-18-745	15-Jun-2020	275,000 USD
	Contact Name	Andrew Loudon, Ph.D.			
	Contact Telephone	301-594-9009			
	Contact Email	<a href="mailto:andrew.louden@nih.gov">andrew.louden@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020 , 13-Nov-2020			
	Synopsis	<p>NIH and its participating Institutes and Centers invite applications for developmental and exploratory research focused on determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also seek to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these populations. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
073603	<a href="#">Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)</a>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-18-745	15-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional)</a>	Health Disparities/NIH/DHHS	747		Specified
	Contact Name	Andrew Louden, Ph.D.			
	Contact Telephone	301-594-9009			
	Contact Email	<a href="mailto:andrew.louden@nih.gov">andrew.louden@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020 , 13-Nov-2020			
	Synopsis	NIH and its participating Institutes and Centers invite applications for investigative and collaborative research focused on determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also seek to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these populations. This FOA will use the NIH Research Project (R01) award mechanism.			
091370	<a href="#">NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)</a>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-20-150	16-Jun-2020	275,000 USD
	Contact Name				
	Contact Telephone	301-402-1366			
	Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023			
	Synopsis	NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.			
033794	<a href="#">NIH Generic Clone Program (non-ASSIST) (Temporarily Suspended)</a>	National Institutes of Health/DHHS		07-May-2020	Not Specified
	Contact Name				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL				
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	invites applications for This FOA will use the NIH award mechanism.			
081385	<a href="#">RFA-MH-20-120 -- BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-MH-20-120	12-May-2020 [Optional][LOI/Pre-App]	900,000 USD
	Contact Name	Ming Zhan, Ph.D.			
	Contact Telephone	301-827-3678			
	Contact Email	<a href="mailto:ming.zhan@mail.nih.gov">ming.zhan@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-May-2020 [Optional][LOI/Pre-App], 11-Jun-2020			
	Synopsis	<p>The BRAIN Initiative and the neuroscience field as a whole are generating massive and diverse research data across different modalities, spatiotemporal scales and species in efforts to advance our understanding of the brain. The data types are being produced through development and application of innovative technologies in high-throughput -omics profiling, optical microscopy, electron microscopy, electrophysiological recording, macroscale neuroimaging, neuromodulation, and others. The BRAIN Initiative has made significant investments in the development of an infrastructure to make data available to the research community in a useful way. This infrastructure includes data archives, data standards, and software for data integration, analysis and machine learning. This Funding Opportunity Announcement (FOA) encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be held in one of the funded BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or novel analytic methods, data science techniques, and machine learning approaches. Support may also be requested to prepare and submit existing data into any of the BRAIN Initiative data archives. Investigators should not underestimate the time and effort that may be necessary to curate or harmonize data. Analyzed data, models and analytical tools generated under this FOA are expected to be deposited into an appropriate data archive. Since the BRAIN Initiative data archives are mostly making the data available to the research community through cloud-based storage, depositing the analyzed data, models and tools are expected to enhance opportunities to create a data sandbox where investigators can easily compare the results of their analysis with those from other research groups. The goal of this FOA is to promote studies that will significantly advance new</p>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					discoveries and accelerate the pace of research of the BRAIN Initiative through harnessing the big data and machine learning opportunities. Awardees are expected to enhance the value of existing data, improve the overall data integration and analysis capability, and strengthen the statistical power and rigor and reproducibility of BRAIN Initiative related data.
080193	<a href="#">Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-19-193	05-Jun-2020	Not Specified
	Contact Name	Avi Rasooly, PhD			
	Contact Telephone	240-276-6196			
	Contact Email	<a href="mailto:rasoolya@mail.nih.gov">rasoolya@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022			
	Synopsis	<p>The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaeobacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies. This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants applying to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy. Complex microbial-tumor interactions are best addressed with a team approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.</p>			
066436	<a href="#">Research on the Health of Transgender and Gender Nonconforming Populations (R21)</a>	National Institutes of Health/DHHS	PA-17-477	07-May-2020	275,000 USD
	Contact Name	Della B. White, PhD			
	Contact Telephone	301-435-2712			
	Contact Email	<a href="mailto:whitede@mail.nih.gov">whitede@mail.nih.gov</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.			
076698	<a href="#">New Paradigms in Tissue Communication-from mediators to metabolic function (RC2 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-18-886	02-Jun-2020	Not Specified
	Contact Name	Olivier Blondel, Ph.D.			
	Contact Telephone	301-451-7334			
	Contact Email	<a href="mailto:blondelol@niddk.nih.gov">blondelol@niddk.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Jun-2020 , 03-Nov-2020 , 01-Jun-2021			
	Synopsis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to generate scientific advancements that are focused on identifying new signals and regulatory networks that mediate metabolic cross talks within and between organs that play a role in the development of diabetes and obesity. The interdisciplinary approaches proposed should be designed to foster novel synergies that will accelerate conceptual and technical breakthroughs in science related to metabolic tissue communication. This FOA will use the NIH RC2 High Impact Research and Research Infrastructure Programs award mechanism.			
087107	<a href="#">RFA-NS-19-044 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-NS-19-044	10-Jun-2020	Not Specified
	Contact Name	Edmund (Ned) Talley, PhD			
	Contact Telephone	301-496-1917			
	Contact Email	<a href="mailto:BRAINDIVERSITYK99R00@nih.gov">BRAINDIVERSITYK99R00@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   10-Jun-2020 , 09-Oct-2020 , 10-Feb-2021 , 09-Jun-2021 , 06-Oct-2021 , 10-Feb-2022 , 08-Jun-2022 , 11-Oct-2022</p> <p>Synopsis   The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (RFA-NS-19-043)</p>				
078543	<a href="#">Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-067	07-May-2020	Not Specified
	<p>Contact Name   Timothy A. Gondré-Lewis, Ph.D.</p> <p>Contact Telephone   240-627-3566</p> <p>Contact Email   <a href="mailto:tglewis@niaid.nih.gov">tglewis@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.</p>				
078750	<a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-19-089	07-May-2020	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
078748	<p><a href="#">Midcareer Investigator Award in Patient-Oriented Research</a></p> <p><a href="#">(Parent K24 Independent Basic Experimental Studies with Humans Required)</a></p>	National Institutes of Health/DHHS	PA-19-088	07-May-2020	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

078546	<a href="#">Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-066	07-May-2020	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	Timothy A. Gondré-Lewis, Ph.D.
Contact Telephone	240-627-3566
Contact Email	<a href="mailto:tglewis@niaid.nih.gov">tglewis@niaid.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

087955	<a href="#">Surgical Disparities Research (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-079	05-Jun-2020	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Benyam Hailu, MD, MPH
Contact Telephone	301-594-8696
Contact Email	<a href="mailto:Benyam.Hailu@nih.gov">Benyam.Hailu@nih.gov</a>
Sponsor Website	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Jun-2021 , 05-Jun-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level.</p>				
087977	<a href="#">RFA-NS-20-006 -- BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	RFA-NS-20-006	03-May-2020 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Sahana N. Kukke, PhD</p> <p>Contact Telephone 301-496-1447</p> <p>Contact Email <a href="mailto:BRAIN-FOAs@nih.gov">BRAIN-FOAs@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-May-2020 [Optional][LOI/Pre-App], 02-Jun-2020 , 01-Sep-2020 [Optional][LOI/Pre-App], 01-Oct-2020 , 03-Jan-2021 [Optional][LOI/Pre-App], 02-Feb-2021 , 02-May-2021 [Optional][LOI/Pre-App], 01-Jun-2021 , 01-Sep-2021 [Optional][LOI/Pre-App], 01-Oct-2021 , 02-Jan-2022 [Optional][LOI/Pre-App], 01-Feb-2022 , 02-May-2022 [Optional][LOI/Pre-App], 01-Jun-2022 , 03-Sep-2022 [Optional][LOI/Pre-App], 03-Oct-2022</p> <p>Synopsis A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system. This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.</p>				
088012	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-082	07-May-2020	275,000 USD
	<p>Contact Name David M. Panchision, Ph.D.</p> <p>Contact Telephone 301-443-5288</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-20-NNN).</p>				
088011	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-055	07-May-2020	Not Specified
	<p>Contact Name David M. Panchision, Ph.D.</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA(PAR-20-082).</p>				
087104	<a href="#">RFA-NS-19-043 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-NS-19-043	10-Jun-2020	Not Specified
	Contact Name Edmund (Ned) Talley, PhD				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-1917</p> <p>Contact Email <a href="mailto:BRAINDIVERSITYK99R00@nih.gov">BRAINDIVERSITYK99R00@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2020 , 09-Oct-2020 , 10-Feb-2021 , 09-Jun-2021 , 06-Oct-2021 , 10-Feb-2022 , 08-Jun-2022 , 11-Oct-2022</p> <p>Synopsis The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA RFA-NS-19-044 .</p>				
088091	<a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-038	07-May-2020	Not Specified
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion FOA PAR-20-037 .</p>				
088090	<a href="#">Development and Application of PET and SPECT Imaging Ligands as</a>	National Institutes of Health/DHHS	PAR-20-	07-May-2020	825,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)</a>		037		USD
	<p>Contact Name Enrique Michelotti, Ph.D.</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR-20-038 .</p>				
089301	<a href="#">RFA-GM-20-001 -- Training Modules to Enhance the Rigor, Reproducibility and Responsible Conduct of Biomedical Data Science Research (R25 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-GM-20-001	19-Jun-2020	250,000 USD
	<p>Contact Name Haluk Resat, Ph.D</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:haluk.resat@nih.gov">haluk.resat@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 19-Jun-2020</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development Specifically, this FOA will support the development of exportable training modules designed to enhance the rigor, reproducibility, and responsible conduct of biomedical and behavioral data science research, targeted to trainees and researchers at any career level.</p>				
089280	<a href="#">High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial</a>	National Institutes of Health/DHHS	PAR-20-	01-Jun-2020	2,000,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Not Allowed</a>		114		USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Guanghu Wang, PhD 301-435-0777 <a href="mailto:HEI@mail.nih.gov">HEI@mail.nih.gov</a>  <a href="#">Link to program URL</a> 01-Jun-2020 The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is \$600,001. There is no maximum price limit for the instrument; however, the maximum award is \$2,000,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, high throughput robotic screening systems, and biomedical imagers.			
089276	<a href="#">Shared Instrumentation Grant (SIG) Program (\$10 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-113	01-Jun-2020	600,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Alena Horska, PhD 301-435-0772 <a href="mailto:SIG@mail.nih.gov">SIG@mail.nih.gov</a>  <a href="#">Link to program URL</a> 01-Jun-2020 The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated systems. The minimum award is \$50,000. There is no maximum price limit for the instrument; however, the maximum award is \$600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.			
089281	<a href="#">RFA-AG-21-013 -- Prodromal a-Synucleinopathies Consortium (PaSS) (U19 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AG-21-013	17-May-2020 [Optional][LOI/Pre-App]	15,000,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Mirosław (Mack) Mackiewicz, Ph.D.			
	Contact Telephone	301-594-7636			
	Contact Email	<a href="mailto:mirsoslaw.mackiewicz@nih.gov">mirsoslaw.mackiewicz@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-May-2020 [Optional][LOI/Pre-App], 17-Jun-2020			
	Synopsis	This funding opportunity announcement (FOA) invites applications to develop a multisite, longitudinal, prospective study of idiopathic REM sleep behavior disorder (iRBD) as a prodromal phase of $\alpha$ -synuclein neurodegenerative disorders.			
065196	<a href="#">Assay Development and Screening for Discovery of Chemical Probes or Therapeutic Agents (R01)</a>	National Institutes of Health/DHHS	PAR-17-438	07-May-2020	Not Specified
	Contact Name	Suzanne Forry, Ph.D.			
	Contact Telephone	240-276-5922			
	Contact Email	<a href="mailto:forryscs@mail.nih.gov">forryscs@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set. This FOA will use the NIH Research Project (R01) award mechanism.			
090082	<a href="#">RFA-AT-21-002 -- Exploring the Mechanisms Underlying Modulation of Glymphatic-Lymphatic Systems by Complementary and Integrative Health Approaches (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AT-21-002	09-Jun-2020 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Yisong Wang, Ph.D.			
	Contact Telephone	301-480-9483			
	Contact Email	<a href="mailto:yisong.wang@nih.gov">yisong.wang@nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL [Link to program URL](#)

Deadline Dates (ALL) 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020

Synopsis This Funding Opportunity Announcement (FOA) encourages research applications that explore the impact of and the mechanisms by which complementary and integrative health approaches regulate the activities of glymphatic and lymphatic systems, or investigate the effect of complementary and integrative health approaches on the interactions between glymphatic/lymphatic functions and physiological/pathological processes. Proposed mechanistic studies may be in relevant animal models and/or human research participants. This FOA will not support clinical trials aiming to assess efficacy or effectiveness of clinical outcomes.

090067	<a href="#">RFA-AT-21-001 -- Exploring the Mechanisms Underlying Modulation of Glymphatic-Lymphatic Systems by Complementary and Integrative Health Approaches (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AT-21-001	09-Jun-2020 [Optional][LOI/Pre-App]	2,500,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	---------------

Contact Name Yisong Wang, Ph.D.

Contact Telephone 301-480-9483

Contact Email [yisong.wang@nih.gov](mailto:yisong.wang@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 09-Jun-2020 [Optional][LOI/Pre-App], 09-Jul-2020

Synopsis This Funding Opportunity Announcement (FOA) encourages research applications that explore the impact of and the mechanisms by which complementary and integrative health approaches regulate the activities of glymphatic/lymphatic systems, or investigate the effect of complementary and integrative health approaches on the interactions between glymphatic/lymphatic functions and physiological/pathological processes. Proposed mechanistic studies may be in relevant animal models and/or human research participants. This FOA will not support clinical trials aiming to assess efficacy or effectiveness of clinical outcomes.

079149	<a href="#">Mentored Quantitative Research Development Award (Parent K25 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-124	07-May-2020	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name

Contact Telephone

Contact Email [grantinfo@nih.gov](mailto:grantinfo@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-125).</p>				
079139	<a href="#">Mentored Quantitative Research Development Award (Parent K25 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-125	07-May-2020	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-124).</p>				
090136	<a href="#">RFA-AI-20-016 -- Harnessing Natural Killer (NK) Cells to Prevent, Control, or Eradicate HIV (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AI-20-016	29-Jun-2020 [Optional][LOI/Pre-App]	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Cesar Boggiano, Ph.D.</p> <p>Contact Telephone 240-627-3038</p> <p>Contact Email <a href="mailto:boggianoca@niaid.nih.gov">boggianoca@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 29-Jun-2020 [Optional][LOI/Pre-App], 28-Jul-2020</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support basic, translational, and clinical research to improve the understanding of the effector or immunoregulatory potentials of NK cells for HIV prevention, control and/or eradication.</p>				
090374	<a href="#">In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-137	05-Jun-2020	2,499,995 USD
	<p>Contact Name Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2020 , 05-Oct-2020 , 05-Jun-2021 , 05-Oct-2021 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.</p>				
090366	<a href="#">Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical</a>	National Institutes of Health/DHHS	PAR-20-133	18-Jun-2020	1,775,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<a href="#">Trial Required</a>					
	<p>Contact Name   Padma Maruvada, PhD</p> <p>Contact Telephone   301-594-8884</p> <p>Contact Email   <a href="mailto:padma.maruvada@nih.gov">padma.maruvada@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   18-Jun-2020 , 08-Jun-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement is to support the development of tools/devices for sampling or monitoring of diet- gastro-intestinal (GI)(contents and mucosa) and microbial interactions (GI- Microbiome Explorer). It is anticipated that successful completion of the projects completed under this FOA will yield implementable devices/tools for gastroenterological research or other clinical applications, along with monitoring and sampling of GI contents and/or mucosa to examine diet-host-microbiome interactions for clinical research or diagnostic applications.</p>				
090369	<a href="#">Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones (R21/R33 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-20-134	18-Jun-2020	1,775,000 USD
	<p>Contact Name   Padma Maruvada, PhD</p> <p>Contact Telephone   301-594-8884</p> <p>Contact Email   <a href="mailto:padma.maruvada@nih.gov">padma.maruvada@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   18-Jun-2020 , 08-Jun-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement is to develop tools and devices that can continuously monitor a broader range of nutrients, metabolites and/or metabolic signals for advancing precision nutrition, microbiome, and circadian metabolism research.</p>				
080196	<a href="#">Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-19-194	16-Jun-2020	550,000 USD
	<p>Contact Name   Avi Rasooly, PhD</p> <p>Contact Telephone   240-276-6196</p> <p>Contact Email   <a href="mailto:rasoolya@mail.nih.gov">rasoolya@mail.nih.gov</a></p> <p>Sponsor Website  </p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022</p> <p>Synopsis The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaeobacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies. This FOA will support basic, mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants responding to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy. The FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy.</p>				
084924	<p><a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	PAR-19-343	12-Jun-2020	Not Specified
	<p>Contact Name Kenneth D. Gibbs, Jr., Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:kenneth.gibbs@nih.gov">kenneth.gibbs@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021 , 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022</p> <p>Synopsis The purpose of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions at research-intensive institutions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.			
068705	<a href="#">Human Subjects Mechanistic and Minimal Risk Studies (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-18-351	07-May-2020	Not Specified
	Contact Name	Ellen Liberman, Ph.D.			
	Contact Telephone	301-451-2020			
	Contact Email	<a href="mailto:ellen.liberman@nih.gov">ellen.liberman@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021			
	Synopsis	<p>National Eye Institute (NEI) invites applications that seek to conduct studies of the visual system. This FOA will support applications that either involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
090789	<a href="#">RFA-HD-21-005 -- Genomic Predictors of Pregnancy Loss (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-HD-21-005	30-Jun-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Lisa M. Halvorson, MD			
	Contact Telephone	301-480-1646			
	Contact Email	<a href="mailto:lisa.halvorson@mail.nih.gov">lisa.halvorson@mail.nih.gov</a>			
	Sponsor Website				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 [Optional][LOI/Pre-App], 30-Jul-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies which utilize emerging genomic technologies to identify variants which predict risk for pregnancy loss in subsequent pregnancies beyond standard karyotype approaches.			
090913	<a href="#">RFA-HG-20-002 -- Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Coordinating Center (U01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-HG-20-002	24-May-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Lucia A. Hindorff, Ph.D, M.P.H.			
	Contact Telephone	240-271-1509			
	Contact Email	<a href="mailto:hindorffl@mail.nih.gov">hindorffl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-May-2020 [Optional][LOI/Pre-App], 23-Jun-2020			
	Synopsis	The goal of this FOA is to establish a Coordinating Center (CC) for PRS Methods and Analysis for Populations of Diverse Ancestry to provide centralized support, infrastructure, coordination, and data analysis for a program to collaboratively generate and refine PRS for populations of diverse ancestry by integrating existing datasets with genomic and phenotype data for a range of complex diseases and traits. Together with PRS Study Sites (described in RFA HG-20-001), grantees funded under this FOA will form a Consortium with the primary objectives of: 1) leveraging genetic diversity to develop methods and improve the applicability of PRS to predict health and disease risk across diverse populations, and for a broad range of health and disease measures; and 2) optimizing the integration of large-scale, harmonized genomic and phenotype data to facilitate collaborative analysis, dissemination of PRS-related data, and development of related methods and resources.			
090902	<a href="#">RFA-HG-20-001 -- Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Study Sites (U01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-HG-20-001	24-May-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	Lucia A. Hindorff, Ph.D, M.P.H.			
	Contact Telephone	240-271-1509			
	Contact Email	<a href="mailto:hindorffl@mail.nih.gov">hindorffl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-May-2020 [Optional][LOI/Pre-App], 23-Jun-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The goal of the intended FOA is to establish Study Sites for PRS Methods and Analysis for Populations of Diverse Ancestry to collaboratively generate and refine PRS for populations of diverse ancestry by integrating existing datasets with genomic and phenotype data for a range of complex diseases and traits. Together with a Coordinating Center (described in a separate FOA), grantees funded under the intended FOA will form a Consortium with the primary objectives of: 1) leveraging genetic diversity to develop methods and improve the applicability of PRS to predict health and disease risk across diverse populations, and for a broad range of health and disease measures; and 2) optimizing the integration of large-scale, harmonized genomic and phenotype data to facilitate collaborative analysis, dissemination of PRS-related data, and development of related methods and resources.			
078753	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-19-090	07-May-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.			
078747	<a href="#">Mentored Patient-Oriented Research Career Development Award</a>	National Institutes of Health/DHHS	PA-19-087	07-May-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[\(Parent K23 Independent Basic Experimental Studies with Humans Required\)](#)

Specified

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022
Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

078746 [Mentored Clinical Scientist Research Career Development Award](#)  
[\(Parent K08 Independent Basic Experimental Studies with Humans Required\)](#)

National Institutes of Health/DHHS

PA-19-086 07-May-2020

Not Specified

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

078744	<a href="#">Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-19-084	07-May-2020	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name  
Contact Telephone  
Contact Email  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022

Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. . The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			
078745	<a href="#">Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-19-085	07-May-2020	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:er@od.nih.gov">er@od.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis</p>	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			
079178	<a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-131	07-May-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-132).			

079179	<a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-132	07-May-2020	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-131).

078397	<a href="#">Research Project Grant (Parent R01 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-055	07-May-2020	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 05-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022
Synopsis	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

079124	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-121	07-May-2020	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022
Synopsis	The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-122).

079101	<a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-116	07-May-2020	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-8580
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022
Synopsis	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-117).

079102	<a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-117	07-May-2020	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-8580
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022
Synopsis	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-116).</p>				
079132	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-122	07-May-2020	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors primarily for clinical residents, clinical fellows and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-121).</p>				
079176	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-130	07-May-2020	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-129).</p>			
079163	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-129	07-May-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	<p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-130).</p>			
079153	<a href="#">Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-127	07-May-2020	Not Specified
	Contact Name				
	Contact Telephone				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [grantsinfo@nih.gov](mailto:grantsinfo@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021

Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-126).

079113	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-118	07-May-2020	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name

Contact Telephone

Contact Email [grantinfo@nih.gov](mailto:grantinfo@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022

Synopsis The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-19-119).

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
---------	---------------	--------------	----------------	---------------	---------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

					Amount
091783	<a href="#">RFA-NS-20-029 -- BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	RFA-NS-20-029	14-Jun-2020 [Optional][LOI/Pre-App]	Not Specified

Contact Name	Karen K David, Ph.D.
Contact Telephone	301-496-9964
Contact Email	<a href="mailto:BRAINCircuits@nih.gov">BRAINCircuits@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	14-Jun-2020 [Optional][LOI/Pre-App], 14-Jul-2020 , 15-Jun-2021
Synopsis	This funding opportunity announcement (FOA) is designed to support teams of investigators that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant advances. These studies at the exploratory stage are intended for the development of experimental capabilities and/or theoretical frameworks in preparation for a future competition for larger-scale or extended efforts, including the BRAIN TargetedBCP R01 or the multi-component, Team-Research BRAIN Circuit Programs (U19). The overall goal of this FOA is to enable a large-scale analysis of neural systems and circuits within the context and during the simultaneous measurement of an ethologically relevant behavior. Toward this end, teams are expected to assemble and leverage multi-disciplinary expertise, and to integrate experimental with computational and theoretical approaches. Teams are expected to bridge fields by incorporating rich information on cell-types, on circuit functionality and connectivity, in conjunction with sophisticated analyses of an ethologically relevant behavior of an organism or a well-defined neural system. Teams are also expected to aim for a mechanistic understanding of the circuits of the central nervous system (CNS) by applying cutting-edge methods such as those for large-scale recording, manipulation, and analysis of neural circuits across multiple regions of the CNS.

079159	<a href="#">Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-126	07-May-2020	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021			
	Synopsis	<p>The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-127).</p>			

079117	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-119	07-May-2020	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 12-Jun-2020 , 07-Sep-2020 , 12-Oct-2020 , 07-Jan-2021 , 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	<p>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial.</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-19-118).				
090063	<a href="#">Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-20-125	24-Jun-2020	4,000,000 USD
	Contact Name	Sheila A. Caldwell, PhD			
	Contact Telephone				
	Contact Email	<a href="mailto:caldwells@mail.nih.gov">caldwells@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-Jun-2020 , 24-Jul-2020 , 24-Jun-2021 , 23-Jul-2021			
	Synopsis	The National Institute of General Medical Sciences, in conjunction with the Institutes/Centers of the National Institutes of Health (NIH) listed above in the "Components of Participating Organizations" section and the Indian Health Service (IHS), invites applications from federally recognized Tribes and Tribal organizations for the Native American Research Centers for Health (NARCH) initiative. The objective of the NARCH initiative is to support biomedical research and career enhancement opportunities to meet health needs prioritized by American Indian/Alaska Native (AI/AN) communities. The NARCH initiative also supports research capacity building and the development of research infrastructure to enhance the biomedical research capabilities of AI/AN communities.			
078756	<a href="#">NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-19-091	07-May-2020	Not Specified
	Contact Name				
	Contact Telephone	301-496-4000			
	Contact Email	<a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

078759	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-19-092	07-May-2020	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	301-496-4000
Contact Email	<a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Optional' FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

078391	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-053	07-May-2020	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

078396	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-19-054	07-May-2020	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.				
091506	<a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-157	05-Jun-2020	Not Specified
	Contact Name	Jovier D. Evans, PhD			
	Contact Telephone	301-443-1369			
	Contact Email	<a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023			
	Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This FOA uses the R01 mechanism, while the companion announcement PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.			
078398	<a href="#">NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-056	07-May-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 05-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s)			
078383	<a href="#">NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-052	07-May-2020	100,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).			
091413	<a href="#">Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-155	05-Jun-2020	Not Specified
	Contact Name	Christopher M. Hartshorn, Ph.D.			
	Contact Telephone	240-781-3315			
	Contact Email	<a href="mailto:christopher.hartshorn@nih.gov">christopher.hartshorn@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

092568	<a href="#">Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-165	05-Jun-2020	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Vicky Whittemore, PhD
Contact Telephone	301-496-1917
Contact Email	<a href="mailto:vicky.whittemore@nih.gov">vicky.whittemore@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023
Synopsis	This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.

092569	<a href="#">Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-168	16-Jun-2020	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Vicky Whittemore, PhD
Contact Telephone	301-496-1917
Contact Email	<a href="mailto:vicky.whittemore@nih.gov">vicky.whittemore@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Applications submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.</p>

091508	<a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-159	16-Jun-2020	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name | Jovier D. Evans, PhD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-1369</p> <p>Contact Email <a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementia (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. PAR-20-157 uses the R01 grant mechanism, while PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>				
078618	<a href="#">Data Science Research: Personal Health Libraries for Consumers and Patients (R01 Clinical Trial Optional)</a>	National Library of Medicine/NIH/DHHS	PAR-19-072	30-Jun-2020 [Optional][LOI/Pre-App]	1,000,000 USD
	<p>Contact Name Alan VanBiervliet, Ph.D.</p> <p>Contact Telephone 301-594-4882</p> <p>Contact Email <a href="mailto:vanbiervlietag@mail.nih.gov">vanbiervlietag@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2020 [Optional][LOI/Pre-App], 31-Jul-2020 , 18-Dec-2020 [Optional][LOI/Pre-App], 19-Jan-2021 , 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis The National Library of Medicine seeks applications for novel informatics and data science approaches that can help individuals gather, manage and use data and information about their personal health. A goal of this program is to advance research and application by patients and the research community through broadly sharing the results via publication, and through open source mechanisms for data or resource sharing.</p>				
076848	<a href="#">NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)</a>	National Library of Medicine/NIH/DHHS	PAR-18-896	07-May-2020	1,000,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name | Dr. Hua-Chuan Sim  
Contact Telephone | 301-594-4882  
Contact Email | [simh@mail.nih.gov](mailto:simh@mail.nih.gov)  
Sponsor Website |  
Program URL | [Link to program URL](#)  
Deadline Dates (ALL) | 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021  
Synopsis | National Library of Medicine (NLM) offers support for innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. Biomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology. NIH defines data science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This FOA will use the NIH Research Project (R01) award mechanism.

073256	<a href="#">Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)</a>	Office of Behavioral and Social Sciences Research/NIH/DHHS	PA-18-722	07-May-2020	Not Specified
--------	--	--	-----------	-------------	---------------

Contact Name | Wendy Nilsen, PhD  
Contact Telephone | 240-276-6971  
Contact Email | [nelsonw@mail.nih.gov](mailto:nelsonw@mail.nih.gov)  
Sponsor Website |  
Program URL | [Link to program URL](#)  
Deadline Dates (ALL) | 07-May-2020 , 05-Jun-2020 , 07-Sep-2020 , 05-Oct-2020 , 07-Jan-2021 , 05-Feb-2021 , 07-May-2021  
Synopsis | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address patient adherence to treatment and prevention regimens to promote health outcomes.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). This FOA will use the NIH Research Project (R01) award mechanism.

073264	<a href="#">Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)</a>	Office of Behavioral and Social Sciences Research/NIH/DHHS	PA-18-723	07-May-2020	275,000 USD
--------	--	--	-----------	-------------	-------------

Contact Name	Wendy Nilsen, PhD
Contact Telephone	240-276-6971
Contact Email	<a href="mailto:nelsonw@mail.nih.gov">nelsonw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

079634	<a href="#">Methods Development for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R21 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-19-176	07-May-2020	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name | Sige Zou, Ph.D.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-0749</p> <p>Contact Email <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.</p>				
085475	<a href="#">Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-19-369	07-May-2020	275,000 USD
	<p>Contact Name Sige Zou, Ph.D.</p> <p>Contact Telephone 301-435-0749</p> <p>Contact Email <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2020 , 16-Jun-2020 , 07-Sep-2020 , 16-Oct-2020 , 07-Jan-2021 , 16-Feb-2021 , 07-May-2021</p> <p>Synopsis This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not acceptable to this FOA.</p>				
089273	<a href="#">Shared Instrumentation for Animal Research (SIFAR) Grant Program (S10 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure	PAR-20-112	01-Jun-2020	750,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Allowed](#)

Programs/NIH/DHHS

Contact Name	Julia Berzhanskaya, PhD
Contact Telephone	301-594-6140
Contact Email	<a href="mailto:julia.berzhanskaya@mail.nih.gov">julia.berzhanskaya@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2020
Synopsis	<p>The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic well-defined area of research using animals or related materials. Priority will be given to uniquely configured systems to support innovative and potentially transformative investigations. This FOA supports requests for state-of-the art commercially available technologies needed for NIH-funded research using any vertebrate and invertebrate animal species. This funding opportunity announcement (FOA) does not support requests for single instruments. At least one item of the requested instrumentation must cost at least \$50,000, after all applicable discounts. No instrument in a cluster can cost less than \$20,000, after all applicable discounts. There is no maximum price requirement; however, the maximum award is \$750,000.</p>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

090120	<a href="#">Future Manufacturing (FM)</a>	National Science Foundation	20-552	05-Jun-2020	Not Specified
--------	---	-----------------------------	--------	-------------	---------------

Contact Name	William Olbricht
Contact Telephone	703-292-4842
Contact Email	<a href="mailto:wolbrich@nsf.gov">wolbrich@nsf.gov</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jun-2020
Synopsis	<p>As stated in the Strategy for American Leadership in Advanced Manufacturing, worldwide competition in manufacturing has been dominated in recent decades by the maturation, commoditization, and widespread application of computation in production equipment and logistics, effectively leveling the global technological playing field and putting a premium on low wages and incremental technical improvements. The next generation of technological competition in manufacturing will be dictated by inventions of new materials, chemicals, devices, systems, processes, machines, design and work methods, social structures and business practices. Fundamental research will be required in robotics, artificial intelligence, biotechnology, materials science, sustainability, education and public policy, and workforce development to take the lead in this global competition. The research supported under this solicitation will enhance U.S. leadership in manufacturing far into the future by providing new capabilities for established companies and entrepreneurs, improving our health and quality of life, and reducing the impact of manufacturing industries on the environment. The goal of this solicitation is to support fundamental research and education of a future workforce that will enable Future Manufacturing: manufacturing that either does not exist today or exists only at such small scales that it is not viable. Future Manufacturing will require the design and deployment of diverse new technologies for synthesis and sensing, and new algorithms for manufacturing new materials, chemicals, devices, components and systems. It will require new advances in artificial intelligence and machine learning, new cyber infrastructure, new approaches for mathematical and computational modeling, new dynamics and control methodologies, new ways to integrate systems biology, synthetic biology and bioprocessing, and new ways to influence the economy, workforce, human behavior, and society.</p>

090270	<a href="#">Dear Colleague Letter: Quantum Algorithm Challenge</a>	National Science Foundation	NSF 20-056	01-May-2020 [LOI/Pre-App]	Not Specified
--------	--	-----------------------------	------------	---------------------------	---------------

Contact Name	
Contact Telephone	703-292-5111
Contact Email	<a href="mailto:QLQA@nsf.gov">QLQA@nsf.gov</a>
Sponsor Website	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-May-2020 [LOI/Pre-App], 15-Jun-2020</p> <p>Synopsis The National Science Foundation has recently sponsored several workshops that are relevant to this DCL: Mathematical Sciences Challenges in Quantum Information, Enabling the Quantum Leap: Quantum Algorithms for Quantum Chemistry and Materials, and Quantum Simulators: Architectures and Opportunities. These workshops are aligned with the NSF Quantum Leap Big Idea, which aims to exploit quantum mechanical concepts such as superposition and entanglement to develop next-generation technologies for sensing, computing, modeling, and communication.</p>				
090445	<a href="#">Multimodal Sensor Systems for Precision Health Enabled by Data Harnessing, Artificial Intelligence, and Learning (SenSE)</a>	National Science Foundation	20-556	08-Jun-2020	750,000 USD
	<p>Contact Name Shubhra Gangopadhyay</p> <p>Contact Telephone 703-292-2485</p> <p>Contact Email <a href="mailto:sgangopa@nsf.gov">sgangopa@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Jun-2020</p> <p>Synopsis The National Science Foundation (NSF) through its Divisions of Electrical, Communications and Cyber Systems (ECCS); Chemical, Bioengineering, Environmental and Transport Systems (CBET); Civil, Mechanical and Manufacturing Innovation (CMMI); Information and Intelligent Systems (IIS); and Mathematical Sciences (DMS) announces a solicitation on Multimodal Sensor Systems for Precision Health enabled by Data Harnessing, Artificial Intelligence (AI), and Learning. Next-generation multimodal sensor systems for precision health integrated with AI, machine learning (ML), and mathematical and statistical (MS) methods for learning can be envisioned for harnessing a large volume of diverse data in real time with high accuracy, sensitivity and selectivity, and for building predictive models to enable more precise diagnosis and individualized treatments. It is expected that these multimodal sensor systems will have the potential to identify with high confidence combinations of biomarkers, including kinematic and kinetic indicators associated with specific disease and disability. This focused solicitation seeks high-risk/high-return interdisciplinary research on novel concepts, innovative methodologies, theory, algorithms, and enabling technologies that will address the fundamental scientific issues and technological challenges associated with precision health.</p>				
090622	<a href="#">Spectrum Innovation Initiative: National Center for Wireless Spectrum Research (SII-Center)</a>	National Science Foundation	20-557	12-Jun-2020	25,000,000 USD
	<p>Contact Name Bevin A. Zauderer</p> <p>Contact Telephone 703-292-2428</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [SII-Center@nsf.gov](mailto:SII-Center@nsf.gov)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 12-Jun-2020 , 01-Feb-2021 [LOI/Pre-App], 01-Apr-2021

Synopsis The worldwide growth of wireless communication, navigation, and telemetry has provided immense societal benefits including mobile broadband data, Internet of Things (IoT), mobile healthcare, and intelligent transportation systems. These and other applications including 5G and beyond wireless systems call for innovations that can circumvent the challenges of radio spectrum scarcity and interference and foster the growth of ubiquitous, high speed, low latency connectivity. Commercial applications like the above must operate in harmony with scientific uses such as research on radio astronomy, Earth and atmospheric sciences, and must not inhibit weather prediction, polar research, and other nationally vital activities, all of which are dependent upon access to the radio spectrum. The National Science Foundation (NSF) continues to support wireless spectrum research and the scientific uses of the electromagnetic spectrum through multiple programs that enable fast, accurate, dynamic coordination and usage of our limited spectrum resource. These programs have created an opportune ground to build and create a large center-based ecosystem for spectrum research, which is the target of this SII-Center program. The focus of a spectrum research SII-Center must go beyond 5G, IoT, and other existing or forthcoming systems and technologies and chart out a trajectory to ensure United States leadership in future wireless technologies, systems, and applications in science and engineering through the efficient use and sharing of the radio spectrum. The SII-Center should also seek to foster scientific and technical collaboration and grow the spectrum workforce. The establishment of an SII-Center will have a transformational impact on wireless spectrum research by serving as a connecting point for the biggest and most challenging questions in spectrum management that the nation is facing.

091094	<a href="#">Dear Colleague Letter: Developing Long-term Strategies to Transform Manufacturing</a>	National Science Foundation	NSF 20-067	30-Jun-2020	100,000 USD
--------	---	-----------------------------	------------	-------------	-------------

Contact Name William Olbricht  
Contact Telephone 703-292-4842  
Contact Email [FutureManufacturing@nsf.gov](mailto:FutureManufacturing@nsf.gov)  
Sponsor Website  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 30-Jun-2020

Synopsis The National Science Foundation (NSF) wishes to notify the community of its intention to support workshops for future manufacturing (FM) science and technology in support of the goals and vision of the report "Strategy for American Leadership in Advanced Manufacturing" by the National Science and Technology Council (NSTC). The conferences should

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	identify areas and thrusts for fundamental research that will enable future manufacturing: manufacturing that is either entirely new or that can be done today but not at a sufficient scale to make it viable. Conferences should explore new, potentially transformative, manufacturing capabilities rather than aiming to improve current manufacturing or make incremental improvements over existing Advanced Manufacturing technologies.				

092267	<a href="#">Cyber-Physical Systems (CPS)</a>	National Science Foundation	20-563	22-Jun-2020	Not Specified
--------	--	-----------------------------	--------	-------------	---------------

Contact Name	David Corman
Contact Telephone	703-292-8754
Contact Email	<a href="mailto:dcorman@nsf.gov">dcorman@nsf.gov</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	22-Jun-2020 , 02-Dec-2020
Synopsis	The CPS program aims to develop the core research needed to engineer these complex CPS, some of which may also require dependable, high-confidence, or provable behaviors. Core research areas of the program include control, data analytics, and machine learning—including real-time learning for control, autonomy, design, Internet of Things (IoT), mixed initiatives including human-in- or human-on-the-loop, networking, privacy, real-time systems, safety, security, and verification. By abstracting from the particulars of specific systems and application domains, the CPS program seeks to reveal cross-cutting, fundamental scientific and engineering principles that underpin the integration of cyber and physical elements across all application domains. The program additionally supports the development of methods, tools, and hardware and software components based upon these cross-cutting principles, along with validation of the principles via prototypes and testbeds. This program also fosters a research community that is committed to advancing education and outreach in CPS and accelerating the transition of CPS research into the real world.

077743	<a href="#">Dear Colleague Letter: Non-Academic Research Internships for Graduate Students (INTERN) Supplemental Funding Opportunity</a>	National Science Foundation	NSF 18-102	08-Jun-2020	55,000 USD
--------	--	-----------------------------	------------	-------------	------------

Contact Name	Elizabeth Blood
Contact Telephone	
Contact Email	<a href="mailto:eblood@nsf.gov">eblood@nsf.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Jun-2020

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | A supplemental funding opportunity is available in fiscal years FY 2019 and FY 2020 to provide support for non-academic research internships for graduate students to support career opportunities in any sector of the U.S. economy. NSF currently invests in a number of graduate student preparedness activities and has historically encouraged principal investigators (PIs) to include such activities in research proposals to NSF. This Dear Colleague Letter (DCL) describes new funding opportunities at NSF to ensure graduate students are well prepared for the 21st-century STEM workforce.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
057648	<a href="#">Large Research Projects for Prevention of Healthcare-Associated Infections (R01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-17-008	05-Jun-2020	2,500,000 USD
	Contact Name	James I. Cleeman, M.D.			
	Contact Telephone	301-427-1330			
	Contact Email	<a href="mailto:james.cleeman@ahrq.hhs.gov">james.cleeman@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects This FOA will utilize the AHRQ R01 Research Project Grant award mechanism.			
074880	<a href="#">AHRQ Small Research Grant Program (R03)</a>	Agency for Healthcare Research and Quality/DHHS	PA-18-794	16-Jun-2020	100,000 USD
	Contact Name	Kishena Wadhwani, Ph.D.			
	Contact Telephone	301-427-1556			
	Contact Email	<a href="mailto:Kishena.Wadhwani@ahrq.hhs.gov">Kishena.Wadhwani@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021			
	Synopsis	The sponsor encourages Small Research Grant (R03) applications, and expresses AHRQ portfolio priority areas of interest for ongoing small research projects. The R03 grant mechanism supports different types of health services research projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and, development of new research technology.			
057071	<a href="#">Developing Measures of Shared Decision Making (R01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-16-424	05-Jun-2020	1,500,000 USD
	Contact Name	Monique D. Cohen, PhD, MPH			
	Contact Telephone	301-427-1630			
	Contact Email	<a href="mailto:Monique.Cohen@ahrq.hhs.gov">Monique.Cohen@ahrq.hhs.gov</a>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022			
	Synopsis	Shared decision making (SDM) is a collaborative process in which patients and members of their clinical team work together to make health care decisions informed by scientific evidence as well as patients' own values and preferences. SDM has proven difficult to measure, and the literature points to significant gaps and limitations in the measurement of SDM. Agency for Healthcare Research and Quality (AHRQ) invites applications to develop, test, and evaluate measures of SDM that can be used to conduct research in clinical settings. This FOA will use the Research Project (R01) award mechanism.			
061542	<a href="#">Health Information Technology (IT) to Improve Health Care Quality and Outcomes (R21)</a>	Agency for Healthcare Research and Quality/DHHS	PA-17-246	16-Jun-2020	300,000 USD
	Contact Name	Bryan B. Kim, Ph.D.			
	Contact Telephone	301-427-1505			
	Contact Email	<a href="mailto:HealthITFunding@ahrq.hhs.gov">HealthITFunding@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jun-2020			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications for funding to conduct exploratory and developmental research grants (R21) for projects in the early and conceptual stages of development that will contribute to the evidence base of how health information technology (IT) improves health care quality and outcomes. This program will use the Exploratory/Developmental (R21) grant mechanism.			
057038	<a href="#">Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-16-423	05-Jun-2020	2,500,000 USD
	Contact Name	James Cleeman, MD			
	Contact Telephone	301-427-1330			
	Contact Email	<a href="mailto:james.cleeman@ahrq.hhs.gov">james.cleeman@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB). This FOA will			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		use the R01 Research Project Grant award mechanism.			
074865	<a href="#">AHRQ Health Services Research Projects (R01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-18-795	05-Jun-2020	2,000,000 USD
	Contact Name	Kishena Washwani, Ph.D.			
	Contact Telephone	301-427-1556			
	Contact Email	<a href="mailto:Kishena.Wadhvani@ahrq.hhs.gov">Kishena.Wadhvani@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications for discrete, specified health services research project. The project will be performed by the named investigator and study team. The R01 research plan proposed by the applicant institution/organization must be related to the mission and priority research interests of AHRQ. This FOA will use the AHRQ Research Project Grant (R01) award mechanism.			
061378	<a href="#">AHRQ Mentored Clinical Scientist Research Career Development Award (K08)</a>	Agency for Healthcare Research and Quality/DHHS	PA-17-232	12-Jun-2020	575,000 USD
	Contact Name	Tamara Willis, PhD, MPH			
	Contact Telephone	301-427-1011			
	Contact Email	<a href="mailto:Tamara.Willis@ahrq.hhs.gov">Tamara.Willis@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021 , 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites individual Mentored Clinical Scientist Research Career Development (K08) grant applications from applicant organizations. The overall goal of AHRQ-supported career development programs is to help ensure that a diverse pool of highly trained health services researchers are available in adequate numbers and in appropriate research areas to address the mission and priorities of AHRQ. This FOA will utilize the K08 Clinical Investigator Award (CIA)			
087351	<a href="#">AHRQ Mentored Research Scientist Career Development Award (K01)</a>	Agency for Healthcare Research and Quality/DHHS	PA-20-067	12-Jun-2020	575,000 USD
	Contact Name	Tamara Willis, PhD, MPH			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	301-427-1011			
	Contact Email	<a href="mailto:Tamara.Willis@ahrq.hhs.gov">Tamara.Willis@ahrq.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021 , 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022			
	Synopsis	The primary purpose of the AHRQ Mentored Research Scientist Career Development Awards (K01) program is to help ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to address the Nation's health services research needs. This AHRQ program provides support and "protected time" to individuals with a research doctoral degree for an intensive, supervised research career development experience in health services research. The K01 award can be used both by individuals who propose to newly embark in health services research training and those who had a hiatus in their research careers because of illness or family circumstances.			
091690	<a href="#">Nurse Education, Practice, Quality and Retention (NEPQR) Simulation Education Training (SET) Program</a>	Bureau of Health Workforce/HRSA/DHHS	HRSA-20-110	01-Jun-2020	500,000 USD
	Contact Name	Kirk Koyama			
	Contact Telephone	301-443-4926			
	Contact Email	<a href="mailto:kkoyama@hrsa.gov">kkoyama@hrsa.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL				
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The Health Resources and Services Administration (HRSA) is accepting applications for Fiscal Year (FY) 2020 Nurse Education, Practice, Quality and Retention (NEPQR) - Simulation Education Training (SET) Program. The purpose of this program is to enhance nurse education and strengthen the nursing workforce through the expansion of experiential learning opportunities. This includes using simulation-based technology, including equipment, to advance the health of patients, families, and communities in rural and medically underserved areas experiencing diseases and conditions that affect public health such as: high burden of stroke, heart disease, behavioral and mental health, maternal mortality, HIV/AIDS, and/or obesity. This program intends to strengthen the capacity of undergraduate public health nursing students to address the complex health care needs of those living in rural and medically underserved areas as authorized by Public Health Service (PHS) Act sections 831 and 831A. The program seeks to accomplish this, through expanding the use of technology-based learning to meet the needs of rural and underserved populations.			
091851	<a href="#">Global Health Security Partner Enhancement:</a>	Center for Global	CDC-RFA-GH20-2117	02-Jun-2020	5,000,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Expanding Efforts and Strategies to Protect and Improve Public Health in Senegal</a>	Health/CDC/DHHS			USD
	Contact Name	Jim Ting, Project Office			
	Contact Telephone	+221 777 408 878			
	Contact Email	<a href="mailto:Jyu8@cdc.gov">Jyu8@cdc.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Jun-2020			
	Synopsis	<p>The 2014 Ebola outbreak has highlighted the importance of international preparedness and coordinated epidemic response efforts across borders and within countries to properly address public health emergencies of international concern. In support of the CDC's global health security responsibilities, this funding opportunity will contribute to two priority strategies in Senegal: (1) strengthening surveillance system for Antimicrobial Resistance (AMR) threat and (2) strengthening national laboratory systems and biosafety and security to respond to public health emergencies. The key strategy-specific activities to be employed include (1) increase geographic coverage and expand maximum load of the specimen referral network; (2) Improvement of biosecurity of medical laboratories (3) Strengthening of laboratory equipment management, (4) improvement of access to and participation in national and international quality assurance programs and proficiency testing; (5) strengthening AMR surveillance system.</p>			
083389	<a href="#">Defense Sciences Office (DSO) Office-Wide Broad Agency Announcement</a>	Defense Advanced Research Projects Agency	HR001119S0071	12-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:HR001119S0071@darpa.mil">HR001119S0071@darpa.mil</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020			
	Synopsis	<p>The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts that address one or more of the following technical domains: (1) Frontiers in Math, Computation and Design, (2) Limits of Sensing and Sensors, (3) Complex Social Systems, and (4) Anticipating Surprise. Each of these domains is</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		described below and includes a list of example research topics that highlight several (but not all) potential areas of interest. Proposals must investigate innovative approaches that enable revolutionary advances. DSO is explicitly not interested in approaches or technologies that primarily result in evolutionary improvements to the existing state of practice.			
085325	<a href="#">RFP -- ASPR NEXT</a>	Department of Health & Human Services	BAA_19_ASPR_NEXT_SOL_75A50119R00044	30-Jun-2020	Not Specified
	Contact Name	Tasha McMillian, Contracting Officer			
	Contact Telephone	202-205-1502			
	Contact Email	<a href="mailto:Tasha.McMillian@hhs.gov">Tasha.McMillian@hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020			
	Synopsis	<p>A -- ASPR NEXT SOL BAA_19_ASPR_NEXT_SOL_75A50119R00044 DUE 063020 POC Tasha McMillian, Contracting Officer, Phone 202-205-1502 , Fax 202-260-0264, Email Tasha.McMillian@hhs.gov ASPR is soliciting proposals for revolutionary advancements in health security products, technologies and innovations, specifically to invigorate operations, response, recovery and medical countermeasure development, deployment and distribution activities. ASPR is seeking innovative proposals to investigate approaches that enable revolutionary advances in science, technologies, or systems.</p> <p>Specifically excluded are basic science, research, development, prototype and process development, data science, clinical studies, and other activities that primarily result in evolutionary improvements to the existing state of the art. ASPR is seeking approaches that are outside the mainstream, challenge assumptions, and have the potential to radically change established practice, lead to extraordinary outcomes, and create entirely new fields and commercial market disruptions with wide-ranging impact that will protect Americans from 21st Century Health Threats.</p> <p>CITE: <a href="https://www.fbo.gov/spg/HHS/OOS/OASPHEP/BAA_19_ASPR_NEXT_SOL_75A50119R00044/listing.html">https://www.fbo.gov/spg/HHS/OOS/OASPHEP/BAA_19_ASPR_NEXT_SOL_75A50119R00044/listing.html</a></p>			
070167	<a href="#">RFP -- AMENDMENT -- Capabilities for Cyber Resiliency</a>	Department of the Air Force	FA8750-18-S-7002	15-Jun-2020	Not Specified
	Contact Name	Jeff DeMatteis, BAA Manager			
	Contact Telephone	315-330-7132			
	Contact Email	<a href="mailto:afri.riga.baa@us.af.mil">afri.riga.baa@us.af.mil</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020 , 15-Jun-2021			
	Synopsis	A -- Capabilities for Cyber Resiliency SOL FA8750-18-S-7002 POC Gail E. Marsh, Contracting Officer, Phone 315-330-7518,			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Email Gail.Marsh@us.af.mil - Jeff DeMatteis, BAA Manager, Phone 315-330-7132, Email afrl.riga.baa@us.af.mil  
 NAICS CODE: 541715 FEDERAL AGENCY NAME: Department of the Air Force, Air Force Materiel Command, AFRL - Rome Research Site, AFRL/Information Directorate, 26 Electronic Parkway, Rome, NY, 13441-4514 BAA ANNOUNCEMENT TYPE: Initial announcement BROAD AGENCY ANNOUNCEMENT (BAA) TITLE: Capabilities for Cyber Resiliency BAA NUMBER: FA8750-18-S-7002 PART I - OVERVIEW INFORMATION This announcement is for an Open, 2 Step BAA which is open and effective until 30 Sep 2022. Only white papers will be accepted as initial submissions; formal proposals will be accepted by invitation only. While white papers will be considered if received prior to 6:00 PM Eastern Standard Time (EST) on 30 Sep 2022, the following submission dates are suggested to best align with projected funding: FY18 - 26 Jan 2018 FY19 - 14 Jun 2018 FY20 - 15 Jun 2019 FY21 - 15 Jun 2020 FY22 - 15 Jun 2021 Offerors should monitor the Federal Business Opportunities website at <http://www.fbo.gov> in the event this announcement is amended. CONCISE SUMMARY OF TECHNOLOGY REQUIREMENT DESCRIPTION: Seeking innovative, next-generation technologies to achieve cyber superiority to integrate and transition into warfighting capabilities. This BAA is a follow-on to BAA AFRL-RIK-2015-0015 and BAA AFRL-RIK-2015-0016. BAA ESTIMATED FUNDING: Total funding for this BAA is approximately \$500M. Individual awards will not normally exceed 36 months with dollar amounts normally ranging from \$200K to \$3M per award. There is also the potential to make awards up to any dollar value as long as the value does not exceed the available BAA ceiling amount. ANTICIPATED INDIVIDUAL AWARDS: Multiple Awards are anticipated. TYPE OF INSTRUMENTS THAT MAY BE AWARDED: Procurement contract, grant, cooperative agreement or other transactions. AGENCY CONTACT INFORMATION: All white paper submissions and any questions of a technical nature shall be directed to the cognizant Technical Point of Contact (TPOC) as specified below (unless otherwise specified in the technical area): BAA MANAGER: Jeff DeMatteis AFRL/RIGA525 Brook Rd Rome, NY 13441-4505 Telephone: (315) 330-7132 Email: Questions of a contractual/business nature shall be directed to the cognizant contracting officer, as specified below (email requests are preferred): Gail Marsh Telephone (315) 330-7518 Email: Emails must reference the solicitation (BAA) number and title of the acquisition. Pre Proposal Communication between Prospective Offerors and Government Representatives: Dialogue between prospective offerors and Government representatives is encouraged. Technical and contracting questions can be resolved in writing or through open discussions. Discussions with any of the points of contact shall not constitute a commitment by the Government to subsequently fund or award any proposed effort. Only Contracting Officers are legally authorized to commit the Government. Proposers are cautioned that evaluation ratings may be lowered and/or proposal rejected if proposal preparation (Proposal format, content, etc.) and/or submittal instructions are not followed. SEE ATTACHMENT 1 FOR FULL REQUIREMENT CITE: <https://www.fbo.gov/spg/USAF/AFMC/AFRLRRS/FA8750-18-S-7002/listing.html>

066746	<a href="#">RFP -- AMENDMENT -- Agent Based Systems (ABS)</a>	Department of the Air Force	FA8750-17-S-7014	30-Jun-2020	Not Specified
--------	---	-----------------------------	------------------	-------------	---------------

Contact Name	Gail Marsh
Contact Telephone	(315) 330-7518
Contact Email	<a href="mailto:Gail.Marsh@us.af.mil">Gail.Marsh@us.af.mil</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 , 30-Jun-2021 , 30-Sep-2022			
	Synopsis	<p>A -- Agent Based Systems (ABS) SOL FA8750-17-S-7014 POC Gail E. Marsh, Contracting Officer, Phone 315-330-7518, Email Gail.Marsh@us.af.mil NAICS CODE: 541712 FEDERAL AGENCY NAME: Department of the Air Force, Air Force Materiel Command, AFRL - Rome Research Site, AFRL/Information Directorate, 26 Electronic Parkway, Rome, NY, 13441-4514 BAA ANNOUNCEMENT TYPE: Initial announcement BROAD AGENCY ANNOUNCEMENT (BAA) TITLE: Agent Based Systems (ABS) BAA NUMBER: FA8750-17-S-7014 PART I - OVERVIEW INFORMATION This announcement is for an Open, 2 Step BAA which is open and effective until 30 Sep 2022. Only white papers are due at this time. While white papers will be considered if received prior to 3PM on 30 Sep 2022, the following submission dates are suggested to best align with projected funding: FY18 by 30 Nov 2017 FY19 by 29 Jun 2018 FY20 by 28 Jun 2019 FY21 by 30 Jun 2020 FY22 by 30 Jun 2021 Offerors should monitor the Federal Business Opportunities website at <a href="http://www.fbo.gov">http://www.fbo.gov</a> in the event this announcement is amended. CONCISE SUMMARY OF FUNDING OPPORTUNITY: The Air Force Research Laboratory, Information Directorate is seeking innovative research, development, integration, test and evaluation of technologies/techniques to rapidly design, build, and field autonomous systems. BAA ESTIMATED FUNDING: Total funding for this BAA is approximately \$24.9M. Individual awards will not normally exceed 36 months with dollar amounts normally ranging from \$500K to \$5M. There is also the potential to make awards up to any dollar value as long as the value does not exceed the available BAA ceiling amount. ANTICIPATED INDIVIDUAL AWARDS: Multiple Awards are anticipated TYPE OF INSTRUMENTS THAT MAY BE AWARDED: Procurement contract, grant, cooperative agreement or other transactions AGENCY CONTACT INFORMATION: All white paper and proposal submissions and any questions of a technical nature shall be directed to the cognizant Technical Point of Contact (TPOC) as specified below (unless otherwise specified in the technical area): All white paper and proposal submissions and any questions of a technical nature shall be directed to the cognizant TPOC as specified below (unless otherwise specified in the technical area): BAA MANAGER: Todd Howlett AFRL/RIGC525 Brook Rd Rome, NY 13441-4505 Telephone: (315)330-4592 Email: Questions of a contractual/business nature shall be directed to the cognizant contracting officer, as specified below (email requests are preferred): Gail Marsh Telephone (315) 330-7518 Email: Emails must reference the solicitation (BAA) number and title of the acquisition. Communication between Prospective Offerors and Government Representatives: Dialogue between prospective offerors and Government representatives is encouraged. Technical and contracting questions can be resolved in writing or through open discussions. Discussions with any of the points of contact shall not constitute a commitment by the Government to subsequently fund or award any proposed effort. Only Contracting Officers are legally authorized to commit the Government. Proposers are cautioned that evaluation ratings may be lowered and/or proposal rejected if proposal preparation (Proposal format, content, etc.) and/or submittal instructions are not followed. PART II - FULL TEXT ANNOUNCEMENT BROAD AGENCY ANNOUNCEMENT (BAA) TITLE: Agent Based Systems (ABS) BAA NUMBER: BAA FA8750-17-S-7014 CATALOG OF FEDERAL DOMESTIC ASSISTANCE (CFDA) Number: 12.800 I. FUNDING OPPORTUNITY DESCRIPTION: The Air Force Research Laboratory is soliciting white papers under this Broad Agency Announcement (BAA) for research, development, integration, test and evaluation of technologies/techniques to rapidly design, build, and field autonomous</p>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

systems. The Department of Defense (DoD) and the Intelligence Community (IC) intend to meet future customer intelligence needs through agent-based systems that are open, model-based, and adaptable to diverse use cases. Focus areas for this BAA include robotic and content production systems that use or produce Geospatial Intelligence (GEOINT), which encompasses all aspects of imagery and geo-positioning. To improve the legacy analytic workflows and capabilities of robotic and content production systems, the DoD & IC stakeholders will require the development of new agent-based techniques and technologies. At the core of this research will be the development of agents and agent-based information frameworks that can quickly integrate new technologies and advanced geospatial sensor data to enable more sophisticated and faster information products and services. The intent is to take advantage of both traditional and non-traditional data sources. Potential solutions must adhere to applicable DoD and IC cybersecurity and information assurance directives while addressing enterprise-wide stakeholder requirements specific to GEOINT accuracy, quality control, timeliness, and safety metrics. Developing innovative, open, model-based, and adaptable agent-based technologies and services will enable the delivery of cost-efficient and flexible solutions that can have broad positive impacts on the diverse missions of the DoD and IC. This BAA seeks significant advances in agent-based systems to support DoD, IC, and other government agency's GEOINT-related missions across the following sub-disciplines: - Open model-based standards- Model-based and semi-autonomous development and integration tools- Open dynamic and pragmatic interoperability frameworks- Open embedded computing systems (hardware and software)- Open hypergraph-based data stores- Open advanced geo-temporal query languages- Open Natural Language processing systems- Semi-autonomous ontology model construction and management tools- Advanced modeling of ontological expressiveness and complex relationships- Semi-autonomous error detection, classification, and correction techniques and systems - Agent-based Machine Learning and Neural Networks (Convolution Neural Networks, Bayesian Networks, etc.)- Semi-autonomous complexity management systems- Computer vision systems (hardware and software)- Language translation systems- Model-based cyber-security and information assurance analysis systems- 3-D printed payloads for robotic systems Additionally, with the Intelligence Community's transition to the Intelligence Community Information Technology Enterprise (IC ITE), additional consideration must be given to Assured Cloud Computing. Security risks related to the technologies, software, and systems under development and the eventual deployment environment should be considered. Investigate assured computing architectures and associated technologies that will address the 1) transition and 2) mission shortfalls of the DoD and IC. The BAA technologies supporting the sub-disciplines above may require the planning and conducting of field tests to demonstrate advancements in specific technology areas. This includes preparing test plans; acquiring, transporting, deploying, and operating all equipment; operating and measuring ground truth sources; evaluating and monitoring test execution; and documenting all test results. The innovative technologies, applications, and techniques being pursued under this BAA will address significant shortfalls in agent-based systems. Candidate technologies will be evaluated against current requirements for open standards, adaptability, latency, quality, and scalability/affordability. Successful candidate technologies will be nominated for transition where appropriate. II. AWARD INFORMATION: 1. FUNDING: Total funding for this BAA is approximately \$24.9M. The anticipated funding to be obligated under this BAA is broken out by fiscal year as follows: FY18 - \$7.5M FY19 - \$5.5M FY20 - \$6.0M FY21 - \$3.0M FY22 - \$2.9M The breakout of funding by fiscal year is a projection. The total awards values in any given year will vary. a. Individual awards will not normally



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

exceed 36 months with dollar values ranging from \$500K to \$5M. There is also the potential to make awards up to any dollar value as long as the value does not exceed the available BAA ceiling amount.

b. The Government reserves the right to select all, part, or none of the proposals received, subject to the availability of funds. All potential Offerors should be aware that due to unanticipated budget fluctuations, funding in any or all areas may change with little or no notice.

2. FORM. Awards of efforts as a result of this announcement will be in the form of contracts, grants, cooperative agreements or other transactions depending upon the nature of the work proposed.

3. BAA TYPE: This is a two-step open broad agency announcement. This announcement constitutes the only solicitation. As STEP ONE - The Government is only soliciting white papers at this time. DO NOT SUBMIT A FORMAL PROPOSAL. Those white papers found to be consistent with the intent of this BAA may be invited to submit a technical and cost proposal. See Section VI of this announcement for further details regarding the proposal.

III. ELIGIBILITY INFORMATION:

1. ELIGIBILITY: All qualified offerors who meet the requirements of this BAA may apply.

2. FOREIGN PARTICIPATION/ACCESS:

a. This BAA is closed to foreign participation at the Prime Contractor level.

b. Foreign Ownership, Control or Influence (FOCI) companies who have mitigated FOCI may inquire as to eligibility by contacting the contracting office focal point, Gail E. Marsh, Contracting Officer, telephone (315) 330-7518 or e-mail Gail.Marsh@us.af.mil for verification prior to submitting a white paper. Please reference BAA FA8750-17-S-7014.

c. Contractor employees requiring access to USAF bases, AFRL facilities, and/or access to U.S. Government Information Technology (IT) networks in connection with the work on contracts, assistance instruments or other transactions awarded under this BAA must be U.S. citizens. For the purpose of base and network access, possession of a permanent resident card ("Green Card") does not equate to U.S. citizenship. This requirement does not apply to foreign nationals approved by the U.S. Department of Defense or U.S. State Department under international personnel exchange agreements with foreign governments. Any waivers to this requirement must be granted in writing by the Contracting Officer prior to providing access. The above requirements are in addition to any other contract requirements related to obtaining a Common Access Card (CAC). If an IT network/system does not require AFRL to endorse a contractor's application to said network/system in order to gain access, the organization operating the IT network/system is responsible for controlling access to its system. If an IT network/system requires a U.S. Government sponsor to endorse the application in order for access to the IT network/system, AFRL will only endorse the following types of applications, consistent with the requirements above:

1. Contractor employees who are U.S. citizens performing work under contracts, assistance instruments or other transactions awarded under this BAA.

2. Contractor employees who are non-U.S. citizens and who have been granted a waiver. Any additional access restrictions established by the IT network/system owner apply.

3. FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTERS AND GOVERNMENT ENTITIES: Federally Funded Research and Development Centers (FFRDCs) and Government entities (e.g., Government/National laboratories, military educational institutions, etc.) are subject to applicable direct competition limitations and cannot propose to this BAA in any capacity unless they meet the following conditions:

a. FFRDCs: FFRDCs must clearly demonstrate that the proposed work is not otherwise available from the private sector; and FFRDCs must provide a letter on official letterhead from their sponsoring organization citing the specific authority establishing their eligibility to propose to Government solicitations and compete with industry, and their compliance with the associated FFRDC sponsor agreement's terms and conditions. This information is required for FFRDCs proposing to be prime contractors or sub-

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

awardees.b. Government Entities: Government entities must clearly demonstrate that the work is not otherwise available from the private sector and provide written documentation citing the specific statutory authority and contractual authority, if relevant, establishing their ability to propose to Government solicitations. While 10 U.S.C. § 2539b may be the appropriate statutory starting point for some entities, specific supporting regulatory guidance, together with evidence of agency approval, will still be required to fully establish eligibility. FFRDC and Government entity eligibility will be determined on a case-by-case basis; however, the burden to prove eligibility for all team members rests solely with the proposer. IV. APPLICATION AND SUBMISSION INFORMATION: All responses to this announcement must be addressed to the Technical Point of Contact (TPOC) listed in SECTION VII. DO NOT send white papers to the Contracting Officer. 1. SUBMISSION DATES AND TIMES: It is recommended that white papers be received by 3 PM Eastern Standard Time (EST) on the following dates to maximize the possibility of award: FY18 by 30 Nov 2017, FY19 by 29 Jun 2018, FY20 by 28 Jun 2019, FY21 by 30 Jun 2020, FY22 by 30 Jun 2021. White papers will be accepted until 3 PM EST on 30 Sep 2022, but it is less likely that funding will be available in each respective fiscal year after the dates cited. This BAA will close on 30 Sep 2022. All offerors submitting white papers will receive notification of their evaluation results within 45 days of submission. Offerors should email the TPOC and the Contracting Officer listed in Section VII, for status of their white paper(s) after 45 days, if no such correspondence has been received. 2. CONTENT AND FORMAT: Offerors are required to submit three copies of a 3 to 5 page white paper summarizing their proposed approach/solution. The purpose of the white paper is to preclude unwarranted effort on the part of an offeror whose proposed work is not of interest to the Government. The white paper will be formatted as follows: a. Section A: Title, Period of Performance, Estimated Cost, Name/Address of Company, Technical and Contracting Points of Contact (phone and email) (this section is NOT included in the page count); b. Section B: Task Objective; and c. Section C: Technical Summary and Proposed Deliverables. All white papers shall be double spaced with a font no smaller than 12 point. In addition, respondents are requested to provide their Commercial and Government Entity (CAGE) Code, their unique entity identifier and electronic funds transfer (EFT) indicator (if applicable), an e-mail address and reference BAA FA8750-17-S-7014 with their submission. Multiple white papers within the purview of this announcement may be submitted by each offeror. If the offeror wishes to restrict its white papers, they must be marked with the restrictive language stated in FAR 15.609(a) and (b). 3. HANDLING AND MAILING INSTRUCTIONS: a. CLASSIFICATION GUIDANCE. All Proposers should review the NATIONAL INDUSTRIAL SECURITY PROGRAM OPERATING MANUAL, (NISPO), dated February 28, 2006 and incorporating Change 2, dated May 18, 2016, as it provides baseline standards for the protection of classified information and prescribes the requirements concerning Contractor Developed Information under paragraph 4-105. Defense Security Service (DSS) Site for the NISPO is: <http://www.dss.mil/>. In the event of a possible or actual compromise of classified information in the submission of your white paper or proposal, immediately but no later than 24 hours, bring this to the attention of your cognizant security authority and AFRL Rome Research Site Information Protection Office (IPO): Information Protection Office (contact only if a security compromise has occurred) Monday-Friday (0730-1630): Call 315-330-4048 or Email: Evenings and Weekends: Call 315-330-2961 b. CLASSIFIED SUBMISSIONS. AFRL/RIGC will accept classified responses to this BAA when the classification is mandated by classification guidance provided by an Original Classification Authority of the U.S. Government, or when the offeror believes the work, if successful, would merit classification. Security classification guidance in the form of a DD Form 254 (DoD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contract Security Classification Specification) will not be provided at this time since AFRL is soliciting ideas only. Offerors that intend to include classified information or data in their white paper submission or who are unsure about the appropriate classification of their white papers should contact the technical point of contact listed in Section VII for guidance and direction in advance of preparation. c. MAILING INSTRUCTIONS. Any mailed responses, unclassified/classified, to this announcement must be sent U.S. Postal Service, registered mail or similar service and addressed to AFRL/RIGC, 525 Brooks Road, Rome NY 13441-4505, and reference BAA FA8750-17-S-7014. When mailing follow the directions regarding the number of copies required. Electronic submission is NOT authorized. Questions can be directed to the TPOC listed in Section VII. 4. OTHER SUBMISSION REQUIREMENTS/CONSIDERATIONS: a. COST SHARING OR MATCHING: Cost sharing is not a requirement. Cost sharing may be proposed and will be considered on a case-by-case basis. b. SYSTEM FOR AWARD MANAGEMENT (SAM). Offerors must be registered in the SAM database to receive a contract award, and remain registered during performance and through final payment of any contract or agreement. Processing time for registration in SAM, which normally takes forty-eight hours, should be taken into consideration when registering. Offerors who are not already registered should consider applying for registration before submitting a proposal. The provision at FAR 52.204-7, System for Award Management (Oct 2016) applies. c. EXECUTIVE COMPENSATION AND FIRST-TIER SUBCONTRACT/ SUBRECIPIENT AWARDS: Any contract award resulting from this announcement may contain the clause at FAR 52.204-10 - Reporting Executive Compensation and First-Tier Subcontract Awards (Oct 2016). Any grant or agreement award resulting from this announcement may contain the award term set forth in 2 CFR, Appendix A to Part 25 which can be viewed at: [http://www.ecfr.gov/cgi-bin/text-idx?SID=8fb6c83606df57968c3e7e145e7d683c&mc=true&node=ap2.1.25\\_1360.a&rgn=div9](http://www.ecfr.gov/cgi-bin/text-idx?SID=8fb6c83606df57968c3e7e145e7d683c&mc=true&node=ap2.1.25_1360.a&rgn=div9) d. ALLOWABLE CHARGES: The cost of preparing white papers/proposals in response to this announcement is not considered an allowable direct charge to any resulting contract or any other contract, but may be an allowable expense to the normal bid and proposal indirect cost specified in FAR 31.205-18. Incurring pre-award costs for ASSISTANCE INSTRUMENTS ONLY are regulated by the DoD Grant and Agreements Regulations (DODGARS). e. GOVERNMENT APPROVED ACCOUNTING SYSTEM: An offeror must have a government approved accounting system prior to award of a cost-reimbursement contract per limitations set forth in FAR 16.301-3(a) to ensure the system is adequate for determining costs applicable to the contract. The acceptability of an accounting system is determined based upon an audit performed by the Defense Contract Audit Agency (DCAA). IMPORTANT: If you do not have a DCAA approved accounting system access the following link for instructions: [http://www.access.gpo.gov/nara/cfr/waisidx\\_07/32cfr219\\_07.html](http://www.access.gpo.gov/nara/cfr/waisidx_07/32cfr219_07.html), and DoD Directive 3216.02, "Protection of Human Subjects and Adherence to Ethical Standards in DoD-Supported Research" found at: <http://www.dtic.mil/whs/directives/corres/pdf/321602p.pdf>. 1. Institutions awarded funding for research involving human subjects must provide documentation of a current Assurance of Compliance with Federal regulations for human subject protection, for example a Department of Health and Human Services, Office of Human Research Protection Federal Wide Assurance found at: <http://www.hhs.gov/ohrp>. 2. All institutions engaged in human subject research, to include

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

subcontractors, must have a valid assurance. In addition, personnel involved in human subject research must document the completion of appropriate training for the protection of human subjects. 3. For all research that will involve human subjects in the first year or phase of the project, the institution must submit evidence of a plan for review by an institutional review board (IRB) as part of the proposal. The IRB conducting the review must be the IRB identified on the institution's Assurance of Compliance. The protocol, separate from the proposal, must include a detailed description of the research plan, study population, risks and benefits of study participation, recruitment and consent process, data collection, and data analysis. The designated IRB should be consulted for guidance on writing the protocol. The informed consent document must comply with 32 CFR 219.116. A valid Assurance of Compliance and evidence of appropriate training by all investigators should accompany the protocol for review by the IRB. 4. In addition to a local IRB approval, an AFRL-level human subject regulatory review and approval is required for all research conducted or supported by the DoD. The Air Force office responsible for managing the award can provide guidance and information about the AFRL-level review process. Confirmation of a current Assurance of Compliance and appropriate human subjects protection training is required before AFRL-level approval can be issued. 5. The time required to complete the IRB review/approval process will vary depending on the complexity of the research and/or the level of risk to study participants; ample time should be allotted to complete the approval process. The IRB approval process can last between 1 to 3 months, followed by a DoD review that could last 3 to 6 months. No funding may be used toward human subject research until all approvals are granted. Therefore, in their cost proposals offerors should separate human use into a separate option. V. APPLICATION REVIEW INFORMATION: 1. CRITERIA: The following criteria, which are listed in descending order of importance and will be used to determine whether white papers and proposals submitted are consistent with the research areas of interest and expected results within the broad topic areas as described in the Funding Opportunity section of this BAA and of interest to the Government: a. Overall Scientific and Technical Merit - The extent to which the offeror demonstrates the detailed approach, development, and testing of the proposed new technology to achieve relevant new capabilities or enhancements, b. Related Experience - The extent to which the offeror demonstrates relevant technology and domain knowledge, c. Openness, Maturity and Assurance of Solution - The extent to which existing capabilities and standards are leveraged and the relative maturity of the proposed technology, and d. Reasonableness and realism of proposed costs and fees (if any). No further evaluation criteria will be used in selecting white papers/proposals. White papers and proposals submitted will be evaluated as they are received. 2. REVIEW AND SELECTION PROCESS: a. Only Government employees will evaluate the white papers/proposals for selection. The Air Force Research Laboratory's Information Directorate has contracted for various business and staff support services, some of which require contractors to obtain administrative access to proprietary information submitted by other contractors. Administrative access is defined as "handling or having physical control over information for the sole purpose of accomplishing the administrative functions specified in the administrative support contract, which do not require the review, reading, and comprehension of the content of the information on the part of non-technical professionals assigned to accomplish the specified administrative tasks." These contractors have signed general non-disclosure agreements and organizational conflict of interest statements. The required administrative access will be granted to non-technical professionals. Examples of the administrative tasks performed include: a. Assembling and organizing information for R&D case files; b. Accessing library files for use by government

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

personnel; and c. Handling and administration of proposals, contracts, contract funding and queries. Any objection to administrative access must be in writing to the Contracting Officer and shall include a detailed statement of the basis for the objection.

b. WHITE PAPER/PROPOSAL REVIEW PROCESS: 1. FIRST STEP - White Paper Reviews: The Government will review White Papers to determine which of them have the potential to best meet the Air Force's needs based on the criteria listed above. If white papers are of interest and funding is available, AFRL/RI will request a formal technical and cost proposal from offeror. If white papers are not of interest or there is not funding available, a letter is sent to the offeror indicating the reason not selected. 2. SECOND STEP - Proposal Review and Selection Process a) Categories: Based on the evaluation, proposals will be categorized as Highly Recommended, Selectable, or Not Selectable (see definitions below). The selection of one or more offerors for award will be based on the evaluation, as well as importance to agency programs and funding availability. 1.) Highly Recommended: Proposals are recommended for acceptance if sufficient funding is available, and normally are displaced only by other Highly Recommended proposals. 2.) Selectable: Proposals are recommended for acceptance if sufficient funding is available, but at a lower priority than Highly Recommended Proposals. May require additional development. To ensure a diversity of approaches, a Selectable proposal may be prioritized over a Highly Recommended proposal if the Selectable proposal presents a unique approach unlike any of the Highly Recommended proposals. 3.) Not Selectable: Even if sufficient funding existed, the proposal should not be funded. c. The Government reserves the right to award some, all, or none of the proposals. When the Government elects to award only a part of a proposal, the selected part may be categorized as Highly Recommended or Selectable, though the proposal as a whole may not merit such a categorization. d. No other evaluation criteria will be used. e. Proposal Risk Assessment: Proposal risk for technical, cost, and schedule will be assessed for formal proposals, should they be requested, as part of the evaluation of the above evaluation criteria. Proposal risk relates to the identification and assessment of the risks associated with an offeror's proposed approach as it relates to accomplishing the proposed effort. Tradeoffs of the assessed risk will be weighed against the potential scientific benefit. Proposal risk for schedule relates to an assessment of the risks associated with the offeror's proposed number of hours, labor categories, materials, or other cost elements as it relates to meeting the proposed period of performance. f. Prior to award of a potentially successful offer, the Contracting Officer will make a determination regarding price reasonableness and realism. 3. FEDERAL AWARDEE PERFORMANCE AND INTEGRITY INFORMATION SYSTEM (FAPIS) PUBLIC ACCESS: The Government is required to review and consider any information about the applicant that is in the FAPIS before making any award in excess of the simplified acquisition threshold (currently \$150,000) over the period of performance. An applicant may review and comment on any information about itself that a federal awarding agency previously entered. The Government will consider any comments by the applicant, in addition to other information in FAPIS in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when completing the review of risk posed by applicants as described in 2 CFR § 200.205 Federal Awarding Agency Review of Risk Posed by Applicants and per FAR 9.104-6. VI. STEP TWO INFORMATION - REQUEST FOR PROPOSAL & AWARD: 1. PROPOSAL FORMATING: When developing proposals, reference the AFRL "Broad Agency Announcement (BAA): Guide for Industry," Mar 2015, and RI-Specific Proposal Preparation Instructions, Jan 2017, which may be accessed at: [cvview=1](#). Always reference the newest versions of these documents. 2. AWARD NOTICES: Those white papers found to be consistent with the research areas



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of interest and expected results within the broad topic areas as described in the Funding Opportunity section of this BAA and of interest to the Government may be invited to submit a technical and cost proposal. Notification by email or letter will be sent by the TPOC. Such invitation does not assure that the submitting organization will be awarded a contract. Those white papers not selected to submit a proposal will be notified in the same manner. Prospective offerors are advised that only Contracting Officers are legally authorized to commit the Government. All offerors submitting proposals will receive notification of their evaluation results within 45 days of submission. Offerors should email the TPOC and the Contracting Officer listed in Section VII, for status of their proposal after 45 days, if no such correspondence has been received. 3. DEBRIEFINGS: If a debriefing is requested in accordance with the time guidelines set out in FAR 15.505 and 15.506, a debriefing will be provided, but the debriefing content may vary to be consistent with the procedures that govern BAAs (FAR 35.016). Debriefings will not be provided for white papers. 4. ADMINISTRATIVE AND NATIONAL POLICY REQUIREMENTS: Depending on the work to be performed, the offeror may require a SECRET or TOP SECRET/SCI facility clearance and safeguarding capability; therefore, personnel identified for assignment to a classified effort must be cleared for access to SECRET or TOP SECRET/SCI information at the time of award. In addition, the offeror may be required to have, or have access to, a certified and Government-approved facility to support work under this BAA. This acquisition may involve data that is subject to export control laws and regulations. Only contractors who are registered and certified with the Defense Logistics Information Service (DLIS) and have a legitimate business purpose may participate in this solicitation. For questions, contact DLIS on-line at <http://www.dla.mil/HQ/InformationOperations/LogisticsInformationServices.aspx> or at the DLA Logistics Information Service, 74 Washington Avenue North, Battle Creek, Michigan 49037-3084, and telephone number 1-800-352-2255 (24/7). You must submit a copy of your approved DD Form 2345, Militarily Critical Technical Data Agreement, with your white paper/proposal. 5. DATA RIGHTS: a. SBIR RIGHTS. The potential for inclusion of Small Business Innovation Research (SBIR) or data rights other than unlimited on awards is recognized. In accordance with (IAW) the Small Business Administration (SBA) SBIR Policy Directive, Section 8(b), SBIR data rights clauses are non-negotiable and must not be the subject of negotiations pertaining to an award, or diminished or removed during award administration. Issuance of an award will not be made conditional based on forfeiture of data rights. If the SBIR awardee wishes to transfer its SBIR data rights to the Air Force or to a third party, it must do so in writing under a separate agreement. A decision by the awardee to relinquish, transfer, or modify in any way its SBIR data rights must be made without pressure or coercion by the agency or any other party. b. NON-SBIR RIGHTS. 1. Non-SBIR data rights less than unlimited will be evaluated and negotiated on a case-by-case basis. Government Purpose Rights are anticipated for data developed with DoD-reimbursed Independent Research and Development (IR&D) funding. 2. The Air Force Research Laboratory is engaged in the discovery, development, and integration of warfighting technologies for our air, space, and cyberspace forces. As such, rights in technical data and noncommercial computer software (NCS) developed or delivered under this contract are of significant concern to the Government. The Government will therefore carefully consider any restrictions on the use of technical data, NCS, and NCS documentation which could result in transition difficulty or less-than full and open competition for subsequent development of this technology. 3. Third Party Software. DFARS 252.227-7014(d) describes requirements for incorporation of third party computer software. Any third party software (commercial and noncommercial) to be incorporated into a deliverable must be clearly

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

identified in the proposal. Prior to delivery of any third party software, the contractor will obtain an appropriate license for the Government, and the written approval of the contracting officer. c. IDENTIFICATION & ASSERTION. IAW DFARS 252.227-7017, the Identification and assertion of Use, Release, or Disclosure Restriction provision applies. See AFRL/RI Specific Proposal Preparation Instructions for further guidance and samples. 6. REPORTING:a. Contract Applicable: Once a proposal has been selected for award, offerors will be given complete instructions on the submission process for the reports.b. FAPIIS Applicable: As required by 2 CFR 200 Appendix XII of the Uniform Guidance and FAR 9.104-6, non-federal entities (NFEs) are required to disclose in FAPIIS any information about criminal, civil, and administrative proceedings, and/or affirm that there is no new information to provide.This applies to NFEs that receive federal awards (currently active grants, cooperative agreements, and procurement contracts) greater than \$10,000,000 for any period of time during the period of performance of an award/project. 7. NOTICE: The following provisions\* apply:a. FAR 52.209-11, Representation by Corporations Regarding Delinquent Tax Liability or a Felony Conviction under any Federal Lawb. DFARS 252.239-7017, Notice of Supply Chain Risk c. DFARS 252.204-7008, Compliance with Safeguarding Covered Defense Information Controls\* Please note that the current versions or deviations of therelated clauses will be included in any resulting contract. 8. GRANT AWARDS ONLY: For efforts proposed as grant awards, offerors must provide an abstract in their proposal (not to exceed one page) that is publically releasable andthat describes - in terms the public may understand - the project or program supported by the grant. If the proposal is selected for award, the DoD will publically post the abstract to comply with Section 8123 of the Department of Defense Appropriations Act, 2015 (Pub. L. 113-235). VII. AGENCY CONTACTS: All white paper and proposal submissions and any questions of a technical nature shall be directed to the cognizant TPOC as specified below (unless otherwise specified in the technical area): TPOC Name: Todd HowettMailing Address: AFRL/RIGC525 Brooks RoadRome NY 13441-4505Telephone: (315) 330-4592Email: Questions of a contractual/business nature shall be directed to the cognizant contracting officer, as specified below (email requests are preferred): Gail MarshTelephone (315) 330-7518Email: Emails must reference the solicitation (BAA) number and title of the acquisition. In accordance with AFFARS 5301.91, an Ombudsman has been appointed to hear and facilitate the resolution of concerns from offerors, potential offerors, and others for this acquisition announcement. Before consulting with an ombudsman, interested parties must first address their concerns, issues, disagreements, and/or recommendations to the contracting officer for resolution. AFFARS Clause 5352.201-9101 Ombudsman (Jun 2016) will be incorporated into all contracts awarded under this BAA. The AFRL Ombudsman and AFRL Alternate Ombudsman are as follows: Ombudsman: Ms Lisette K. LeDuc,1864 Fourth St.Wright-Patterson AFB OH 45433-7130937-904-4407 Alternate Ombudsman: Ms Kimberly L. Yoder1864 Fourth St.Wright-Patterson AFB OH 45433-7130937-255-4967 All responsible organizations may submit a white paper which shall be considered. CITE: <https://www.fbo.gov/spg/USAF/AFMC/AFRLRRS/FA8750-17-S-7014/listing.html>

092168	<a href="#">Prostate Cancer Research Program--Population Science and Outcomes Research Award</a>	Department of the Army	W81XWH-20-PCRP-PSORA	25-Jun-2020 [LOI/Pre-App]	Not Specified
--------	--	------------------------	----------------------	------------------------------	---------------

Contact Name	
Contact Telephone	301-682-5507

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a>				
	Sponsor Website				
	Program URL <a href="#">Link to program URL</a>				
	Deadline Dates (ALL) 25-Jun-2020 [LOI/Pre-App], 16-Jul-2020				
	Synopsis	<p>The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges:</p> <ul style="list-style-type: none"> <li>• Improve the quality of life for survivors of prostate cancer</li> <li>• Develop treatments that improve outcomes for men with lethal prostate cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.</li> <li>• Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.</li> <li>• Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.</li> </ul>			
092182	<a href="#">Prostate Cancer Research Program--Health Disparity Research Award</a>	Department of the Army	W81XWH-20-PCR-PHDRA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone 301-682-5507				
	Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a>				
	Sponsor Website				
	Program URL <a href="#">Link to program URL</a>				
	Deadline Dates (ALL) 25-Jun-2020 [LOI/Pre-App], 16-Jul-2020				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges:</p> <ul style="list-style-type: none"> <li>• Improve the quality of life for survivors of prostate cancer</li> <li>• Develop treatments that improve outcomes for men with lethal prostate cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.</li> <li>• Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.</li> <li>• Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer. The FY20 PCRP Health Disparity Research Award supports promising research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship.</li> </ul>			
092280	<a href="#">Peer Reviewed Medical Research Program-- Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health</a>	Department of the Army	W81XWH-20-PRMRP-IIRA-COV	28-May-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	28-May-2020 [LOI/Pre-App], 12-Jun-2020			
	Synopsis	The vision of the FY20 PRMRP is to improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries, and its mission is to encourage, identify, select, and manage medical research projects of clear scientific merit			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>and direct relevance to military health. Thus, the proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The PRMRP challenges the scientific and clinical communities to address at least one of the FY20 PRMRP Topic Areas of Emerging Viral Diseases and Respiratory Health with original ideas that foster new directions along the entire spectrum of research and clinical care. The PRMRP Investigator-Initiated Research Award is intended to support studies that will make an important contribution toward research and/or patient care in one or more Focus Areas published in this Funding Opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature.</p>			
092297	<a href="#">Peer Reviewed Medical Research Program-- Clinical Trial Award for Emerging Viral Diseases and Respiratory Health</a>	Department of the Army	W81XWH-20-PRMRP-CTA-COV	08-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jun-2020 [LOI/Pre-App], 22-Jun-2020			
	Synopsis	<p>The vision of the FY20 PRMRP is to improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries, and its mission is to encourage, identify, select, and manage medical research projects of clear scientific merit and direct relevance to military health. Thus, the proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The PRMRP challenges the scientific and clinical communities to address at least one of the FY20 PRMRP Topic Areas of Emerging Viral Diseases and Respiratory Health with original ideas that foster new directions along the entire spectrum of research and clinical care. The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact in one or more of the Focus Areas published in this funding opportunity for the FY20 PRMRP Congressionally specified Topic Areas of Emerging Viral Diseases and Respiratory Health. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial and cannot be used for animal studies.</p>			
092273	<a href="#">Peer Reviewed Medical Research Program--</a>	Department of the Army	W81XWH-20-PRMRP-TTDA-COV	28-May-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health</a>			[LOI/Pre-App]	Specified
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-May-2020 [LOI/Pre-App], 12-Jun-2020</p> <p>Synopsis The vision of the FY20 PRMRP is to improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries, and its mission is to encourage, identify, select, and manage medical research projects of clear scientific merit and direct relevance to military health. Thus, the proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The PRMRP challenges the scientific and clinical communities to address at least one of the FY20 PRMRP Topic Areas of Emerging Viral Diseases and Respiratory Health with original ideas that foster new directions along the entire spectrum of research and clinical care. The PRMRP Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas published in this funding opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.</p>				
090766	<a href="#">Prostate Cancer Research Program--Physician Research Award</a>	Department of the Army	W81XWH-20-PCRP-PRA	04-Jun-2020 [LOI/Pre-App]	600,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-682-5507</p> <p>Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-Jun-2020 [LOI/Pre-App], 18-Jun-2020</p> <p>Synopsis The FY20 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		clinical prostate cancer research. All applications for the FY20 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the Mentor(s).			
092188	<a href="#">Prostate Cancer Research Program - Clinical Trial Award</a>	Department of the Army	W81XWH-20-PCRP-CTA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 16-Jul-2020			
	Synopsis	<p>The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges:</p> <ul style="list-style-type: none"> <li>• Improve the quality of life for survivors of prostate cancer</li> <li>• Develop treatments that improve outcomes for men with lethal prostate cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.</li> <li>• Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.</li> <li>• Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.</li> </ul>			
091435	<a href="#">Neurofibromatosis Research Program--Exploration – Hypothesis Development Award</a>	Department of the Army	W81XWH-20-NFRP-EHDA	25-Jun-2020 [LOI/Pre-App]	100,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 25-Jun-2020 [LOI/Pre-App], 09-Jul-2020  Synopsis The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The NFRP Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. Studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a wellformulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is encouraged, but not required.				
090754	<a href="#">Prostate Cancer Research Program--Early Investigator Research Award</a>	Department of the Army	W81XWH-20-PCRP-EIRA	04-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone 301-682-5507 Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a> Sponsor Website Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 04-Jun-2020 [LOI/Pre-App], 18-Jun-2020  Synopsis The FY20 PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated Mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY20 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the Mentor(s).				
091443	<a href="#">Neurofibromatosis Research Program--Early Investigator Research Award</a>	Department of the Army	W81XWH-20-NFRP-EIRA	25-Jun-2020 [LOI/Pre-App]	450,000 USD
	Contact Name Contact Telephone 301-682-5507				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a>				
	Sponsor Website				
	Program URL <a href="#">Link to program URL</a>				
	Deadline Dates (ALL) 25-Jun-2020 [LOI/Pre-App], 09-Jul-2020				
	Synopsis	<p>The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The Early Investigator Research Award supports NF-focused research opportunities for individuals in the early stages of their careers, under the guidance of a designated Mentor. This opportunity allows for early-stage investigators to develop a research project, investigate a problem or question in NF research, and further their intellectual development as an NF researcher of the future. The postdoctoral investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of NF research; however, the PI is not required to have previous NF research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in NF research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary Mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary Mentor with a more robust track record in NF research and mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as an NF researcher.</p>			
091487	<a href="#">Neurofibromatosis Research Program--New Investigator Award</a>	Department of the Army	W81XWH-20-NFRP-NIA	25-Jun-2020 [LOI/Pre-App]	450,000 USD
	Contact Name				
	Contact Telephone 301-682-5507				
	Contact Email <a href="mailto:help@eBRAP.org">help@eBRAP.org</a>				
	Sponsor Website				
	Program URL <a href="#">Link to program URL</a>				
	Deadline Dates (ALL) 25-Jun-2020 [LOI/Pre-App], 09-Jul-2020				
	Synopsis	<p>The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The intent of the NFRP New Investigator Award is to support the</p>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		continued development of promising early-stage investigators and/or the transition of established investigators from other research fields into a career in the field of NF research. Prior experience in NF research is not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field.			
092173	<a href="#">DoD Prostate Cancer Research Program - Translational Science Award</a>	Department of the Army	W81XWH-20-PCRP-TSA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 16-Jul-2020			
	Synopsis	<p>The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges:</p> <ul style="list-style-type: none"> <li>• Improve the quality of life for survivors of prostate cancer</li> <li>• Develop treatments that improve outcomes for men with lethal prostate cancer--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.</li> <li>• Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations--High-risk populations include, but are not limited to, people of African descent (including Caribbean Americans), genetically predisposed populations, Service members, and Veterans. Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.</li> <li>• Define the biology of lethal prostate cancer to reduce death--Applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc. Applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.</li> </ul>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
091489	<a href="#">Neurofibromatosis Research Program--Clinical Trial Award</a>	Department of the Army	W81XWH-20-NFRP-CTA	25-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jun-2020 [LOI/Pre-App], 09-Jul-2020			
	Synopsis	<p>The vision of the FY20 NFRP is to decrease the clinical impact of NF. Toward this end, the NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF1, NF2, and schwannomatosis. The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.</p>			
090407	<a href="#">Lung Cancer Research Program--Concept Award</a>	Department of the Army	W81XWH-20-LCRP-CA	27-May-2020 [LOI/Pre-App]	100,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-May-2020 [LOI/Pre-App], 10-Jun-2020			
	Synopsis	<p>The FY20 LCRP Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of lung cancer</p>			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		or develop an innovative and novel course of investigation. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.			
091680	<a href="#">Tuberous Sclerosis Complex Research Program-- Idea Development Award</a>	Department of the Army	W81XWH-20-TSCR-IDA	18-Jun-2020 [LOI/Pre-App]	450,000 USD
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jun-2020 [LOI/Pre-App], 09-Jul-2020			
	Synopsis	<p>The Idea Development Award promotes ideas that have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong preliminary data and scientific rationale. The following are important aspects of the Idea Development Award: --Impact: Applications should articulate both the short- and long-term impact of the proposed research. High-impact research will, if successful, significantly advance TSC research and/or patient care. --Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities that may include high-risk/potentially high-gain approaches to TSC research. Research that is merely an incremental advance (the next logical step) is not considered innovative. --Preliminary Data: Unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, and/or data from the published literature that are relevant to TSC and the proposed research project, are expected.</p>			
087885	<a href="#">Breast Cancer Research Program--Breakthrough Award Level 4</a>	Department of the Army	W81XWH-20-BCRP-BTA4	24-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-Jun-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.</p>			
087904	<a href="#">Breast Cancer Research Program--Innovator Awards</a>	Department of the Army	W81XWH-20-BCRP-INNOV	24-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-Jun-2020			
	Synopsis	<p>The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer.</p>			
087902	<a href="#">Breast Cancer Research Program--Breakthrough Award Level 3</a>	Department of the Army	W81XWH-20-BCRP-BTA3	24-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone	301-682-5507			
	Contact Email	<a href="mailto:help@eBRAP.org">help@eBRAP.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	24-Jun-2020			
	Synopsis	The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.			
092447	<a href="#">Removal Emergency Response Program</a>	Environmental Protection Agency	EPA-OLEM-OEM-19-08	10-Jun-2020	500,000 USD
	Contact Name	Ellen Treimel			
	Contact Telephone	202-564-2520			
	Contact Email	<a href="mailto:treimel.ellen@epa.gov">treimel.ellen@epa.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2020			
	Synopsis	The Environmental Protection Agency announces the availability of funds and solicits applications from eligible entities to promote the participation of individual state and territorial programs in research activities with the mission of advocating for and supporting state emergency response readiness and removal program planning and preparedness. The total estimated funding available under this competitive opportunity is \$500,000.			
090396	<a href="#">RFA-FD-20-030 -- Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional</a>	Food and Drug Administration/DHHS	RFA-FD-20-030	05-Jun-2020	6,000,000 USD
	Contact Name	Dianne Paraoan			
	Contact Telephone	301-796-2500			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	<a href="mailto:dianne.paraoan@fda.hhs.gov">dianne.paraoan@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine real-world data (RWD), real-world evidence (RWE), and related issues such as data analytics, the use of digital health tools, and innovative trial designs utilizing healthcare settings.			
091877	<a href="#">RFA-FD-20-033 -- Drug Development Science Support (U01) Clinical Trials Optional</a>	Food and Drug Administration/DHHS	RFA-FD-20-033	29-Apr-2020 [Optional][LOI/Pre-App]	5,000,000 USD
	Contact Name	RADM Denise Hinton, Chief Scientist			
	Contact Telephone	301-796-4880			
	Contact Email	<a href="mailto:Denise.Hinton@fda.hhs.gov">Denise.Hinton@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Apr-2020 [Optional][LOI/Pre-App], 08-Jun-2020			
	Synopsis	The Food and Drug Administration (FDA) Office of the Chief Scientist (OCS) and FDA Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP) is announcing its intent to accept and consider applications for the award of a co-operative agreement to protect and promote the health of the American public by creating new, applied scientific knowledge, tools, standards and approaches to evaluate products more effectively, predictably and efficiently.			
088034	<a href="#">RFA-FD-20-007 -- Center for Collaborative Research on Complex Generics (U18) Clinical Trials Optional</a>	Food and Drug Administration/DHHS	RFA-FD-20-007	13-Jun-2020	5,000,000 USD
	Contact Name	Stephanie Choi			
	Contact Telephone	240-402-7960			
	Contact Email	<a href="mailto:stephanie.choi@fda.hhs.gov">stephanie.choi@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	13-Jun-2020			
	Synopsis	The Food and Drug Administration (FDA) seeks to establish a Center for Research on Complex Generics under the terms and			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		conditions of a cooperative agreement. The Center for Research on Complex Generics will support the FDA's efforts to enhance research collaborations with the generic industry to further the FDA's mission of increasing access to safe and effective generic drugs.			
092387	<a href="#">RFA-FD-20-032 -- CBER FY20 FOA for AAV Vector Manufacturing for Diseases Affecting Very Small Populations ((R01 Clinical Trial Not Allowed))</a>	Food and Drug Administration/DHHS	RFA-FD-20-032	23-Jun-2020	1,200,000 USD
	Contact Name	Manuel Osorio			
	Contact Telephone				
	Contact Email	<a href="mailto:Manuel.Osorio@fda.hhs.gov">Manuel.Osorio@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-Jun-2020			
	Synopsis	CBER seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals, by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors			
091728	<a href="#">RFA-FD-20-029 -- Cooperative Agreement to Support an Evidence-based Clinical Practice Guideline for the Treatment of Acute Dental Pain (U01) Clinical Trials Not Allowed</a>	Food and Drug Administration/DHHS	RFA-FD-20-029	20-Apr-2020 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Janelle Derbis			
	Contact Telephone	312-596-6516			
	Contact Email	<a href="mailto:janelle.derbis@fda.hhs.gov">janelle.derbis@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Apr-2020 [Optional][LOI/Pre-App], 01-Jun-2020			
	Synopsis	The U.S. Food and Drug Administration (FDA) seeks applications to develop, disseminate, implement, and evaluate, an evidence-based Clinical Practice Guideline (CPG) for the treatment of acute dental pain (surgical and non-surgical). Applicants must propose a comprehensive evidence-based plan that advances appropriate prescribing of opioid analgesics for patients with acute dental pain.			
091521	<a href="#">Cooperative Agreement to Support FDA Land</a>	Food and Drug	RFA-FD-20-034	01-Jun-2020	1,250,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">and Water Initiative (U01) Clinical Trial Not Allowed</a>	Administration/DHHS			USD
	Contact Name	Julie Moss			
	Contact Telephone	240-402-2031			
	Contact Email	<a href="mailto:julie.moss@fda.hhs.gov">julie.moss@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The purpose of this Funding Opportunity is to provide funds for the exploration of scientific methods related to understanding the geospatial link between foodborne pathogens in environmental water sources and to food safety.			
090055	<a href="#">NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens (U01) Clinical Trials Not Allowed</a>	Food and Drug Administration/DHHS	PAR-20-124	01-Jun-2020	1,000,000 USD
	Contact Name	Claudine Kabera, NARMS Project Manager			
	Contact Telephone	240-402-5430			
	Contact Email	<a href="mailto:claudine.kabera@fda.hhs.gov">claudine.kabera@fda.hhs.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020 , 03-May-2021 , 02-May-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements is intended to improve the detection of antibiotic resistance among bacteria in food commodities, as well as expand to new sites to expand the scope of sampling. Measurable outcomes of the program will be in alignment with the NARMS Objectives.			
089312	<a href="#">ROSES 2020: Global Ecosystem Dynamics Investigation (GEDI) Science Team</a>	National Aeronautics & Space Administration	NNH20ZDA001N-GEDI	01-May-2020 [LOI/Pre-App]	Not Specified
	Contact Name	Hank Margolis, Program Manager			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 202-358-4760</p> <p>Contact Email <a href="mailto:Hank.A.Margolis@nasa.gov">Hank.A.Margolis@nasa.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-May-2020 [LOI/Pre-App], 16-Jun-2020</p> <p>Synopsis NASA launched the Global Ecosystem Dynamics Investigation (GEDI) instrument to the International Space Station (ISS) in December 2018 and GEDI's science data collection phase began in April 2019. This program element solicits proposals for studies that use GEDI data to address scientific questions in terrestrial ecology, carbon cycle science, biodiversity, and interactions of the biosphere with the atmosphere and hydrosphere. Selected principal investigators will become members of the GEDI Science Team.</p>				
092587	<a href="#">Advancing the Centers of Excellence in Newcomer Health</a>	National Center for Emerging and Zoonotic Infectious Diseases/CDC/DHHS	CDC-RFA-CK20-2002	09-Jun-2020	1,000,000 USD
	<p>Contact Name Nekeia Gray, Project Officer</p> <p>Contact Telephone 404-639-0712</p> <p>Contact Email <a href="mailto:Hvq6@cdc.gov">Hvq6@cdc.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2020</p> <p>Synopsis Measurable outcomes of the program will be in alignment with at least one of the following performance goal(s) for the National Center for Emerging and Zoonotic Infectious Diseases: Protect Americans from Infectious Diseases. This announcement is only for non-research activities supported by CDC. CDC's Division of Global Migration and Quarantine (DGMQ) is focused on improving the health among immigrants (including Special Immigrant Visa holders), asylees, parolees, survivors of victims of torture, human trafficking victims, and refugees through public health partnerships, science, and response. This funding opportunity will advance the Centers of Excellence in Refugee Health to the Centers of Excellence in Newcomer Health to improve newcomer health outcomes, increase healthcare provider capacity, and to increase the evidence-base for health policy decisions around these populations. These Centers will provide expertise in these program areas, build upon existing infrastructure, and collaborate with partners focusing on these at-risk populations.</p>				
074989	<a href="#">NIOSH Exploratory/Developmental Grant Program (R21)</a>	National Institute for Occupational Safety & Health/CDC/DHHS	PAR-18-798	16-Jun-2020	275,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Viji Potula, PhD</p> <p>Contact Telephone   404-498-2551</p> <p>Contact Email   <a href="mailto:VPotula@cdc.gov">VPotula@cdc.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023</p> <p>Synopsis   The purpose of the R21 grant program is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. NIOSH supports exploratory and developmental research projects (R21) that identify and address novel scientific ideas or new model systems, tools, or technologies with the potential for significant impact on occupational safety and health. Applicants must concisely describe the occupational health burden addressed in their proposals and must link the need for the proposed research activities to planned outputs that will help alleviate this burden. Applicants should clearly articulate the anticipated impacts of the proposed research, both during the project period and beyond.</p>				
074995	<a href="#">NIOSH Small Research Grant Program (R03)</a>	National Institute for Occupational Safety & Health/CDC/DHHS	PAR-18-797	16-Jun-2020	100,000 USD
	<p>Contact Name   Joan F. Karr, PhD</p> <p>Contact Telephone   404-498-2506</p> <p>Contact Email   <a href="mailto:SChiou@cdc.gov">SChiou@cdc.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2020 , 16-Oct-2020 , 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023</p> <p>Synopsis   The purpose of the R03 grant program is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. The NIOSH Small Research grant mechanism (R03) supports occupational safety and health research projects that can be carried out with limited resources, such as pilot and feasibility studies, secondary data analysis, or development of research methods. Applicants must concisely describe the</p>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		occupational health burden addressed in their proposal and must link the need for the proposed research activities to planned outputs that will help alleviate this burden. Applicants should clearly articulate the anticipated impacts of the proposed research, both during the project period and beyond.			
074988	<a href="#">NIOSH Mentored Research Scientist Development Award (K01)</a>	National Institute for Occupational Safety & Health/CDC/DHHS	PAR-18-799	12-Jun-2020	Not Specified
	Contact Name	Linda West, MSPH			
	Contact Telephone	404-498-5767			
	Contact Email	<a href="mailto:LWest@cdc.gov">LWest@cdc.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020 , 12-Feb-2021 , 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023			
	Synopsis	National Institute for Occupational Safety and Health (NIOSH) invites grant applications to provide support and 75% “protected time” for an intensive, supervised (mentored) career development experience in occupational health and safety research leading to research independence. NIOSH supports K01 grants to help ensure the availability of an adequate number and diversity of highly trained scientists and educators to address critical occupational safety and health issues. Applicants must concisely describe the occupational health burden addressed in their proposal and must link the need for the proposed research activities to planned outputs that will help alleviate this burden. Applicants should clearly articulate the anticipated impacts of the proposed research, both during the project period and beyond. This FOA will utilize the K01 - Research Scientist Development Award - Research & Training mechanism.			
075196	<a href="#">Occupational Safety and Health Research (R01)</a>	National Institute for Occupational Safety & Health/CDC/DHHS	PAR-18-812	05-Jun-2020	1,600,000 USD
	Contact Name	Maria Lioce, MD			
	Contact Telephone	404-498-2575			
	Contact Email	<a href="mailto:MLioce@cdc.gov">MLioce@cdc.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020 , 05-Oct-2020 , 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The purpose of the R01 grant program is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. The Research Project Grant (R01) supports a discrete, specified, circumscribed project in scientific areas that represent the investigators' specific interests and competencies and that fall within the mission of NIOSH. Applicants must concisely describe the occupational health burden addressed in their proposal and must link the need for the proposed research activities to planned outputs that will help alleviate this burden. Applicants should clearly articulate the anticipated impacts of the proposed research, both during the project period and beyond.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
060608	<a href="#">Research Innovation Collaborations Program</a>	23andme		12-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL				
	Deadline Dates (ALL)	12-Jun-2020			
	Synopsis	23andMe endeavors to advance biomedical science through genetic research. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.			
098360	<a href="#">Singapore International Graduate Award</a>	Agency for Science, Technology & Research		01-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone	(65) 6826 6111			
	Contact Email	<a href="mailto:singa_enquiries@hq.a-star.edu.sg">singa_enquiries@hq.a-star.edu.sg</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL				
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The Singapore International Graduate Award (SINGA) is a collaboration between the Agency for Science, Technology & Research (ASTAR), the National University of Singapore (NUS), and the Nanyang Technological University (NTU). PhD training will be carried out in English at the recipient's chosen lab at ASTAR Research Institutes, NUS, or NTU. Students will be supervised by distinguished and world-renowned researchers in these labs. Upon successful completion, students will be conferred a PhD degree by either NUS or NTU.			
064669	<a href="#">Resident International Grant</a>	American Academy of Dermatology		30-Jun-2020	Not

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Janine Mueller 847-240-1737 <a href="mailto:jmueller@aad.org">jmueller@aad.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 30-Jun-2020			
	Synopsis	The AAD provides funding for fifteen U.S. and Canadian senior dermatology residents to participate in a four- to six-week elective in Gaborone, Botswana, where participants rotate between the Princess Marina Hospital, in conjunction with the Botswana-UPenn Partnership, and the Baylor International Pediatric AIDS Initiative (BIPAI). Residents take part in dermatologic HIV care for both children and adults, and visit outreach sites in Francistown and Southern Botswana.			
064670	<a href="#">SkinCare for Developing Countries Program</a>	American Academy of Dermatology		30-Jun-2020	5,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	847-240-1280 <a href="mailto:RIGNAHS@aad.org">RIGNAHS@aad.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 30-Jun-2020			
	Synopsis	The Academy offers grants to individuals and organizations to fund international volunteer and humanitarian projects under the SkinCare for Developing Countries program. Grants vary between \$2,500 and \$5,000 depending on the proposal, scope of the project, and availability of funds.			
053808	<a href="#">Foundation Research Award</a>	American Academy of Otolaryngic Allergy Foundation		01-Jun-2020	10,000 USD
	Contact Name	Elisabeth Herzfeld-Rice			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	202-955-5010 x600			
	Contact Email	<a href="mailto:foundation@aaoallergy.org">foundation@aaoallergy.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The AAOA Foundation seeks to advance allergy research and knowledge for the treatment of otolaryngic conditions by inviting applications for grants to conduct research in the pathogenesis, pathophysiology, diagnosis, prevention, or treatment of otolaryngic allergy. Funds are available to support multiple projects each year; each project may have total direct costs of \$10,000.			
092553	<a href="#">AAP Teaching Fellowships</a>	American Academy of Periodontology		01-Jun-2020	50,000 USD
	Contact Name	Robert Vitas, Executive Director			
	Contact Telephone	800-282-4867 x3256			
	Contact Email	<a href="mailto:bob@perio.org">bob@perio.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	AAP Teaching Fellowships are intended to support the young periodontal educator's commitment to a career in academia by providing debt relief to qualified applicants.			
092554	<a href="#">Educator Scholarships</a>	American Academy of Periodontology		01-Jun-2020	25,000 USD
	Contact Name	Robert Vitas, Executive Director			
	Contact Telephone	800-282-4867 x3256			
	Contact Email	<a href="mailto:bob@perio.org">bob@perio.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	AAP Educator Scholarships stimulate the development of periodontal educators by providing financial relief to students intending to pursue a career as full-time teachers at U.S. periodontal programs upon graduation from U.S. periodontal postdoctoral training programs.			
064693	<a href="#">Schoor Research Award</a>	American Academy of Periodontology Foundation		01-Jun-2020	2,000 USD
	Contact Name	Robert Vitas			
	Contact Telephone	800-282-4867 x3256			
	Contact Email	<a href="mailto:bob@perio.org">bob@perio.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The American Academy of Periodontology Foundation supports resident research in the field of periodontology through the Robert S. Schoor Research Award Program, a \$2,000 annual award for resident-written manuscript. A wide range of research subjects that are significant to the clinical practice of periodontology will be supported.			
064695	<a href="#">Dr. James T. Mellonig Regeneration Research Award</a>	American Academy of Periodontology Foundation		01-Jun-2020	10,000 USD
	Contact Name	Robert Vitas			
	Contact Telephone	800-282-4867 x3256			
	Contact Email	<a href="mailto:bob@perio.org">bob@perio.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The \$10,000 Dr. James T. Mellonig Regeneration Research Award recognizes excellence in original research by a resident or recent graduate in the specialty of periodontics that advances clinical therapies in periodontal regeneration.			
032751	<a href="#">Eva King Killiam Research Award</a>	American College of Neuropsychopharmacology		29-Jun-2020	Not Specified

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 615-324-2360</p> <p>Contact Email <a href="mailto:acnp@acnp.org">acnp@acnp.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 29-Jun-2020</p> <p>Synopsis The American College of Neuropsychopharmacology (ACNP) presents the Eva King Killam Award to an early career researcher on the basis of outstanding translational research contributions to neuropsychopharmacology. Award recipients will be announced at the ACNP Annual Meeting during the President's Plenary.</p>				
023798	<a href="#">Elizabeth Barrett-Connor Research Award for Young Investigators</a>	American Heart Association		10-Jun-2020	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-242-8721</p> <p>Contact Email <a href="mailto:council.awards@heart.org">council.awards@heart.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2020</p> <p>Synopsis The Elizabeth Barrett-Connor Research Award in Epidemiology recognizes excellence in research by early career investigators and trainees and encourages continued biomedical research careers broadly related to cardiovascular function and diseases, including basic science, integrated physiology and clinical problems. The first-prize winner will receive a plaque and \$1,000.</p>				
023802	<a href="#">Melvin Judkins Young Clinical Investigator Award</a>	American Heart Association		10-Jun-2020	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone 214-570-5978</p> <p>Contact Email <a href="mailto:council.awards@heart.org">council.awards@heart.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 10-Jun-2020  
 Synopsis The Melvin Judkins Young Clinical Investigator Award recognizes meritorious research from early career investigators and promotes careers in cardiovascular radiology.

079306	<a href="#">Council on Lifestyle and Cardiometabolic Health Young Investigator Award</a>	American Heart Association		10-Jun-2020	Not Specified
--------	--	----------------------------	--	-------------	---------------

Contact Name  
 Contact Telephone 214-706-1181  
 Contact Email [council.awards@heart.org](mailto:council.awards@heart.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 10-Jun-2020  
 Synopsis The Council on Lifestyle and Cardiometabolic Health Young Investigator Award recognizes and awards early career investigator and trainee council members for their achievements and their continuing research. The award also encourages young scientists to become involved in the Council on Lifestyle and Cardiometabolic Health and to develop and maintain productive careers.

066120	<a href="#">Katharine A. Lembright Award</a>	American Heart Association		10-Jun-2020	2,000 USD
--------	--	----------------------------	--	-------------	-----------

Contact Name  
 Contact Telephone 214-570-5978  
 Contact Email [council.awards@heart.org](mailto:council.awards@heart.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 10-Jun-2020  
 Synopsis The award recognizes and encourages excellence in cardiovascular research by established nurse scientists.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
083059	<a href="#">Surgery Mentoring Award</a>	American Heart Association		10-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:council.awards@heart.org">council.awards@heart.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2020			
	Synopsis	The Council on Cardiovascular Surgery and Anesthesia (CVSA) annually honors one of its members who has actively guided junior researchers to build future generations of cardiovascular scientists and surgeons. The honoree will be recognized at the CVSA Council Dinner at Scientific Sessions in November.			
023809	<a href="#">Vivien Thomas Young Investigator Award</a>	American Heart Association		10-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:council.awards@heart.org">council.awards@heart.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2020			
	Synopsis	The Vivien Thomas Early Career Investigator Award acknowledges the accomplishments of early career investigator members of the Council on Cardiovascular Surgery and Anesthesia (CVSA) who are focusing on fundamental and applied surgical research.			
080457	<a href="#">Award for Outstanding Doctoral Thesis Research in Biological Physics</a>	American Physical Society		01-Jun-2020	Not Specified
	Contact Name				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone 301-209-3200  
 Contact Email [honors@aps.org](mailto:honors@aps.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 01-Jun-2020  
 Synopsis The Award for Outstanding Doctoral Thesis Research in Biological Physics recognizes doctoral thesis research of outstanding quality and achievement in any area of experimental, computational, engineering, or theoretical Biological Physics, broadly construed, and to encourage effective written and oral presentation of research results.

076770	<a href="#">Alexander Gralnick, M.D. Award for Research in Schizophrenia</a>	American Psychiatric Association Foundation		01-Jun-2020	3,000 USD
--------	--	---	--	-------------	-----------

Contact Name Kit Hall  
 Contact Telephone 202-559-3900  
 Contact Email [khall@psych.org](mailto:khall@psych.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 01-Jun-2020  
 Synopsis APA Foundation invites submissions for The Alexander Gralnick, M.D. Award for Research in Schizophrenia annually in the fall. Named after the late Alexander Gralnick, M.D., the award acknowledges research achievements in the treatment of schizophrenia, emphasizing early diagnosis and treatment and psychosocial aspects of the disease process.

068786	<a href="#">Forrest M. Bird, MD, PhD, ScD Lifetime Scientific Achievement Award</a>	American Respiratory Care Foundation		01-Jun-2020	Not Specified
--------	---	--------------------------------------	--	-------------	---------------

Contact Name Crystal Maldonado  
 Contact Telephone 972-243-2272  
 Contact Email [crystal.maldonado@aacrc.org](mailto:crystal.maldonado@aacrc.org)  
 Sponsor Website [Link to sponsor website](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL  
 Deadline Dates (ALL) 01-Jun-2020  
 Synopsis This award acknowledges outstanding individual scientific contributions in the area of respiratory care of cardiopulmonary disorders.

068798	<a href="#">Thomas L. Petty, MD Invacare Award for Excellence in Home Respiratory Care</a>	American Respiratory Care Foundation		01-Jun-2020	Not Specified
--------	--	--------------------------------------	--	-------------	---------------

Contact Name Crystal Maldonado  
 Contact Telephone 972-243-2272  
 Contact Email [crystal.maldonado@aac.org](mailto:crystal.maldonado@aac.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL  
 Deadline Dates (ALL) 01-Jun-2020  
 Synopsis This award recognizes outstanding individual achievement in home respiratory care.

060491	<a href="#">Mike West, MBA, RRT Patient Education Achievement Award</a>	American Respiratory Care Foundation		01-Jun-2020	Not Specified
--------	---	--------------------------------------	--	-------------	---------------

Contact Name Attn: Crystal Maldonado  
 Contact Telephone 972-243-2272  
 Contact Email  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 01-Jun-2020  
 Synopsis The Mike West, MBA, RRT Patient Education Achievement Award has been established to recognize excellence in patient education. This award includes a plaque, coach airfare, one night's lodging, and registration for the AACRC Congress.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

068800	<a href="#">H. Frederic Helmholtz, Jr., MD Educational Research Fund</a>	American Respiratory Care Foundation		01-Jun-2020	5,000 USD
--------	--	--------------------------------------	--	-------------	-----------

Contact Name	
Contact Telephone	972-243-2272
Contact Email	<a href="mailto:crystal.maldonado@aacrc.org">crystal.maldonado@aacrc.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	
Deadline Dates (ALL)	01-Jun-2020
Synopsis	The National Board for Respiratory Care/Applied Measurement Professionals, Inc. has provided an endowment to the American Respiratory Care Foundation to support up to \$5,000 for educational or credentialing research. A Master's Thesis, or Doctoral Dissertation with practical value to the respiratory care profession are acceptable submissions by a candidate.

097671	<a href="#">Hector Leon Garza, MD International Achievement Award</a>	American Respiratory Care Foundation		01-Jun-2020	Not Specified
--------	---	--------------------------------------	--	-------------	---------------

Contact Name	Crystal Maldonado
Contact Telephone	972-243-2272
Contact Email	<a href="mailto:crystal.maldonado@aacrc.org">crystal.maldonado@aacrc.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2020
Synopsis	The Hector Leon Garza, MD International Achievement Award recognizes respiratory therapists, physicians, and other health care providers who have had a profound impact on the development of international respiratory care.

075269	<a href="#">Cutting Edge Research Grant Program</a>	American Society for Dermatologic Surgery		26-Jun-2020	20,000 USD
--------	---	---	--	-------------	------------

Contact Name	
Contact Telephone	847-956-9139

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [847-956-0900](tel:847-956-0900)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 26-Jun-2020  
Synopsis The Cutting Edge Research Grant Program (CERG) awards grants of up to \$20,000 in order to stimulate a broad scope of research relevant to dermatologic surgeons and the dermatology specialty at large.

011252	<a href="#">Fellowship Research Award</a>	American Surgical Association Foundation		15-Jun-2020	75,000 USD
--------	---	--	--	-------------	------------

Contact Name  
Contact Telephone 978-927-8330  
Contact Email  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 15-Jun-2020  
Synopsis The purpose of the ASAF Fellowship is to support and encourage gifted young surgeons who choose careers in investigation and academic surgery. Fellows will be supported in an initial year; the Fellowship can be renewed by review of the Fellowship Committee for a succeeding year.

036867	<a href="#">Research Grants</a>	Ataxia UK		01-Jun-2020 [LOI/Pre-App]	Not Specified
--------	---------------------------------	-----------	--	------------------------------	---------------

Contact Name Dr Julie Greenfield  
Contact Telephone 020 7582 1444  
Contact Email [research@ataxia.org.uk](mailto:research@ataxia.org.uk)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 01-Jun-2020 [LOI/Pre-App]

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis Ataxia UK supports research leading towards the treatment or cure of ataxias, both hereditary and non hereditary (excluding ataxia telangiectasia). Approaches that enable people to be diagnosed effectively, and live successfully with ataxia (e.g. physio or other therapy techniques) can also be supported.

018455	<a href="#">Sir Harcourt Caughey Award</a>	Auckland Medical Research Foundation		24-Jun-2020	15,000 USD
--------	--	--------------------------------------	--	-------------	------------

Contact Name	
Contact Telephone	+64 9 923 1701
Contact Email	<a href="mailto:amrf@medicalresearch.org.nz">amrf@medicalresearch.org.nz</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	24-Jun-2020
Synopsis	The Sir Harcourt Caughey Award provides funds up to \$25,000 for recipients who may (i) be a graduate of New Zealand who, having trained in research overseas, is returning to New Zealand to a part-time appointment in Auckland and who has sufficient experience in research to deserve part-time support (or similar to a part-time Senior Research Fellowship) in such research; or (ii) be a New Zealand medical graduate in Auckland who is deserving of assistance to train in a specific field overseas and to undertake research in that area, especially where there is a local deficiency in expertise in that field; or (iii) be sufficiently prestigious in a particular field of medical knowledge and/or research to visit Auckland, normally for 3-4 weeks, to foster interest and research in that specialty.

020225	<a href="#">Travel Grants</a>	Auckland Medical Research Foundation		24-Jun-2020	1,800 USD
--------	-------------------------------	--------------------------------------	--	-------------	-----------

Contact Name	
Contact Telephone	09 923 1706
Contact Email	<a href="mailto:hannah.gibbons@medicalresearch.org.nz">hannah.gibbons@medicalresearch.org.nz</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	24-Jun-2020
Synopsis	Travel grants provide support for medical researchers who wish to present their research at a meeting or conference.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Funds may also be provided to support a training course on research methods and/or for visiting a laboratory to learn a new research technique.			
047751	<a href="#">CSL Florey Next Generation Award</a>	Australian Institute of Policy and Science		05-Jun-2020	12,800 USD
	Contact Name	Stephen Burke			
	Contact Telephone	(02) 9351 0023			
	Contact Email	<a href="mailto:tallpoppies@aips.net.au">tallpoppies@aips.net.au</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jun-2020			
	Synopsis	The CSL Florey Next Generation Award will be conferred to a current PhD candidate who has demonstrated outstanding capability, creativity and potential in the biomedical sciences and/or health and medical research.			
048020	<a href="#">Avant Doctor in Training Research Scholarship Program</a>	Avant Mutual Group		01-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone	1800 128 268			
	Contact Email	<a href="mailto:scholarship@avant.org.au">scholarship@avant.org.au</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The Avant Doctor in Training Research Scholarship Program helps emerging researchers to conduct studies that contribute to a stronger future for healthcare, while advancing their careers. The program provides funding for life-changing research to promote better patient health outcomes. The scholarship was created in response to the difficulties young doctors face in securing research funding, and has since supported research across a wide range of specialities.			
096334	<a href="#">Frontiers of Knowledge Awards</a>	BBVA Foundation		30-Jun-2020	436,000

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					USD
	Contact Name				
	Contact Telephone	+34 94 424 46 21			
	Contact Email	<a href="mailto:awards-info@fbbva.es">awards-info@fbbva.es</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020			
	Synopsis	The BBVA Foundation Frontiers of Knowledge Awards are intended to recognize basic research and creative work of excellence, as embedded in theoretical advances, models and fundamental perspectives for an improved understanding of the natural, social and artificial or technological worlds, technological innovations and developments, and the creation of outstanding works or new artistic or interpretative styles in contemporary classical music. Awards also go to significant achievements that advance our understanding or deliver material progress with regard to two key challenges of the global society of the 21st century: climate change and development cooperation.			
089931	<a href="#">PhD Fellowships</a>	Boehringer Ingelheim Fonds		01-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone	+49 (0)6131 2750 80			
	Contact Email	<a href="mailto:secretariat@bifonds.de">secretariat@bifonds.de</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020 , 01-Oct-2020			
	Synopsis	The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships of two to three years to junior scientists worldwide who wish to pursue an ambitious PhD project in basic biomedical research in an internationally leading laboratory.			
005150	<a href="#">Laboratory Visit Grant</a>	British Microcirculation Society		30-Jun-2020	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name | Dr Jacqueline Whatmore  
Contact Telephone | +44(0) 1392 262944  
Contact Email | [J.L.Whatmore@exeter.ac.uk](mailto:J.L.Whatmore@exeter.ac.uk)  
Sponsor Website | [Link to sponsor website](#)  
Program URL | [Link to program URL](#)  
Deadline Dates (ALL) | 30-Jun-2020  
Synopsis | The British Microcirculation Society provides support annually to assist an eligible postgraduate student or junior postdoctoral worker, either of whom must be a member of the British Microcirculation Society, to visit a laboratory in this country or abroad for the purpose of learning new techniques or other worthwhile scientific purposes related to microvascular research.

064543	<a href="#">Visiting Fellowships</a>	British Society for Haematology		30-Jun-2020	22,680 USD
--------	--------------------------------------	---------------------------------	--	-------------	------------

Contact Name |  
Contact Telephone | 020 7713 0990  
Contact Email | [grants@b-s-h.org.uk](mailto:grants@b-s-h.org.uk)  
Sponsor Website | [Link to sponsor website](#)  
Program URL | [Link to program URL](#)  
Deadline Dates (ALL) | 30-Jun-2020  
Synopsis | The British Society for Haematology (BSH) provides support for short term (less than one year) visits overseas to gain experience in a different field or to learn new research.

060544	<a href="#">Research Grants - 21st Century Development Grants</a>	Cervical Spine Research Society		05-Jun-2020	75,000 USD
--------	---	---------------------------------	--	-------------	------------

Contact Name | Zoher Ghogawala, MD  
Contact Telephone | 847-698-1626  
Contact Email | [csrs@aaos.org](mailto:csrs@aaos.org)  
Sponsor Website | [Link to sponsor website](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 Synopsis The CSRS Grant program will fund 21st Century Development Grants for up to \$75,000 for the the highest quality applications likely to make the greatest impact on cervical spine research. This grant is limited to basic science projects only.				
084275	<a href="#">Medical Research Grants</a>	Children's Heart Foundation		05-Jun-2020	100,000 USD
	Contact Name Contact Telephone 847-634-6474 Contact Email <a href="mailto:ResearchGrants@ChildrensHeartFoundation.org">ResearchGrants@ChildrensHeartFoundation.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 Synopsis The Children's Heart Foundation funds life-saving, life-changing congenital heart defect (CHD) research in clinical cardiology, translational research, population science, and advancement, prevention, detection of surgical and interventional techniques. No single project may receive more than \$100,000 in funds during any calendar year.				
061151	<a href="#">Research Grant Program</a>	Children's Heart Foundation		05-Jun-2020	100,000 USD
	Contact Name Contact Telephone 847-634-6474 Contact Email <a href="mailto:ResearchGrants@ChildrensHeartFoundation.org">ResearchGrants@ChildrensHeartFoundation.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 Synopsis The Children's Heart Foundation funds life-saving, life-changing congenital heart defect (CHD) research in clinical				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

cardiology, translational research, population science, and advancement, prevention, detection of surgical and interventional techniques.

021439	<a href="#">Research Grants</a>	Children's Leukemia Research Association/National Leukemia Research Association, Inc.		30-Jun-2020	Not Specified
--------	---------------------------------	---	--	-------------	---------------

Contact Name	
Contact Telephone	516-222-1944
Contact Email	
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	
Deadline Dates (ALL)	30-Jun-2020
Synopsis	CLRA funds research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure.

002586	<a href="#">Grants Program</a>	Cure Parkinsons Trust		04-Jun-2020	Not Specified
--------	--------------------------------	-----------------------	--	-------------	---------------

Contact Name	
Contact Telephone	020 7487 3892
Contact Email	<a href="mailto:leah@cureparkinsons.org.uk">leah@cureparkinsons.org.uk</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	04-Jun-2020 , 15-Oct-2020
Synopsis	The Cure Parkinson's Trust (CPT) funds and facilitates laboratory or clinical research projects with the potential to advance knowledge that might lead to a cure for Parkinson's disease. Only research applications that meet the following criteria are accepted: Disease modifying (slow, stop, reverse); Translate into clinic (Phase 2b trial) within 5 years.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
006883	<a href="#">Research Grants</a>	Cure Starts Now Foundation (The)		01-Jun-2020	100,000 USD
	Contact Name	Keith Desserich			
	Contact Telephone	513-772-9006			
	Contact Email	<a href="mailto:keith@thecurestartsnow.org">keith@thecurestartsnow.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The Cure Starts Now annually awards research grants to institutions and medical professionals whose research focuses on cancers that present the greatest opportunities for a homerun cancer cure.			
092504	<a href="#">Elevate Prize</a>	Elevate Prize Foundation		29-Jun-2020	300,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jun-2020			
	Synopsis	The Prize will award up to USD \$5 million annually to multiple Global Heroes, as well as offer valuable resources for two years after being selected, helping amplify their work and build a massive movement to galvanize people all over the world to do good in their own community. The Elevate Prize is open to applicants with a demonstrated history of catalyzing social and/or environmental impact through their work and leadership.			
030970	<a href="#">Eppendorf &amp; Science Prize for Neurobiology</a>	Eppendorf AG		15-Jun-2020	25,000 USD
	Contact Name				
	Contact Telephone	202-326-6550			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:eppendorfsceinceprize@aaas.org">eppendorfsceinceprize@aaas.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2020
Synopsis	The International Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years, as described in a 1,000-word entrance essay. The essays are rated in two areas: scientific quality and significance, and clarity and style of the writing.

058675	<a href="#">Seeding Solutions Research Grants</a>	Foundation for Food and Agriculture Research		24-Jun-2020	1,000,000 USD
--------	---	--	--	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grants@foundationfar.org">grants@foundationfar.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	24-Jun-2020
Synopsis	FFAR's Seeding Solutions Grants are an open call for applicants to submit innovative and transformative research proposals that furthers any of their Challenge Areas, and foster unique partnerships. Every year, FFAR funds at least one proposal in each of the Challenge Areas, typically awarding each applicant between \$300,000 and \$1 million.

092104	<a href="#">AI 4 COVID-19: Data Science and Artificial Intelligence in the Public Administration to Strengthen the Fight Against COVID-19 and Future Pandemics - 2020</a>	Foundation for Science and Technology		28-May-2020	261,600 USD
--------	---	---------------------------------------	--	-------------	-------------

Contact Name	
Contact Telephone	+351 21 392 44 08
Contact Email	<a href="mailto:concursoprojetos@fct.pt">concursoprojetos@fct.pt</a>

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	28-May-2020 , 15-Jun-2020			
	Synopsis	Fundação para a Ciência e Tecnologia (FCT) is launching a new competition aimed at data processing within the current pandemic of the new coronavirus SARS CoV2 and the disease COVID-19 and in the context of the situation of increasing uncertainty and social alarm in which we live. The objective is to support R&D projects and initiatives that can contribute to new responses to this and future pandemics, with an emphasis on supporting citizens and health care services.			
058140	<a href="#">Harvard Medical School Fellowship in General Medicine and Primary Care</a>	Harvard Medical School		15-Jun-2020	Not Specified
	Contact Name	Jennifer Haas M.D., M.Sc.			
	Contact Telephone	617-525-7651			
	Contact Email	<a href="mailto:GIMFellowship@bidmc.harvard.edu">GIMFellowship@bidmc.harvard.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020			
	Synopsis	The Harvard Medical School Fellowship in General Medicine and Primary Care offers 2-year academic fellowships to prepare talented physicians for careers in academic medicine. The Program offers each Fellow an appointment at Harvard Medical School and one of its affiliated hospitals or departments. All fellows qualifying for acceptance to the Harvard School of Public Health pursue a rigorous curriculum that can lead to a Master of Public Health or Master of Science degree. Each Fellow is expected to design, conduct, present, and publish several original investigative projects that lay the foundation for future careers as leaders in general medicine and research.			
001561	<a href="#">Visiting Scholars Program</a>	Hastings Center		01-Jun-2020	Not Specified
	Contact Name				
	Contact Telephone	845-424-4040			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email <a href="mailto:visitors@thehastingscenter.org">visitors@thehastingscenter.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jun-2020 Synopsis The Hastings Center welcomes scholars in all disciplines and practitioners from health care, law, education, journalism, and other fields to our Garrison, N.Y. campus for independent research on bioethics.				
012624	<a href="#">International Travel and Subsistence Grants</a>	Houghton Trust		15-Jun-2020	Not Specified
	Contact Name Dr. Susan Baigent Contact Telephone Contact Email <a href="mailto:sue.baigent@outlook.com">sue.baigent@outlook.com</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 15-Jun-2020 , 15-Nov-2020 Synopsis The Houghton Trust Ltd awards travel grants for the furtherance of study or research in avian diseases by attending/participating in relevant scientific meetings, visiting appropriate laboratories for discussions and learning specific techniques or attending training courses in countries other than the applicant's own.				
021861	<a href="#">Neurotology Clinical Fellowship Program</a>	House Research Institute		01-Jun-2020	Not Specified
	Contact Name William H. Slattery, M.D., Director, Neurotology Fellowship Program Contact Telephone 213-483-9930 Contact Email <a href="mailto:MZamora@houseclinic.com">MZamora@houseclinic.com</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Jun-2020				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The neurotology lateral skull base surgery program at House Clinic provides advanced education beyond that afforded in the otolaryngology residency in the diagnosis and management of disorders of the temporal bone, lateral skull base, and related anatomical structures. Surgery of the lateral skull base that involves the mesial aspect of the dura or intradural structure requires the joint effort of a neurotology and neurological surgery team.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

024927	<a href="#">Travel Fellowships</a>	International Society for Eye Research		15-Jun-2020	Not Specified
--------	------------------------------------	--	--	-------------	---------------

Contact Name	
Contact Telephone	415-561-8569
Contact Email	<a href="mailto:mail@iser.org">mail@iser.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2020
Synopsis	The ISER Travel Fellowship program is funded through a variety of sources to support the participation of young scientists at each Biennial meeting of the International Society for Eye Research.

023519	<a href="#">Britton Chance Biomedical Optics Award</a>	International Society for Optics and Photonics		01-Jun-2020	2,000 USD
--------	--	--	--	-------------	-----------

Contact Name	
Contact Telephone	360-676-3290
Contact Email	<a href="mailto:awards@spie.org">awards@spie.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2020



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Britton Chance Biomedical Optics Award is presented annually in recognition of outstanding lifetime contributions to the field of biomedical optics through the development of innovative, high impact technologies.			
041826	<a href="#">Biophotonics Technology Innovator Award</a>	International Society for Optics and Photonics		01-Jun-2020	2,000 USD
	Contact Name				
	Contact Telephone	360-676-3290			
	Contact Email	<a href="mailto:awards@spie.org">awards@spie.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The SPIE Biophotonics Technology Innovator Award is presented for extraordinary achievements in biophotonics technology development that show strong promise or potential impact in Biology, Medicine, and Biomedical Optics. The award consists of \$2,000.			
061954	<a href="#">Asia Pacific Chapter Scholarship</a>	International Society for Peritoneal Dialysis		30-Jun-2020	3,000 USD
	Contact Name				
	Contact Telephone	+1 567 251 4018			
	Contact Email	<a href="mailto:admin@ispd.org">admin@ispd.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 , 31-Dec-2020			
	Synopsis	The Asia Pacific Chapter Scholarship provides International Society for Peritoneal Dialysis (ISPD) members financial support for visiting a centre of excellence for 2-3 months. The training centre has to be a center in Asia or Australia/Oceania with more than 75 home PD patients and has been established for not less than 5 years.			
024383	<a href="#">Scholarship Program</a>	International Team for		30-Jun-2020	31,200 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Implantology (ITI)

Contact Name	Anna Häuptli
Contact Telephone	+41 (0) 61 270 83 83
Contact Email	<a href="mailto:scholarship@iticenter.ch">scholarship@iticenter.ch</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	30-Jun-2020
Synopsis	The International Team for Implantology (ITI) offers a post-graduate program for young clinicians to gain international experience in implant dentistry. The program allows ITI Scholars to gain insight into case planning, implant surgery and prosthetic restorations and, in most ITI Scholarship Centers, also into research and teaching.

066688	<a href="#">Clinical Research Grants for Robotic-Assisted Surgery</a>	Intuitive Surgical Inc.		12-Jun-2020 [LOI/Pre-App]	60,000 USD
--------	---	-------------------------	--	------------------------------	------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grants@intuitive-foundation.org">grants@intuitive-foundation.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	12-Jun-2020 [LOI/Pre-App], 18-Sep-2020
Synopsis	The purpose of these grants is to support clinical research in the field of robotic-assisted surgery. Successful proposals will address important clinical questions or support clinically relevant technology development. Grants will be awarded to researchers at non-profit institutions worldwide.

092484	<a href="#">COVID-19 Open Research Dataset Challenge (CORD-19)</a>	Kaggle		16-Apr-2020	1,000 USD
--------	--	--------	--	-------------	-----------

Contact Name	
Contact Telephone	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 16-Apr-2020 , 16-Jun-2020  
Synopsis Kaggle is sponsoring a \$1,000 per task award to artificial intelligence experts to develop text and data mining tools that can help the medical community develop answers to high priority scientific questions about COVID-19, SARS-CoV-2, and related coronaviruses.

061435	<a href="#">Grants Program</a>	LEO Foundation		22-Jun-2020	Not Specified
--------	--------------------------------	----------------	--	-------------	---------------

Contact Name  
Contact Telephone + 45 32 72 51 10  
Contact Email [applications@leo-foundation.org](mailto:applications@leo-foundation.org)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 22-Jun-2020 , 04-Sep-2020  
Synopsis LEO Foundation open competition grants are given to support the best dermatology research projects worldwide.

061336	<a href="#">Research Grant Program</a>	LGS Foundation		01-Jun-2020	Not Specified
--------	--	----------------	--	-------------	---------------

Contact Name  
Contact Telephone 718-374-3800  
Contact Email [info@lgsfoundation.org](mailto:info@lgsfoundation.org)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 01-Jun-2020

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis The LGS Foundation Research Award provides funding for young and established investigators, physician residents, and clinicians who seek to advance our understanding of Lennox-Gastaut Syndrome (LGS). Grants may be one-year or two-years and support research projects that answer questions related to the underlying biology, clinical aspects, therapies, and/or causes of LGS. Grant recipients are asked to give a presentation at the LGS Foundation's annual research meeting at the American Epilepsy Society the following year to discuss their work.

077770	<a href="#">Emerging Leader Award</a>	Mark Foundation for Cancer Research		04-Jun-2020 [LOI/Pre-App]	750,000 USD
--------	---------------------------------------	-------------------------------------	--	------------------------------	----------------

Contact Name  
Contact Telephone 646-866-5950  
Contact Email [info@themarkfoundation.org](mailto:info@themarkfoundation.org)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 04-Jun-2020 [LOI/Pre-App], 24-Aug-2020  
Synopsis The Mark Foundation Emerging Leader Awards support innovative research from the next generation of leaders in cancer research. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.

067186	<a href="#">Pediatric Dermatology Fellowship (Minnesota)</a>	Mayo Clinic College of Medicine and Science		30-Jun-2020	Not Specified
--------	--	---	--	-------------	---------------

Contact Name Kelly J. Ihrke  
Contact Telephone 507-284-3736  
Contact Email [mayodermfellows@mayo.edu](mailto:mayodermfellows@mayo.edu)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 30-Jun-2020  
Synopsis Mayo Clinic in Rochester, Minnesota, offers a one-year Pediatric Dermatology Fellowship. The program focuses on

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

advanced care of infants and children with severe skin disease. During this fellowship, fellows will work with Mayo Clinic staff members and residents in clinical, laboratory and procedural dermatology, as well as colleagues in plastic surgery, rheumatology, ophthalmology and other departments.

013312	<a href="#">Surgery - Abdominal Transplant Surgery Fellowship (Minnesota)</a>	Mayo Clinic College of Medicine and Science		10-Jun-2020	Not Specified
--------	---	---	--	-------------	---------------

Contact Name	Patrick G. Dean, M.D.; Program Director
Contact Telephone	507-266-8731
Contact Email	<a href="mailto:dean.patrick2@mayo.edu">dean.patrick2@mayo.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	10-Jun-2020
Synopsis	The Abdominal Transplant Surgery Fellowship at Mayo Clinic's campus in Rochester, Minnesota, provides fellows with the best possible foundation for a career in transplantation surgery. The American Society of Transplant Surgeons has accredited Mayo Clinic for training in liver and kidney transplantation.

061247	<a href="#">Merck MISP Clostridium Difficile Grant</a>	Merck		15-Jun-2020	Not Specified
--------	--	-------	--	-------------	---------------

Contact Name	Lei Ba
Contact Telephone	267-305-6551
Contact Email	<a href="mailto:lei.ba@merck.com">lei.ba@merck.com</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jun-2020
Synopsis	The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

publications.

061248	<a href="#">Merck MISP CMV Grant</a>	Merck		08-Jun-2020	Not Specified
--------	--------------------------------------	-------	--	-------------	---------------

Contact Name	Christopher Coyle
Contact Telephone	267-305-0947
Contact Email	<a href="mailto:christopher.coyle@merck.com">christopher.coyle@merck.com</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Jun-2020
Synopsis	The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.

058805	<a href="#">Investigator Studies Program (MISP) -- Surgery -- Anesthesia</a>	Merck		01-May-2020 [LOI/Pre-App]	Not Specified
--------	--	-------	--	------------------------------	---------------

Contact Name	Lisa Mount
Contact Telephone	267-305-1258
Contact Email	<a href="mailto:lisa_mount@merck.com">lisa_mount@merck.com</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-May-2020 [LOI/Pre-App], 19-Jun-2020 , 02-Jul-2020 [LOI/Pre-App], 17-Aug-2020 , 01-Sep-2020 [LOI/Pre-App], 19-Oct-2020
Synopsis	The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

publications.

090799	<a href="#">Health Security and Pandemics Challenge</a>	MIT Solve		18-Jun-2020	10,000 USD
--------	---	-----------	--	-------------	------------

Contact Name	Hala Hanna
Contact Telephone	
Contact Email	<a href="mailto:hala@solve.mit.edu">hala@solve.mit.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	18-Jun-2020
Synopsis	MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers. Solve is also seeking solutions that focus on preventative and mitigation measures that strengthen access to affordable primary healthcare systems, enhance disease surveillance systems, and improve healthcare supply chains. All solutions selected for Solve's five current Global Challenges will receive a \$10,000 grant funded by Solve.

059980	<a href="#">Early Investigator Travel Awards</a>	MSA Coalition		01-Jun-2020	2,000 USD
--------	--	---------------	--	-------------	-----------

Contact Name	Pam Bower
Contact Telephone	902-817-0902
Contact Email	<a href="mailto:pbower@msacoalition.org">pbower@msacoalition.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2020 , 01-Oct-2020
Synopsis	The MSA Coalition provides travel awards to defray costs of attending medical and scientific congresses in order to help attract talented early career investigators to the field of multiple system atrophy research.

084836	<a href="#">Don Summers Memorial Travel Award</a>	Multiple System Atrophy Coalition		05-Jun-2020	2,000 USD
--------	---	-----------------------------------	--	-------------	-----------

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email <a href="mailto:info@multiplesystematrophy.org">info@multiplesystematrophy.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 Synopsis The Don Summers Memorial MSA Travel Award provides a \$2000 cash prize and a plaque in recognition of outstanding MSA research by an early career investigator. Applications are now being accepted to attend the International Symposium on the Autonomic Nervous System, Maui, Hawaii USA (Nov 4 – 7, 2020).				
067593	<a href="#">Pilot Project Grants</a>	Myositis Association		01-May-2020 [LOI/Pre-App]	100,000 USD
	Contact Name Mary McGowan Contact Telephone 703-553-2631 Contact Email <a href="mailto:McGowan@myositis.org">McGowan@myositis.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-May-2020 [LOI/Pre-App], 30-Jun-2020 Synopsis This funding is to fund new and innovative research pilot projects in the hope that they will attract funding from other sources (such as NIH).				
067591	<a href="#">Mentored Research Fellowships</a>	Myositis Association		01-May-2020 [LOI/Pre-App]	100,000 USD
	Contact Name Mary McGowan Contact Telephone 703-553-2631 Contact Email <a href="mailto:mcgowan@myositis.org">mcgowan@myositis.org</a> Sponsor Website <a href="#">Link to sponsor website</a>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-May-2020 [LOI/Pre-App], 30-Jun-2020			
	Synopsis	Mentored Research Fellowships are designed to help promising junior investigators (MDs and PhDs) for a period of two years, subject to satisfactory progress, at the salary level approved by the participating institution, to a maximum received annually of \$50,000. Candidates should have completed residency or fellowship training or have received a PhD within the three years prior to commencing the Fellowship and be performing research under the supervision of an established mentor. Recipients must devote at least 50% of their time to research, but may include some study and clinical experience in allied fields. There should be limited supplementation of salary from outside sources.			
026827	<a href="#">Centers of Excellence in Gambling Research Grants</a>	National Center for Responsible Gaming		01-Jun-2020 [LOI/Pre-App]	402,500 USD
	Contact Name	Christine Reilly			
	Contact Telephone	978-338-6610			
	Contact Email	<a href="mailto:creilly@ncrg.org">creilly@ncrg.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020 [LOI/Pre-App], 01-Oct-2020			
	Synopsis	The National Center for Responsible Gaming (NCRG) will provide funding for research on gambling disorder.			
004820	<a href="#">Research Grants</a>	National Headache Foundation		30-Jun-2020	Not Specified
	Contact Name	Dr. Timothy R. Smith, Research Committee Chair			
	Contact Telephone	312-274-2650			
	Contact Email	<a href="mailto:tsmith@studymetrix.com">tsmith@studymetrix.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Headache Foundation supports research in the field of headache and pain as part of our mission, which also includes offering education and information to headache sufferers.			
091597	<a href="#">Grants Program</a>		National Operating Committee on Standards for Athletic Equipment	01-Jun-2020 [LOI/Pre-App]	Not Specified
	Contact Name	Frederick O. Mueller			
	Contact Telephone	919-537-8948			
	Contact Email	<a href="mailto:mueller537@nc.rr.com">mueller537@nc.rr.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020 [LOI/Pre-App], 10-Sep-2020			
	Synopsis	The mission of the National Operating Committee on Standards for Athletic Equipment (NOCSAE) is to commission research in sports medicine and science and, where feasible, establish standards for athletic equipment. Accordingly, the intent of the NOCSAE grant program is to commission investigator-initiated research and to provide support for education, health, and safety research and development.			
078566	<a href="#">Research Grants Program</a>		National Rosacea Society	15-Jun-2020	25,000 USD
	Contact Name				
	Contact Telephone	847-382-8971			
	Contact Email	<a href="mailto:rosaceas@aol.com">rosaceas@aol.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020			
	Synopsis	The National Rosacea Society's research grants program was established to encourage and support research into the potential causes and other key aspects of this condition that may lead to improvements in its treatment and potential prevention or cure.			
096282	<a href="#">Graduate Research Fellowships</a>		National Swimming Pool	01-Jun-2020	1,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Foundation					
	Contact Name				
	Contact Telephone	719-540-9119			
	Contact Email	<a href="mailto:dmalocsay@phta.org">dmalocsay@phta.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The National Swimming Pool Foundation provides support for fellowships to encourage and support graduate students and post-doctoral fellows who focus research in two areas associated with aquatic venues that are treated to maintain a sanitary condition (e.g., swimming pools, spas/hot tubs, therapy pools, water parks, etc).			
068408	<a href="#">Grants Program</a>		Noble (Samuel Roberts) Foundation	01-Jun-2020	Not Specified
	Contact Name	Stacy Newman, Program Officer			
	Contact Telephone	580-224-6347			
	Contact Email	<a href="mailto:granting@noblefoundation.org">granting@noblefoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The primary focus of the Noble Foundation granting program is funding agricultural research conducted by the Noble Research Institute. In addition, funding is provided to charitable organizations that cultivate good health, support education and build stronger communities.			
019022	<a href="#">Department of Urology - Endourology Fellowship at Northwestern</a>		Northwestern University Feinberg School of Medicine	29-May-2020	Not Specified
	Contact Name	Robert B. Nadler, MD c/o Kelly Ross			
	Contact Telephone	312-503-3238			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email [k-ross@northwestern.edu](mailto:k-ross@northwestern.edu)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 29-May-2020 , 19-Jun-2020  
Synopsis The Northwestern Feinberg School of Medicine Endourology Fellowship is a two-year program with clinical, operative and research components.

081961	<a href="#">Antimicrobial Stewardship Fellowship Award</a>	Pediatric Infectious Diseases Society		03-Jun-2020	Not Specified
--------	--	---------------------------------------	--	-------------	---------------

Contact Name  
Contact Telephone 703-299-6764  
Contact Email [pids@idsociety.org](mailto:pids@idsociety.org)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 03-Jun-2020  
Synopsis The goal of this award is to support the development of future researchers in pediatric antimicrobial stewardship by providing mentorship to complete a scholarly research project in a timely manner during fellowship or residency. Applicants may propose any type of study focusing on antimicrobial stewardship. The project should be able to be completed in one year, and the award will provide travel funds for awardees to present their work at the annual Pediatric Antimicrobial Stewardship Conference in St. Louis in June of 2021.

090624	<a href="#">Hemophilia Research in Africa-Middle East, Asia Pacific, China and Latin America Competitive Grant Program</a>	Pfizer Pharmaceuticals		22-Jun-2020	25,000 USD
--------	--	------------------------	--	-------------	------------

Contact Name Jessica Romano, Grant Officer  
Contact Telephone 212-733-2323  
Contact Email [jessica.romano@pfizer.com](mailto:jessica.romano@pfizer.com)  
Sponsor Website [Link to sponsor website](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Jun-2020			
	Synopsis	Projects that will be considered for Pfizer support will focus on the following prioritized areas: Burden of disease: Clinical Hemophilia A and B; Basic Science of TFPI & Anti-TFPI Monoclonal Antibodies; Basic Science of Gene Therapy for Hemophilia.			
089518	<a href="#">Medical Education Grants -- Preventing Cardiovascular Diseases Such As Venous Thromboembolism in Cancer Patients by Raising Awareness and Promoting Medical Cooperation</a>	Pfizer Pharmaceuticals		30-Jun-2020	0 USD
	Contact Name	Akihiro Kamina, Grant Officer			
	Contact Telephone	212-733-2323			
	Contact Email	<a href="mailto:meg.japan@pfizer.com">meg.japan@pfizer.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020			
	Synopsis	Pfizer requests applications focused on preventing cardiovascular diseases such as venous thromboembolism in cancer patients by raising awareness and promoting medical collaboration. Individual projects of up to 10.0 million Yen will be considered.			
082991	<a href="#">Transthyretin Cardiac Amyloidosis Fellowship</a>	Pfizer Pharmaceuticals		29-Jun-2020	80,000 USD
	Contact Name	Amanda Stein			
	Contact Telephone	212-733-2323			
	Contact Email	<a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Jun-2020			
	Synopsis	Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g.,			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies. It is the sponsors intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis.

090613	<a href="#">Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research – U.S. Competitive Grant Program/ASPIRE</a>	Pfizer Pharmaceuticals		03-Jun-2020	81,750 USD
--------	---	------------------------	--	-------------	------------

Contact Name | Amanda Stein, Grant Officer  
 Contact Telephone |  
 Contact Email | [amanda.j.stein@pfizer.com](mailto:amanda.j.stein@pfizer.com)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 03-Jun-2020

Synopsis | The intent of this Request for Proposal (RFP) is to improve the care of patients with ATTR-CM by improving our understanding of disease epidemiology, pathophysiology, early diagnosis, prognosis, and emerging treatment paradigms. Individual projects requesting up to \$75,000 USD will be considered.

081786	<a href="#">Gene &amp; Anti-TFPI Therapies in Hemophilia Competitive Grant Program</a>	Pfizer Pharmaceuticals		15-Jun-2020	250,000 USD
--------	--	------------------------	--	-------------	-------------

Contact Name | Amanda Stein  
 Contact Telephone | 212-733-2323  
 Contact Email | [amanda.j.stein@pfizer.com](mailto:amanda.j.stein@pfizer.com)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 15-Jun-2020

Synopsis | Projects that will be considered for Pfizer support will focus on the following areas: Basic Science of Gene Therapy for Hemophilia Basic Science of TFPI & Anti-TFPI Monoclonal Antibodies Burden of disease: Clinical Hemophilia A and B

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092351	<a href="#">RFP--Providing Enhanced Medical Support for Patients with Primary Immunodeficiency (PI) Disorders</a>	Pfizer Pharmaceuticals		08-Jun-2020	250,000 USD
	Contact Name	Angelo Carter			
	Contact Telephone	212-733-2323			
	Contact Email	<a href="mailto:angelo.carter@pfizer.com">angelo.carter@pfizer.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jun-2020			
	Synopsis	Through this RFP it is the sponsors intent to support patient-focused programs that help patients and providers address the heightened medical and educational needs of patients with PI during this pandemic. Priority will be awarded to projects that leverage the utilization of innovative technology platforms for distant learning to reach the intended audience with a focus on patient outreach, medical support and telework.			
070888	<a href="#">RPB Stein Innovation Awards</a>	Research to Prevent Blindness		15-Jun-2020 [LOI/Pre-App]	300,000 USD
	Contact Name	Pattie Moran			
	Contact Telephone	646-892-9566			
	Contact Email	<a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	15-Jun-2020 [LOI/Pre-App], 01-Jul-2020			
	Synopsis	The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of understanding the visual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to proposed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box thinking.			
006942	<a href="#">Career Development Awards</a>	Research to Prevent Blindness		15-Jun-2020 [LOI/Pre-App]	300,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name  
Contact Telephone 646-892-9566  
Contact Email [pmoran@rpbusa.org](mailto:pmoran@rpbusa.org)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 15-Jun-2020 [LOI/Pre-App], 01-Jul-2020  
Synopsis The RPB Career Development Award helps recruit young MDs, PhDs, or PhDs to eye research and support promising junior ophthalmology faculty. The \$300,000 grant is payable for up to four (4) years.

070892	<a href="#">RPB International Research Collaborators Award</a>	Research to Prevent Blindness		15-Jun-2020	75,000 USD
--------	--	-------------------------------	--	-------------	------------

Contact Name Pattie Moran  
Contact Telephone 646-892-9566  
Contact Email [pmoran@rpbusa.org](mailto:pmoran@rpbusa.org)  
Sponsor Website [Link to sponsor website](#)  
Program URL [Link to program URL](#)  
Deadline Dates (ALL) 15-Jun-2020 , 01-Jul-2020  
Synopsis The RPB International Research Collaborators Award promotes international collaborations through which collaborating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international collaborations have the potential to accelerate the development of treatments for blinding disorders, positively affecting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers from any institution of higher education in the United States. A three- to six-month stay in the other country is expected by each researcher, with a minimum stay of three months.

001723	<a href="#">Clinical Research Proposals</a>	ResMed Foundation		15-Jun-2020	250,000 USD
--------	---	-------------------	--	-------------	-------------

Contact Name Kristi Burlingame, Executive Director  
Contact Telephone 858-361-0755



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:kristib@resmedfoundation.org">kristib@resmedfoundation.org</a>				
Sponsor Website	<a href="#">Link to sponsor website</a>				
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	15-Jun-2020 , 15-Sep-2020				
Synopsis	<p>The Foundation's key mission is to promote novel research as well as public and physician awareness of sleep disordered breathing (SDB), with a primary focus on positive airway pressure therapies and ventilation-based treatments. The Foundation will consider proposals focused on the evaluation, diagnosis, treatment and management of SDB and other respiratory disorders. Research areas of interest are also other morbidities that are associated with SDB which include cardiovascular disease, metabolic syndrome, diabetes and morbid obesity. In the cardiovascular area, there is a particular emphasis on hypertension, coronary artery disease, heart failure, and atrial fibrillation. Other areas of focus are: SDB in conjunction with occupational health safety, asthma and anesthesiology; chronic obstructive pulmonary disease; and, pregnancy/preeclampsia. Specific focus is on outcomes that can influence clinical practice in the near term.</p>				

090089	<a href="#">Roddenberry Prize</a>	Roddenberry Foundation		05-Jun-2020	250,000 USD
--------	-----------------------------------	------------------------	--	-------------	-------------

Contact Name					
Contact Telephone					
Contact Email					
Sponsor Website	<a href="#">Link to sponsor website</a>				
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	05-Jun-2020				
Synopsis	<p>The Roddenberry Prize seeks to highlight extraordinary organizations and support their efforts towards greater impact; seek out creative approaches from diverse members of our global community; and inspire others to take innovative and creative approaches to global problems. Four awards of \$250,000 will be granted to organizations working in the areas of Education, Environment, Science, or Humanity. In addition to the four \$250,000 awardees, up to five organizations in each field will be recognized publicly as Prize Finalists.</p>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
027718	<a href="#">International Exchanges</a>	Royal Society		03-Jun-2020	15,120 USD
	Contact Name				
	Contact Telephone	+44(0) 20 7451 2557			
	Contact Email	<a href="mailto:international.exchanges@royalsociety.org">international.exchanges@royalsociety.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	03-Jun-2020 , 24-Sep-2020			
	Synopsis	These schemes are for scientists based in the UK who want to stimulate collaborations with leading scientists overseas through either a one-off visit or bilateral travel.			
005931	<a href="#">Scotland's Saltire Scholarship</a>	Scotland.org		01-Jun-2020	10,080 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:ScotlandsSaltireScholarships@scotland.gsi.gov.uk">ScotlandsSaltireScholarships@scotland.gsi.gov.uk</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	Scotland's Saltire Scholarships is a programme of scholarships offered by the Scottish Government in collaboration with Scottish universities in the areas of science, technology, creative industries, healthcare and medical sciences, and renewable and clean energy.			
088392	<a href="#">SFARI Collaborations - SFARI Collaboration on Sex Differences in Autism Request for Applications</a>	Simons Foundation		05-Jun-2020 [LOI/Pre-App]	8,000,000 USD
	Contact Name				
	Contact Telephone	646-654-0066			
	Contact Email	<a href="mailto:sfarigrants@simonsfoundation.org">sfarigrants@simonsfoundation.org</a>			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	<a href="#">Link to sponsor website</a>				
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	05-Jun-2020 [LOI/Pre-App], 02-Oct-2020				
Synopsis	<p>The Simons Foundation Autism Research Initiative (SFARI) is pleased to announce its 2020 SFARI Collaboration on Sex Differences in Autism request for applications (RFA). SFARI Collaborations are a new funding mechanism which will provide substantive and stable funding support to multi-disciplinary teams of investigators tackling critical issues in the autism research field. Collaborations will be led by a director who oversees interdisciplinary, synergistic research efforts across multiple laboratories. Investigative groups within a Collaboration will focus on the same conceptually unified topic but will incorporate different scientific disciplines, multiple levels of analysis, and will include a robust data-sharing infrastructure. SFARI Collaborations have a maximum budget of \$8,000,000 over an initial period of four years, with a possible three-year extension.</p>				

060678	<a href="#">Dr. Ernest J. Ring Academic Development Grant</a>	SIR Foundation		15-Jun-2020 [LOI/Pre-App]	100,000 USD
--------	---	----------------	--	------------------------------	----------------

Contact Name					
Contact Telephone	703-691-1805				
Contact Email	<a href="mailto:grants@sirfoundation.org">grants@sirfoundation.org</a>				
Sponsor Website	<a href="#">Link to sponsor website</a>				
Program URL	<a href="#">Link to program URL</a>				
Deadline Dates (ALL)	15-Jun-2020 [LOI/Pre-App], 15-Jan-2021				
Synopsis	<p>The Dr. Ernest J. Ring Academic Development Grant program is designed to provide support to junior interventional radiology faculty members early in their academic careers to allow time for the conduct of research. The goal of this program is to have grant recipients subsequently obtain additional funding from other sources, such as National Institutes of Health (NIH) grants.</p>				

060679	<a href="#">Academic Transition Grant</a>	SIR Foundation		15-Jun-2020 [LOI/Pre-App]	25,000 USD
--------	---	----------------	--	------------------------------	------------

Contact Name

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 703-691-1805 Contact Email <a href="mailto:grants@sirfoundation.org">grants@sirfoundation.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 15-Jun-2020 [LOI/Pre-App], 15-Oct-2020 [LOI/Pre-App], 15-Jan-2021 Synopsis The Academic Transition Grant is designed for interventional radiologists over the age of 40 who have recently begun academic careers after spending several years in non-academic practice. The grant is intended to facilitate the establishment of a record of independent research by the investigator in order to promote a successful academic career.				
023640	<a href="#">Louise Hanson Marshall Special Recognition Award</a>	Society for Neuroscience		05-Jun-2020	Not Specified
	Contact Name Contact Telephone 202-962-4000 Contact Email <a href="mailto:awards@sfn.org">awards@sfn.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jun-2020 Synopsis The Louise Hanson Marshall Special Recognition Award honors an individual who has significantly promoted the professional development of women in neuroscience through teaching, organizational leadership, public advocacy, or other efforts that are not necessarily research-related.				
023639	<a href="#">Bernice Grafstein Award for Outstanding Accomplishments in Mentoring</a>	Society for Neuroscience		05-Jun-2020	2,500 USD
	Contact Name Contact Telephone 202-962-4000 Contact Email <a href="mailto:awards@sfn.org">awards@sfn.org</a> Sponsor Website <a href="#">Link to sponsor website</a>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 05-Jun-2020  
 Synopsis The Bernice Grafstein Award for Outstanding Accomplishments in Mentoring recognizes individuals dedicated to women's advancement in neuroscience through mentorship. Recipients receive a \$2,500 award and complimentary registration, transportation (economy air or ground), and two nights hotel accommodations for the SfN annual meeting.

081634	<a href="#">Application of Personality and Social Psychology Award</a>	Society for Personality and Social Psychology		01-Jun-2020	1,000 USD
--------	--	---	--	-------------	-----------

Contact Name Brannan Meyers  
 Contact Telephone 202-869-3240  
 Contact Email [awards@spsp.org](mailto:awards@spsp.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 01-Jun-2020  
 Synopsis The Application of Personality and Social Psychology Award is a senior career award that honors a social or personality psychologist who has applied theoretical and/or empirical psychological discoveries and advances to the understanding and improvement of important practical problems across his or her career. Recipients of this award receive a \$1,000 honorarium and accompanying plaque.

066849	<a href="#">Mentored Clinical Scientist Research Career Development Award (K08)</a>	Society for Vascular Surgery		12-Jun-2020	Not Specified
--------	---	------------------------------	--	-------------	---------------

Contact Name Jane D. Scott  
 Contact Telephone 301-435-0535  
 Contact Email [scottj2@nhlbi.nih.gov](mailto:scottj2@nhlbi.nih.gov)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	12-Jun-2020 , 12-Oct-2020			
	Synopsis	The SVS Foundation offers this award in partnership with the NHLBI as a means to facilitate the research career development of individuals pursuing a career in vascular research. This award provides financial support over and above that offered by the NHLBI K08 mechanism.			
091553	<a href="#">Student Scholarship Program</a>	Society of Diagnostic Medical Sonography Foundation		30-Jun-2020	2,500 USD
	Contact Name				
	Contact Telephone	214-473-8057			
	Contact Email	<a href="mailto:scholarship@sdmsfoundation.org">scholarship@sdmsfoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 , 31-Dec-2020			
	Synopsis	The SDMS Foundation Sonography Student Scholarship provides a \$2,500 scholarship to a deserving sonography student who has been accepted or is currently enrolled in an educational program in diagnostic medical sonography or cardiovascular technology which has been accredited by the Commission on Accreditation of Allied Health Educational Programs (CAAHEP).			
067272	<a href="#">Grants Program</a>	Sorenson Legacy Foundation		01-Jun-2020	Not Specified
	Contact Name	Lisa Meiling			
	Contact Telephone	801-461-9700			
	Contact Email	<a href="mailto:lisa@sorensonlegacyfoundation.org">lisa@sorensonlegacyfoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	The Sorenson Legacy Foundation was created to improve the lives of others and the world in which we live. Founded			

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

by the late biotechnology pioneer and entrepreneur James LeVoy Sorenson and his wife, education philanthropist Beverley Taylor Sorenson, the foundation provides support for a wide range of endeavors, from community development and education to health care, scientific and artistic pursuits.

067237	<a href="#">Stanford Molecular Imaging Scholars (SMIS) Program</a>	Stanford University		01-Jun-2020	Not Specified
--------	--	---------------------	--	-------------	---------------

Contact Name	Sofia Gonzales
Contact Telephone	650-724-9139
Contact Email	<a href="mailto:sofias@stanford.edu">sofias@stanford.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Jun-2020
Synopsis	The Stanford Molecular Imaging Scholars (SMIS) program is an integrated, three-year cross-disciplinary postdoctoral training program at Stanford University that brings together 33 faculty mentors from 14 departments in the Schools of Medicine, Engineering, and Humanities and Sciences.

090355	<a href="#">Industry Program 2020</a>	Translational Research Institute for Space Health		26-Jun-2020	Not Specified
--------	---------------------------------------	---	--	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:SpaceHealth-info@bcm.edu">SpaceHealth-info@bcm.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	26-Jun-2020
Synopsis	The Translational Research Institute for Space Health (TRISH) is awarding \$100,000 to \$500,000 to companies ready to confront behavioral health challenges astronauts will face on a three-year journey to Mars. This solicitation seeks new ideas and technologies to predict, prevent, diagnose and/or treat adverse changes in behavioral health and cognitive

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		performance in astronauts. This must be achieved with solutions for detection and intervention which are minimally intrusive to the user and are feasible in a resource constrained environment. Recipients are required to match TRISH funding at one-to-one level (a 100% cost-share) from a non-federal source.			
096603	<a href="#">Vilcek Prize for Creative Promise in Biomedical Science</a>	Vilcek Foundation		10-Jun-2020	50,000 USD
	Contact Name				
	Contact Telephone	212-472-2500			
	Contact Email	<a href="mailto:info@vilcek.org">info@vilcek.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jun-2020			
	Synopsis	The Vilcek Foundation will award three Creative Promise Prizes of \$50,000 each to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be in basic, applied, and/or translational biomedical science.			
086006	<a href="#">Sir Henry Wellcome Postdoctoral Fellowships</a>	Wellcome Trust		22-Apr-2020 [LOI/Pre-App]	378,000 USD
	Contact Name				
	Contact Telephone	+44 (0)20 7611 5757			
	Contact Email				
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	22-Apr-2020 [LOI/Pre-App], 23-Jun-2020			
	Synopsis	This scheme offers recently qualified postdoctoral researchers the opportunity to start independent research careers, working in some of the best research environments in the world.			
057939	<a href="#">Research Awards for Health Professionals</a>	Wellcome Trust		30-Jun-2020 [LOI/Pre-App]	504,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name				
	Contact Telephone	+44(0)20 7611 5757			
	Contact Email	<a href="mailto:hss@wellcome.ac.uk">hss@wellcome.ac.uk</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	30-Jun-2020 [LOI/Pre-App], 10-Sep-2020			
	Synopsis	This scheme offers practising health professionals the opportunity to carry out humanities or social science research, in any area of health.			

001134	<a href="#">Requests for Proposals in Leukemia Research</a>	When Everyone Survives Foundation, Inc.		01-Jun-2020	50,000 USD
--------	---	---	--	-------------	------------

	Contact Name				
	Contact Telephone	770-595-3573			
	Contact Email	<a href="mailto:contact@wheneveryonesurvives.org">contact@wheneveryonesurvives.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jun-2020			
	Synopsis	This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia.			